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Vasculitis means inflammation of blood vessels. The International Chapel 
Hill Consensus Conference Nomenclature of Vasculitides (CHCC) provides 
definitions for the different vasculitides and subcategorises them into three 
major categories: large-vessel vasculitis, medium-vessel vasculitis, and small-
vessel vasculitis (figure 1).1, 2
Figure 1. The International Chapel Hill Consensus Conference Nomenclature of Vasculitides 
(CHCC) 
The International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC) 
subcategorises the different vasculitides into three major categories: large-vessel vasculitis, me-
dium-vessel vasculitis, and small-vessel vasculitis. The figure depicts (from left to right) aorta, 
large artery, medium artery, small artery/arteriole, capillary, venule, and vein. Anti-GBM = 
anti–glomerular basement membrane; ANCA = antineutrophil cytoplasmic antibody. Repro-
duced from Jennette et al.2 with permission.
Large-vessel vasculitis predominantly affects the aorta and its major branches. 
Two important vasculitides within this category are Takayasu arteritis and 
giant cell arteritis. Medium-vessel vasculitis predominantly affects medium 
sized arteries. Kawasaki disease is an example of a medium-vessel vasculitis. 
Small-vessel vasculitis is further subcategorised into immune complex small-
vessel vasculitis and antineutrophil cytoplasmic antibodies (ANCA)-associated 
vasculitis. Immune complex small-vessel vasculitis shows immunoglobulin (Ig) 
and complement deposits in the blood vessel walls. Two important vasculitides 
within this category are IgA vasculitis and anti–glomerular basement membrane 
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(anti-GBM) disease. ANCA-associated vasculitis is a necrotizing vasculitis with 
few or no immune deposits that is typically associated with ANCA-seropositivity 
by indirect immunofluorescence or enzyme-linked immunosorbent assay 
(ELISA).3
ANCA-associated vasculitis
This thesis focuses on different aspects of ANCA-associated vasculitis. ANCA 
first became widely recognized after a key publication in The Lancet in 1985 
in which van der Woude et al. described circulating antibodies in patients with 
vasculitis that were in several ways similar to the granulocyte-specific antinuclear 
antibodies (GS-ANA) described in rheumatoid arthritis.4 It should however be 
mentioned that Davies et al. had already described the presence of this class of 
antibodies in patients with pauci-immune glomerulonephritis in 1982.5 Van der 
Woude et al. first named these antibodies ACPA (anticytoplasmic antibodies). This 
term was later replaced by ANCA, as the antibodies were found to be directed 
against neutrophil (and monocyte) constituents. The two most important ANCA 
antigens are proteinase 3 (PR3)6-8 and myeloperoxidase (MPO)9.
ANCA-associated vasculitis comprises the clinical diagnoses granulomatosis 
with polyangiitis (GPA, formerly Wegener’s granulomatosis10-12), microscopic 
polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, 
formerly Churg-Strauss Syndrome).2
GPA is a necrotizing granulomatous inflammation usually involving the upper 
and lower respiratory tract.13 Approximately 90-95% of patients with active, 
generalized GPA are ANCA-positive; a small subset of GPA patients is ANCA-
negative.14-17 Thus, the absence of ANCA does not exclude the diagnosis of GPA. 
About 70% of the ANCA-positive GPA patients are PR3-ANCA positive; the 
remainder are MPO-ANCA positive.18
MPA is characterized by a non-granulomatous necrotizing systemic vasculitis. 
Nearly 90% of patients with MPA are ANCA-positive.14-17 About 60% of the 
ANCA-positive MPA patients are MPO-ANCA positive; the remainder are PR3-
ANCA positive.9, 18 Because PR3-ANCA and MPO-ANCA may occur in both 
GPA and MPA, these conditions cannot be distinguished on the basis of ANCA-
serotype.
EGPA is an eosinophil-rich and necrotizing granulomatous inflammation 
often involving the respiratory tract. In contrast to GPA and MPA, EGPA is 
associated with asthma and eosinophilia. Although variable from study to study, 
approximately 50% of patients with EGPA are ANCA-positive.19, 20 About 
70-90% of the ANCA-positive EGPA patients are MPO-ANCA positive.20, 21
The clinical diagnoses GPA and MPA are often grouped together on the 
grounds of striking similarities in clinical presentation and comparable histologic 
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findings.18, 22 Nevertheless, there are marked differences between these disease 
entities, fuelling an ongoing debate as to whether GPA and MPA are different 
entities within the same disease spectrum or represent distinct auto-immune 
diseases.23-25 Although there are overlaps, a clinical diagnosis of GPA usually 
involves PR3-ANCA positivity whereas a clinical diagnosis of MPA usually 
involves MPO-ANCA positivity. In this respect, data from a large genome-wide 
association study (GWAS) are interesting.26 These data indicate that within the 
spectrum of ANCA-associated vasculitis distinct subtypes may be recognized. 
ANCA-serotype was demonstrated to be the main indicator of these subtypes.26
To date, the concept of a single disease spectrum has led to the inclusion of 
GPA and MPA patients in the same clinical trials and the development of similar 
treatment strategies for these patients.14-17, 27, 28 Evidence that the different entities 
in ANCA-associated vasculitis actually represent distinct auto-immune diseases 
may in the future lead to the development of more specific therapeutic strategies. 
The existence of different subtypes within the spectrum of ANCA-associated 
vasculitis and their clinical implications are further investigated in Chapter 2 
and Chapter 3 of this thesis.
Aetiology and pathogenesis of ANCA-associated vasculitis
The pathogenesis of ANCA-associated vasculitis has not been completely 
elucidated. However, over the past decades, significant progress has been made 
in the understanding of this complex disease. Environmental exposures, genetic 
factors, influences of the immune system, and the intensity and duration of the 
injury are all hypothesized to be involved in the pathogenesis of ANCA-associated 
vasculitis. Interestingly, the variability in aetiological and synergistic factors that 
may lead to the development of ANCA-associated vasculitis is hypothesized to 
contribute to the clinicopathologic differences between patients.29
Onset and exacerbation of ANCA-associated vasculitis occur more often 
during winter and spring. This points towards the existence of pathogenic, 
infectious or other environmental, factors that are typically present during these 
seasons.30 Numerous studies demonstrated that pro-inflammatory factors, for 
example induced by infections, act synergistically in ANCA-associated vasculitis 
onset and exacerbation.31, 32 In particular, Staphylococcus aureus infection was linked 
to ANCA-associated vasculitis onset.33-35 Moreover, nasal carriage of Staphylococcus 
aureus was demonstrated to be an important risk factor for relapse in patients with 
GPA,36 and treatment with trimethoprim-sulfamethoxazole was shown to aid in 
the induction of remission37-46 and the prevention of relapses37. These treatment 
effects could be ascribed to the immunosuppressant and/or anti-staphylococcal 
properties of trimethoprim-sulfamethoxazole.
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Evidence that genetic factors contribute to the pathogenesis of ANCA-associated 
vasculitis comes from familial association studies,47-51 differences in the prevalence 
of ANCA-associated vasculitis between ethnic groups,52 and numerous candidate 
gene associations studies53. Quite recently, two GWAS performed by the 
Vasculitis Clinical Research Consortium and the European Vasculitis Genetic 
Consortium also identified genetic associations in ANCA-associated vasculitis.26, 
54 Both GWAS found a strong association with a single nucleotide polymorphism 
(SNP) in human leukocyte antigen (HLA)-DPB1. The European Vasculitis Genetic 
Consortium GWAS also found a strong association between PR3-ANCA 
vasculitis and PRTN3 (the gene encoding PR3) and SERPINA1 (the gene encoding 
α1-antitrypsin; a major inhibitor of PR3), and between MPO-ANCA vasculitis 
and HLA-DQ. Moreover, this GWAS demonstrated genetic distinctions between 
GPA and MPA patients and between PR3-ANCA positive and MPO-ANCA 
positive patients. The numerous candidate gene association studies and two 
GWAS have revealed a great number of genetic variants that possibly contribute 
to the pathogenesis of ANCA-associated vasculitis. In Chapter 2 of this thesis, 
we conducted a meta-analysis to investigate the genetic variants that are most 
likely associated with ANCA-associated vasculitis. We included raw data from 
the European Vasculitis Genetic Consortium GWAS to increase the validity of 
the meta-analysis.
Are ANCA pathogenic?
In vitro and in vivo evidence support a pathogenic role for ANCA in the 
pathogenesis of ANCA-associated vasculitis.55, 56 In vitro data include experiments 
demonstrating that ANCA IgG activates cytokine-primed neutrophils,57-59 that 
ANCA-activated neutrophils induce endothelial cell injury,60, 61 and that ANCA-
activated neutrophils activate the alternative complement pathway62.
The most convincing evidence that ANCA are pathogenic comes from animal 
models. Xiao et al. demonstrated that intravenous injection of purified murine 
anti-MPO IgG into wild type mice or immunodeficient Rag2-/- mice (these mice 
fail to generate mature T and B lymphocytes) induces proteinuria and haematuria 
in these mice. Moreover, the histopathologic lesions found in the kidneys of 
these mice were comparable to those in renal biopsies of patients with ANCA-
associated glomerulonephritis.56 Furthermore, Little et al. demonstrated that 
rats immunised with human MPO develop anti-human MPO-ANCA that binds 
these rats’ neutrophils and induces pauci-immune crescentic glomerulonephritis 
and pulmonary haemorrhage with histologic evidence of lung vasculitis in these 
rats.63 Thus far, it has not been possible to successfully reproduce these findings 
in a PR3-ANCA vasculitis animal model.29, 64
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Clinical evidence for the pathogenicity of ANCA includes the occurrence of 
pulmonary-renal syndrome in a neonate shortly after birth from a mother 
with MPO-ANCA positive MPA, most likely caused by transplacental transfer 
of maternal MPO-ANCA.65, 66 This clinical evidence is limited, however, in 
that it comprises only one case-report and until today no sequelae have been 
reported. Further clinical evidence for the pathogenicity of ANCA includes the 
induction of ANCA, particularly high titres of MPO-ANCA, by certain drugs 
(e.g. propylthiouracil and hydralazine67) and the subsequent onset of disease 
manifestations in humans. More clinical evidence is found in the beneficial effect 
of plasma exchange in the treatment of ANCA-associated vasculitis.17
One observation plaguing the contention that ANCA are pathogenic was the 
presence of ANCA in only 90-95% of ANCA-associated vasculitis patients.14-17 
However, the remaining 5-10% of patients that have long been assumed to be 
ANCA-negative based on the results of conventional clinical assays might be 
classified as ANCA-positive after all. Roth et al. demonstrated that, when using a 
highly sensitive epitope-excision method, ANCA-negative patients’ purified IgG 
reacts with a specific MPO-epitope.68 This MPO-ANCA epitope was blocked 
from reacting with ANCA IgG in serum because of competitive binding by 
ceruloplasmin, which is a natural inhibitor of MPO that is naturally present in 
serum.
The pathogenicity of ANCA was also questioned since healthy individuals were 
also demonstrated to have ANCA.69-72 Interestingly, Roth et al. demonstrated that 
compared with MPO-ANCA occurring in vasculitis, natural MPO-ANCA are 
present in lower titres, have lower avidity, have less subclass diversity, and are less 
capable of activating neutrophils in vitro.68 Moreover, the epitope specificity of the 
repertoire of MPO-ANCA occurring in vasculitis patients was shown to differ 
from the epitope specificity of MPO-ANCA occurring in healthy individuals.68 
Thus, not all ANCA seem to be equal.73
Presumed pathogenic sequence for acute vascular injury in 
ANCA-associated vasculitis
The putative pathogenic sequence inducing acute vascular inflammation 
in ANCA-associated vasculitis is depicted in figure 2.29 Starting from the 
upper left, resting neutrophils have ANCA autoantigens (e.g. PR3 and MPO) 
sequestered in their cytoplasmic granules. Exposure to priming factors, e.g. 
cytokines induced by infection or pathogenic factors released by complement 
activation, leads to the exposure of ANCA-antigens on the neutrophil’s surface 
and in the microenvironment. Circulating ANCA bind to these antigens and 
activate them by Fcγ receptor engagement and F(ab′)2 binding. ANCA-activated 
neutrophils penetrate vessel walls and release factors that initiate necrosis and 
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apoptosis of the neutrophils and the environment. Meanwhile, the alternative 
complement pathway is activated and generates C5a, a chemoattractant for 
neutrophils that also primes the arriving neutrophils for activation by ANCA, 
generating a positive feedback effect.
Figure 2. The putative pathogenic sequence inducing acute vascular inflammation in antineu-
trophil cytoplasmic antibodies (ANCA)-associated vasculitis. 
Starting from the upper left, resting neutrophils have ANCA-antigens (e.g. proteinase 3 (PR3) 
and myeloperoxidase (MPO)) in their cytoplasmic granules. Exposure to priming factors, e.g. 
cytokines induced by infection or pathogenic factors released by complement activation, leads 
to the exposure of the ANCA-antigens on the neutrophil’s surface and in the microenviron-
ment. Circulating ANCA bind to these antigens and activate the neutrophils. ANCA-activated 
neutrophils penetrate vessel walls and release factors that initiate necrosis and apoptosis of the 
neutrophils and the environment. Meanwhile, the alternative complement pathway is activated 
and generates C5a, a chemoattractant for neutrophils that also primes the arriving neutrophils 
for activation by ANCA, generating a positive feedback effect. Reproduced from Xiao et al.29 
with permission.
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Disease manifestations
The peak age of ANCA-associated vasculitis onset is 65-74 years.74 Men are 
more often affected than women, but when women are affected, they tend 
to have a younger age at disease onset than men.75 Patients typically present 
with prodromal ‘flu-like’ symptoms that have been present for several weeks 
to months.3 These symptoms include malaise, fever, headache, polyarthralgia, 
polymyalgia, and unintended weight loss.13, 76 Presenting symptoms can be 
very similar to symptoms of non-vasculitic diseases such as infections, post-
viral syndrome, and malignancies. It can therefore be challenging for clinicians 
to pinpoint the diagnosis early in the diagnostic process. A survey including 
701 patients with ANCA-associated vasculitis demonstrated a lag of three to 12 
months between disease onset and diagnosis, suggesting that diagnostic delay is 
a problem.75 Correct diagnosis on the first visit to a physician was accomplished 
in only 7% of patients and 50% of patients had to visit at least four physicians 
before the correct diagnosis was made.
Figure 3 depicts the various manifestations of ANCA-associated vasculitis. 
Although disease symptoms in GPA and MPA overlap, the incidences of these 
symptoms can differ significantly between the two conditions. For instance, 
ear, nose, and throat (ENT) symptoms occur in 90% of GPA patients and in 
only 35% of MPA patients.13, 76 Large observational studies demonstrated that 
the airways and lung parenchyma are commonly affected, as are the kidneys, 
although renal involvement can be asymptomatic until renal failure occurs.76-78 
Approximately half of patients develop skin manifestations.76-78 Clearly, ANCA-
associated vasculitis can become manifest in virtually all organs. Therefore, 
thorough physical examination is important to determine the full extent of the 
disease.3
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Figure 3. The various manifestations of antineutrophil cytoplasmic antibodies (ANCA)-asso-
ciated vasculitis. 
*These lesions can be seen on chest radiography and computed tomography. Reproduced from 
Berden et al.3 with permission.
Chapters 3 and 4 of this thesis focus on renal involvement in ANCA-associated 
vasculitis. Renal involvement is common and is important with respect to patient 
morbidity and mortality.22 The kidneys become involved in approximately 80% 
of GPA patients and 90% of MPA patients.13 A key study published in 1958 
demonstrated that the main cause of death in untreated ANCA-associated 
vasculitis patients is uraemia due to rapidly progressive renal failure.79
Rapidly progressive renal failure with an active sediment (i.e. red cell casts 
and/or proteinuria) in patients who are seropositive for ANCA is suggestive of 
ANCA-associated glomerulonephritis. The morphologic changes in the renal 
biopsy are the gold standard for establishing the diagnosis of ANCA-associated 
glomerulonephritis.80, 81 In these biopsies, light microscopy shows necrotizing and 
crescentic glomerulonephritis.82 Immunofluorescence microscopy shows little or 
no immunoglobulin or complement staining (the so-called pauci-immune staining 
pattern). By electron microscopy, subendothelial edema, microthrombosis, and 
degranulation of neutrophils are present, but immune deposits are absent.83
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Several studies have demonstrated strong associations between histopathological 
parameters in the renal biopsy and renal outcome. The most consistent findings 
were associations between the percentage of normal glomeruli and favorable 
renal outcome and between the percentage of sclerotic glomeruli and poor 
renal outcome.84-87 Moreover, the presence of active lesions such as cellular 
crescents was found to be positively associated with renal recovery under 
immunosuppressive treatment.84, 85 In 2010, the histopathological classification 
of ANCA-associated glomerulonephritis was devised within the collaboration of 
the European Vasculitis Society (EUVAS) with the aim of further adding to the 
prognostication of patients with ANCA-associated glomerulonephritis.88 This 
classification system is built around glomerular pathology and distinguishes four 
classes: focal class biopsies contain ≥50% normal glomeruli; crescentic class 
biopsies contain ≥50% glomeruli with cellular crescents; sclerotic class biopsies 
contain ≥50% sclerotic glomeruli; and biopsies without predominant lesions are 
assigned to the mixed class. Examples of glomerular lesions typically for each of 
the four classes are depicted in figure 4. The classification flowchart is depicted 
in figure 5.
Figure 4. Examples of glomerular lesions that can be observed in the four classes of the his-
topathological classification of antineutrophil cytoplasmic antibodies (ANCA)-associated glo-
merulonephritis. 
A-C show examples of normal glomeruli; D-G show examples of cellular crescents; H-J show 
examples of fibrous crescents; and K shows an example of global glomerulosclerosis. Reproduced 
from Berden et al.88 with permission.
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Figure 5. The classification flowchart for the histopathological classification of ANCA-asso-
ciated glomerulonephritis. 
Reproduced from Berden et al.88 with permission.
The study by Berden et al. wherein the classification system was proposed 
incorporated a validation study including 100 patients.88 Multiple regression 
analysis showed that baseline renal function and the histopathological classification 
were the only independent predictors of renal outcome. The histopathological 
classification of ANCA-associated glomerulonephritis has been validated in various 
cohorts.89-109 The outcomes of these validation studies, points of consideration, 
and future perspectives are discussed in Chapter 4 of this thesis.
Treatment of ANCA-associated vasculitis
Early diagnosis of ANCA-associated vasculitis is of major importance as prompt 
instigation of treatment is essential to prevent progressive organ damage, 
particularly end-stage renal disease, and death.79 In the last 20 years, a significant 
number of large, international trials were performed with the aim of improving 
the treatment modalities in ANCA-associated vasculitis.14-17, 27, 28, 110-112
Treatment of ANCA-associated vasculitis traditionally consists of two 
phases.113 Phase I consists of aggressive remission-inducing immunosuppression 
classically consisting of cyclophosphamide and corticosteroids for the duration of 
three to six months. Phase II consists of remission maintenance treatment with, 
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amongst others, azathioprine or methotrexate while corticosteroids are tapered 
and if possible stopped.114 The choice of treatment depends on disease severity 
and organ manifestations. Recently, rituximab was introduced for both induction 
and remission maintenance treatment in ANCA-associated vasculitis.27, 28, 115
Induction treatment
Induction treatment of ANCA-associated vasculitis consists of cyclophosphamide 
treatment until complete clinical remission is achieved, which is often after three 
to six months. The CYCLOPS trial demonstrated that, while achieving similar 
remission rates, intravenous pulsed cyclophosphamide treatment results in a lower 
cumulative cyclophosphamide dose than oral cyclophosphamide treatment.15 
However, long-term analysis of this cohort demonstrated a higher relapse risk 
in the intravenous group than in the oral group.116 The increased frequency of 
relapses in the intravenous group was not associated with increased mortality 
or renal damage.
Two randomised controlled trials, RITUXVAS27 and RAVE28, investigated 
rituximab – a chimeric monoclonal antibody directed against pre-B cells and 
mature B lymphocytes – in the treatment of ANCA-associated vasculitis. 
RITUXVAS included only newly diagnosed patients, whereas in RAVE both new 
and relapsing patients were included. In both trials, rituximab was non-inferior to 
cyclophosphamide for remission induction. Moreover, both trials demonstrated 
no significant difference between the number of adverse events in the rituximab 
group and the cyclophosphamide group. However, concerns were raised about a 
possible higher malignancy rate in patients treated with rituximab.117, 118 Chapter 
5 of this thesis reports the first 10-year follow-up study investigating malignancy 
risk in patients with ANCA-associated vasculitis treated with cyclophosphamide 
according to current treatment regimens. Chapter 6 reports the first study to 
compare the long-term malignancy risks between rituximab-based treatment and 
cyclophosphamide-based treatment in ANCA-associated vasculitis.
The NORAM trial investigated methotrexate induction treatment in 
patients with ANCA-associated vasculitis with early systemic disease without 
significant renal involvement.14 Methotrexate was demonstrated to have similar 
efficacy to cyclophosphamide for remission induction, but was associated with 
a higher relapse rate. Long-term follow-up of these patients demonstrated that 
methotrexate treatment is associated with less effective disease control and 
prolonged use of steroids.119
Evidence from a retrospective study120 and a prospective pilot trial121 
indicates that mycophenolate mofetil is effective in the induction treatment 
of ANCA-associated vasculitis. An advantage of mycophenolate mofetil over 
cyclophosphamide includes a more favourable safety profile in terms of toxicity. 
The MYCYC trial compares mycophenolate mofetil to cyclophosphamide 
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for induction treatment in ANCA-associated vasculitis (ClinicalTrials.gov 
NCT00414128). The MYCYC trial results are expected in 2018.
Maintenance treatment
Maintenance treatment aims at the prevention of relapses. The landmark EUVAS 
trial CYCAZAREM demonstrated that cyclophosphamide exposure in patients 
with ANCA-associated vasculitis can be safely reduced by the substitution 
of cyclophosphamide by azathioprine shortly after remission achievement.16 
Relapse risk and severe adverse event occurrence were similar between the 
cyclophosphamide group and the azathioprine group. Currently, azathioprine, 
alongside with methotrexate, is the first choice for maintenance treatment in 
ANCA-associated vasculitis.122
Methotrexate can be used as an alternative to azathioprine for remission 
maintenance in patients with ANCA-associated vasculitis in whom renal function 
is not severely impaired. The WEGENT trial demonstrated similar remission 
maintenance and adverse events rates between methotrexate and azathioprine 
maintenance treatment.114
Rituximab was recently introduced for remission maintenance treatment in 
ANCA-associated vasculitis patients who relapsed on other maintenance therapies 
or who are at high risk of relapse. The MAINRITSAN trial demonstrated a 
superiority of rituximab over azathioprine as maintenance treatment after 
cyclophosphamide induction treatment.115 Adverse events rates were similar in 
the rituximab group and the azathioprine group. The ongoing RITAZERAM 
trial compares rituximab to azathioprine as maintenance treatment in relapsing 
patients who achieved remission following rituximab induction treatment 
(ClinicalTrials.gov NCT01697267).
The IMPROVE trial demonstrated that mycophenolate mofetil is less effective 
than azathioprine in remission maintenance after remission induction with 
cyclophosphamide.111 Therefore, mycophenolate mofetil maintenance treatment 
is only considered in ANCA-associated vasculitis patients in whom azathioprine 
and methotrexate are contraindicated.
Prognosis of patients with ANCA-associated vasculitis
As stated previously, the natural history of untreated ANCA-associated vasculitis 
is that of a rapidly progressive, usually fatal disease.79 The introduction of 
immunosuppressive therapy in the 1960s has dramatically reduced the 1-year 
mortality rate of patients with ANCA-associated vasculitis from 82% to 10%.32, 79, 
123 Nevertheless, patients continue to have an increased mortality risk compared 
to the general population.123
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A large, prospective 5-year follow-up study that included 535 patients 
demonstrated that ANCA-associated vasculitis patients have a 2.6 times increased 
mortality risk compared to the general population.123 Infection (48%) and 
active vasculitis (19%) were the main causes of death during the first year after 
diagnosis. This finding emphasizes the importance of finding the right balance 
between disease control and immunosuppressive treatment. After the first year 
of diagnosis, patients continued to have a 1.3 times increased mortality risk.123 
Cardiovascular disease (26%), malignancy (22%), and infection (20%) accounted 
for the majority of these deaths.
About 14% of patients will experience at least one major cardiovascular event 
within 5 years after ANCA-associated vasculitis diagnosis.124 Patients with GPA 
are reported to have a 3.6 times increased myocardial infarction risk compared 
to the general population.125 In addition, when matched for renal function and 
other traditional risk factors, cardiovascular risk is still doubled in patients with 
ANCA-associated vasculitis.126 PR3-ANCA positivity, older age, and diastolic 
hypertension were shown to be independent determinants of poor cardiovascular 
outcome.124 Factors contributing to the increased cardiovascular risk in 
vasculitis include the chronic inflammatory state, endothelial dysfunction, renal 
dysfunction, and the use of corticosteroids, which accelerates the development 
of hypertension, dyslipidaemia, and diabetes.127, 128
Malignancies were demonstrated to be the second leading cause of death 
after the first year of ANCA-associated vasculitis diagnosis.123 A number of 
studies, using data from retrospective monocentre cohorts,76, 129-131 prospective 
multicentre clinical trials,132, 133 and nationwide registry linkage,134 demonstrated 
that patients with ANCA-associated vasculitis have an increased malignancy risk 
compared to the general population.135 In particular, the risks of leukaemia, 
lymphoma, bladder cancer, and non-melanoma skin cancer (NMSC) were 
increased. Except for one 7-year follow-up study published in 1992,76 average 
follow-up in these studies was at most five years129-132. Moreover, the observation 
period in most studies was 1960-1990. Thus, the patients included in these studies 
were treated with treatment regimens that are outdated and, consequently, the 
findings of these studies do not represent current malignancy risks.76, 129, 131, 134 
As explained previously, treatment regimens in ANCA-associated vasculitis 
have changed significantly in recent years based on efforts to reduce cumulative 
cyclophosphamide exposure.14-17 Moreover, rituximab has emerged as a promising 
substitute for cyclophosphamide in the treatment of ANCA-associated vasculitis.27, 
28, 136, 137 Chapter 5 of this thesis reports the first 10-year follow-up study that 
investigates malignancy risk in ANCA-associated vasculitis patients treated with 
cyclophosphamide according to current treatment regimens. Chapter 6 reports 
the first study to compare the long-term malignancy risks between rituximab-
based treatment and cyclophosphamide-based treatment in ANCA-associated 
vasculitis.
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Several factors have been hypothesized to contribute to the increased malignancy 
risk in patients with ANCA-associated vasculitis. Firstly, immunosuppressive 
treatment may decrease the immune system’s ability to recognize and eradicate 
malignant cells. The importance of a well-functioning immune system in the 
prevention of malignancies is well-demonstrated by the increased malignancy 
risk observed in HIV-positive patients.138 Moreover, immunosuppressive therapy 
itself may have direct mutagenic properties, as, for example, demonstrated in 
cyclophosphamide-induced bladder cancer.139-143 Furthermore, long-standing 
immune activation per se may be oncogenic; for example, long-standing immune 
activation is hypothesized to contribute to the increased lymphoma risk seen in 
a number of chronic autoimmune rheumatic conditions.144
The European Vasculitis Society and the European Vasculitis 
Genetics Consortium
Research in ANCA-associated vasculitis is hindered by the low incidence of 
this complex disease. Therefore, in 1994 the EUVAS was founded with the 
objective of uniting vasculitis researchers and clinicians and promoting the 
study of vasculitis. The apparent need for clinical trials was demonstrated by 
the wide heterogeneity in treatment, poor patient outcomes, and high levels of 
treatment-related toxicity.122 Thus far, the EUVAS has conducted a significant 
number of clinical trials with the aim of optimizing the treatment of ANCA-
associated vasculitis.14-17, 27, 110, 111, 145 Long-term follow-up studies of the first 
four EUVAS trials (CYCAZAREM,16 NORAM,14 MEPEX,17 and CYCLOPS15) 
have been published and longer follow-up is pending. The aim of these studies 
was to investigate several long-term outcomes in ANCA-associated vasculitis, 
including long-term patient survival,123 disease relapse,146 cardiovascular events,124 
malignancies,132 disease-related damage,147-149 and severe adverse events150. To 
harmonize the clinical trials, scoring systems were created for both presenting 
clinical manifestations151-153 and renal histology154. Other studies conducted 
by the EUVAS include ANCA assay standardization studies18, 155, 156 and renal 
histopathological studies84, 85, 88, 157-162. The study presented in Chapter 3 of this 
thesis was performed within the collaboration of the EUVAS. The European 
Vasculitis Genetics Consortium has grown out of EUVAS activity and focuses 
on the genetics of ANCA-associated vasculitis. In 2010, the European Vasculitis 
Genetic Consortium published the first GWAS in ANCA-associated vasculitis.26 
The study presented in Chapter 2 of this thesis was performed within the 
collaboration of the European Vasculitis Genetic Consortium.
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Outline of this thesis
The role of genetic variants in ANCA-associated vasculitis is explored in Chapter 
2 of this thesis. The numerous candidate gene association studies and two 
GWAS have revealed a great number of genetic variants that could contribute 
to the pathogenesis of ANCA-associated vasculitis. In Chapter 2 we report 
the results of a meta-analysis investigating the genetic variants that are most 
likely associated with ANCA-associated vasculitis. We included raw data from 
the European Vasculitis Genetic Consortium GWAS to increase the validity of 
the meta-analysis.26 Moreover, in the light of the ongoing debate as to whether 
the different subtypes within ANCA-associated vasculitis represent different 
entities within the same disease spectrum or are distinct auto-immune diseases, 
we investigated whether these subtypes have distinct genetic backgrounds. In 
Chapter 3 we investigated whether ENT involvement represents a separate 
phenotype in ANCA-associated vasculitis by exploring the relationship between 
ENT manifestations and renal outcome.
As discussed previously, renal disease is a common and severe manifestation 
of ANCA-associated vasculitis that can lead to end-stage renal disease and death. 
Chapter 4 reviews the outcomes of studies validating the histopathological 
classification of ANCA-associated glomerulonephritis and discusses points of 
consideration and future perspectives.
The prognosis of patients with ANCA-associated vasculitis has improved 
dramatically in recent years, shifting attention towards the long-term 
complications these patients experience. In Chapter 5 the malignancy risk in 
patients with ANCA-associated vasculitis treated with current immunosuppressive 
regimens was investigated and its relationship with cyclophosphamide treatment 
was explored. Recently, rituximab was introduced for both induction and 
remission maintenance treatment in ANCA-associated vasculitis with the promise 
of, amongst others, further reducing malignancy risk. Chapter 6 reports the 
first study to date to compare the long-term malignancy risks between rituximab-
based treatment and cyclophosphamide-based treatment in ANCA-associated 
vasculitis.
The findings of this thesis will be summarized and placed in a more general 
perspective in Chapter 7.
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Genetic factors may influence the pathogenic pathways leading to antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We performed a 
meta-analysis to determine the genetic variants most likely associated with AAV 
and investigated whether diagnostic and serological subtypes within AAV have 
distinct genetic backgrounds.
Methods 
Studies investigating the association between genetic variants and AAV in 
humans were searched in PubMed, EMBASE and Web of Science. All variants 
investigated in at least two studies were selected. Subsequently, all studies 
assessing these variants were included in this meta-analysis. Additionally, data 
on these variants from the largest genome-wide association studies in AAV were 
included to increase the validity of this meta-analysis.
Results 
The literature search yielded 5180 articles. 62 articles investigating 140 genetic 
variants were included, 33 of which were associated with AAV in a meta-
analysis. These genetic variants were in or near the following genes: CD226, 
CTLA-4, FCGR2A, HLA-B, HLA-DP, HLA-DQ , HLA-DR, HSD17B8, IRF5, PTPN22, 
RING1/RXRB, RXRB, STAT4, SERPINA1 and TLR9. Moreover, we identified 
genetic distinctions between granulomatosis with polyangiitis and microscopic 
polyangiitis and between proteinase 3 ANCA vasculitis and myeloperoxidase 
ANCA vasculitis. In 76% of the genetic variants, subdivision based on ANCA 
serotype resulted in higher ORs than subdivision based on clinical diagnosis.
Conclusions 
This meta-analysis identified 33 genetic variants associated with AAV, supporting 
a role for alpha-1-antitrypsin, the major histocompatibility complex system, 
and several distinct inflammatory processes in AAV pathogenesis. Our results 
indicate that subdivision of AAV based on ANCA serotype has a stronger genetic 
basis than subdivision based on clinical diagnosis.
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Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) 
is a systemic autoimmune disease in which patients often have circulating 
proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA.1,2 The clinical 
syndromes within the spectrum of AAV are granulomatosis with polyangiitis 
(GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with 
polyangiitis.
The subtypes within AAV show significant differences in clinical and 
epidemiological characteristics,3,4 leading to debate regarding whether these 
subtypes are part of a single disease spectrum or represent distinct diseases.5–7 
To date, the prevailing concept of a single disease spectrum has resulted in 
similar treatment strategies in clinical trials8–10 and to suggestions that genetic 
studies should consider the subtypes together.11 Evidence that these subtypes 
are pathogenically distinct may lead to the development of syndrome-specific 
therapeutic strategies.
Both environmental and genetic factors are thought to be involved in the 
pathogenesis of AAV.12 Evidence for the role of genetic factors comes from 
differences in the prevalence of AAV between ethnic groups,13 familial association 
studies14 and genetic associations studies including the two genome-wide 
association studies (GWAS) performed in AAV.15,16
Attempts to replicate findings of genetic association studies performed in 
AAV have yielded inconsistent outcomes. Small sample sizes and false-positive 
results arising from the low prior probabilities of genetic associations may be 
responsible for these inconsistencies.17 These factors are especially relevant in 
complex diseases such as AAV.18
The aim of this study was to determine the genetic variants associated with 
AAV. Therefore, we performed a meta-analysis to assess the pooled effect of all 
genetic variants that have been investigated in AAV in at least two studies. To 
increase the validity of this meta-analysis, we also included previously unpublished 
data from the largest GWAS performed in AAV.15 Moreover, we conducted 
stratified analyses based on clinical diagnosis and ANCA serotype to investigate 
whether these different AAV subtypes have distinct genetic backgrounds.
Methods
Literature search and eligibility
A comprehensive search string was carried out in collaboration with a librarian. 
PubMed, EMBASE and Web of Science were searched until April 2014 for studies 
investigating genetic variants in patients with AAV. The search strategy consisted 
of multiple queries combining ‘Anti-Neutrophil Cytoplasmic Antibody-Associated 
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Vasculitis’, ‘ANCA’, ‘vasculitis’, ‘Granulomatosis with Polyangiitis’, ‘Wegener’s 
Granulomatosis’, ‘Microscopic polyangiitis’, ‘Eosinophilic granulomatosis with 
polyangiitis’, ‘Churg Strauss Syndrome’, ‘PR3’, ‘MPO’, ‘Polymorphisms’ or 
‘Genes’. To minimise the chance of omitting references, a second broader search 
was performed for genetic variants in vasculitis in general rather than AAV alone 
(supplementary table S1). The specific genes and polymorphisms that resulted 
from the previous searches were added in a next search to minimise the chance of 
omitting references. To ensure maximum sensitivity, no limits, filters or language 
restrictions were placed on the searches.
Two observers (CR and DvH) independently reviewed the titles and abstracts 
of the citations retrieved by the search and read potentially relevant studies 
independently. Studies that compared genetic variants between patients with 
AAV and controls without AAV derived from the general population were 
eligible. Cases had to have an AAV by fulfilling either the Chapel Hill Consensus 
Conference criteria,19 American College of Rheumatology criteria,20 European 
Medicines Agency algorithm,21 1998 Japanese criteria proposed by the Research 
Committee on Intractable Vasculitides, the Ministry of Health, Labour and 
Welfare of Japan,22 or clinical, histological and serological criteria. Definitions 
of cases and controls in each included study are depicted in supplementary table 
S2. All genetic variants investigated in at least two studies were included. Genetic 
variants investigated in multiple cohorts in one publication were also included. 
This was the case for genetic variants in GHSR,23 LEPR23 and TLR9.24 For the 
included genetic variants, all genetic studies were identified to estimate the pooled 
effect of the genetic variant in a meta-analysis, irrespective of their p values. To 
increase the validity of this meta-analysis, we also included unpublished data on 
these genetic variants from the Lyons et al15 GWAS. This was possible for the 
genetic variants in this meta-analysis that were not human leucocyte antigen 
(HLA) serotypes or tandem repeats and that were genotyped in the Lyons et 
al GWAS. Moreover, we included data from the stage 1 analysis including all 
single-nucleotide polymorphisms (SNPs) with a p value <10−4 from the Xie et 
al16 GWAS.
Data extraction
Minor allele frequencies of the included genetic variants were extracted from 
included studies. Studies investigating the same genetic variant published by the 
same author(s) were checked for overlapping patient groups, in which case only 
the study with the largest patient group was included. Studies that reported 
insufficient data to calculate an OR were excluded.
Statistical analysis
ORs and 95% CIs were calculated at the allele level. To account for potential 
heterogeneity, random-effects model was performed in all analyses that included 
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at least five studies.25 Because the HLA serotypes are not completely independent 
from the HLA alleles, the following HLA variants were collapsed in the analyses: 
HLA-DR1, HLA-DRB1*01 and HLA-DRB1*0101; HLA-DR3 and HLA- DRB1*03; 
HLA-DR7 and HLA-DRB1*07; HLA-DR8 and HLA-DRB1*08; and HLA-DR9, HLA-
DRB1*09 and HLA-DRB1*0901. Collapsing other HLA variants was not possible 
because some studies investigated multiple, closely related, HLA variants in the 
same patients. If these HLA variants had been collapsed, the same patients would 
have been included in the same analysis multiple times, increasing their weight in 
the analysis and introducing a systematic error. To determine whether the disease 
subtypes within AAV represent parts of a single disease spectrum or distinct 
clinical entities, we performed pre-specified subgroup analysis stratifying patients 
according to clinical diagnosis (GPA/MPA) and ANCA serotype (PR3-ANCA/
MPO-ANCA and cytoplasmic (c)-ANCA/perinuclear (p)-ANCA), if enough data 
were available. Moreover, we performed stratified analyses based on ethnicity 
for all genetic variants investigated in both Caucasian and Asian patients. We 
assumed difference in effect estimates likely to be present in case subgroups 
showed significant effects in opposite directions, that is, having a protective effect 
in one subgroup but leading to an increased risk of AAV in the other subgroup. 
Heterogeneity within studies was displayed by I2, which reflects the percentage 
of total variation across studies beyond chance.26 Egger and Harbord tests were 
used to assess publication bias.27 All of the p values presented are nominal p 
values and are not corrected for multiple testing. Correction for multiple testing 
was not performed as the strong linkage disequilibrium between variants tested 
in the major histocompatibility complex (MHC) region makes calculating an 
appropriate multiple correction factor impractical. All analyses were performed 
using STATA V.12 (StataCorp. 2011; Stata Statistical Software: Release 12, 
College Station, Texas, USA).
Results
Initial search and results
Our literature search yielded 5180 articles, from which we identified 140 
genetic variants published in 62 articles. All included studies were case–control 
studies, two of which were GWAS. These articles were published from 1978 
through 2014, and the number of patients with AAV included ranged from 12 to 
1445. The characteristics of all included studies are provided in supplementary 
table S2. Additionally, previously unpublished data from the Lyons et al15 
GWAS were available and included in the meta-analysis for 18 genetic variants: 
CD226 rs763361, CTLA-4 rs231775, CTLA-4 rs3087243, FCAR rs16986050, 
FCGR2Ars1801274, GHSR rs509035, HLA-DPB2 rs3130215, IL1β rs1143634, IL6 
rs1800795, IL10 rs1800896, IRF5 rs10954213, PTPN22 rs2476601, RING1/RXRB 
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rs213213, RXRB rs6531, RXRB rs9277935, STAT4 rs7574865, SERPINA1 Z allele 
and TNFαrs1800629.
Thirty-three genetic variants were significantly associated with AAV after 
meta-analysis (table 1 and supplementary figure S1), and 107 genetic variants 
were not associated with AAV after meta-analysis (supplementary table S3). The 
ORs for the significant associations after meta-analysis ranged from 0.35 to 0.81 
for protective genetic variants and from 1.13 to 2.94 for the genetic variants 
associated with an increased risk of AAV.
AAV is associated with the Z and S alleles of SERPINA1
Both the S allele and Z allele of SERPINA1 were significantly associated with AAV, 
with pooled ORs of 1.30 (95% CI 1.03 to 1.63) and 2.94 (95% CI 2.22 to 3.88), 
respectively. Subgroup analysis showed that the association with the SERPINA1 Z 
allele was present in both PR3-ANCA (pooled OR 2.58 (95% CI 1.57 to 4.25)) 
and MPO-ANCA (pooled OR 2.01 (95% CI 1.04 to 3.87)) positive patients and 
in both c-ANCA (pooled OR 3.53 (95% CI 2.28 to 5.49)) and p-ANCA (pooled 
OR 3.13 (95% CI 1.21 to 8.13)) positive patients (supplementary table S4 and 
figure S2).
AAV is associated with genetic variants in the MHC region
Seventeen genetic variants in HLA-B, HLA-DP, HLA-DQ and HLA-DR remained 
significantly associated with AAV after meta-analysis (table 1). HLA-DPA1 
rs9277341 had the strongest protective effect (pooled OR 0.35 (95% CI 0.30 to 
0.40)), and HLA-DPB1*0401was the strongest contributor to an increased risk 
of AAV (pooled OR 1.99 (95% CI 1.44 to 2.74)). RING1/RXRB rs213213, RXRB 
rs6531 and RXRB rs9277935 were also significantly associated with AAV with 
pooled ORs of 1.71 (95% CI 1.57 to 1.86), 1.63 (95% CI 1.50 to 1.77) and 0.44 
(95% CI 0.37 to 0.50), respectively.
AAV is associated with genetic variants involved in inflammatory processes
CTLA-4 rs231775 was associated with an increased risk of AAV (pooled OR of 
1.16 (95% CI 1.06 to 1.28)) while CTLA-4 rs3087243 and CTLA-4 (AT)86 had 
a protective effect (pooled ORs of 0.81 (95% CI 0.75 to 0.87) and 0.54 (95% 
CI 0.43 to 0.67), respectively). PTPN22 rs2476601, CD226 rs763361 and IRF5 
rs10954213 were also significantly associated with AAV, with pooled ORs of 
1.39 (95% CI 1.24 to 1.56), 1.14 (95% CI 1.07 to 1.21) and 0.77 (95% CI 0.70 
to 0.83), respectively. Moreover, TLR9 rs352162 and rs352140 were significantly 
associated with AAV with pooled ORs of 1.58 (95% CI 1.43 to 1.75) and 1.13 
(95% CI 1.02 to 1.25), respectively.
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Genetic associations differ for the different diagnostic and serological sub-
types of AAV
A significant association with GPA and /or MPA was present for 25 genetic 
variants, and a significant association with both GPA and MPA was present for 
ten genetic variants (supplementary table S4 and figure S2). In six of these ten 
genetic variants (60%), the associations were in opposite directions, that is, 
having a protective effect in one subgroup but leading to an increased risk of AAV 
in the other subgroup (figure 1). A significant association with PR3-ANCA and/
or MPO-ANCA was present for 25 genetic variants, and a genetic association 
with both PR3-ANCA and MPO-ANCA was present for seven genetic variants. 
In four of these seven genetic variants (57%), the associations were in opposite 
directions, that is, having a protective effect in one subgroup but leading to an 
increased risk of AAV in the other subgroup (figure 1). Moreover, ORs were 
higher for ANCA serotype than for clinical diagnosis in 76% (16/21) of the 
genetic variants that were significantly associated with both clinical diagnosis 
and ANCA serotype.
Genetic associations differ for AAV patients of Caucasian and Asian origin
The results of the stratified analyses performed for 42 variants investigated in both 
Caucasian and Asian patients are depicted in supplementary table S5. CTLA-4 
(AT)86, CTLA-4 (AT)106 and HLA-DR6 were significantly associated with AAV 
in the Caucasian patients but not in the Asian patients. Conversely, HLA-B55 was 
significantly associated with AAV in the Asian patients but not in the caucasian 
patients. Of interest, IRF5 rs10954213 (G) was significantly associated with AAV 
in both the Caucasian and Asian patients; however, it had a protective effect in 
the Caucasian patients while it increased the risk of AAV in the Asian patients. 
The results of these analyses should be interpreted with caution, because each 
analysis included only one study involving Asian patients.
Genetic variants identified by GWAS
To date, two GWAS have been performed in AAV. The first GWAS included 
patients with GPA and MPA and found HLA-DP rs3117242, COL11A2 rs3130233, 
COL11A2 rs3117016 and SERPINA1 rs7151526 to be associated with AAV.15 
Moreover, HLA-DP rs3117242, ARHGAP18 rs1705767 and SERPINA1 rs7151526 
were associated with PR3-ANCA vasculitis, and HLA-DQ rs5000634 was 
associated with MPO-ANCA vasculitis. The second GWAS included only 
patients with GPA and found HLA-DPB1 rs9277554 and HL-DPA1 rs9277341 
to be associated with GPA.16 SEMA6A rs26595 was associated with GPA at a 
genome-wide significance level when the results of the two cohorts that were 
included in this GWAS were combined. However, although SEMA6A rs26595 
was not genotyped in the first GWAS,15 data for a large number of proxy SNPs 
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across this locus were available, and these did not reach statistical significance 
(data not shown).
Discussion
This meta-analysis identified 33 genetic variants, in or near 15 genes, associated 
with AAV. Twenty of these 33 genetic variants were present in the MHC region. 
This study provides the first complete and comprehensive overview including all 
genetic variants investigated in AAV in at least two studies. Genetic variants in 
or near CD226, CTLA-4, FCGR2A, HLA-B, HLA-DP, HLA-DQ , HLA-DR, HSD17B8, 
IRF5, PTPN22, RING1/RXRB, RXRB, STAT4, SERPINA1 and TLR9 were associated 
with AAV in this meta-analysis. Of interest, FCGR2A and STAT4 were not 
associated with AAV in the individual studies, but were significantly associated 
with AAV after meta-analysis. Moreover, we showed genetic distinctions between 
the clinical diagnoses GPA and MPA and between the ANCA serotypes PR3-
ANCA and MPO-ANCA. Additionally, our results confirm that subdivision of 
AAV based on ANCA serotype has a stronger genetic basis than subdivision based 
on clinical diagnosis.
A number of the genetic variants associated with AAV in this meta-
analysis have also been associated with other autoimmune diseases, such as 
CTLA-4 rs3087243 in rheumatoid arthritis28,29 and type 1 diabetes30,31 and 
PTPN22 rs2476601 in Crohn’s disease,32–34 Behçet’s disease,35 systemic lupus 
erythematosus36–38 and giant cell arteritis.39,40 These findings are in line with 
the fact that first-degree relatives of patients with AAV have an increased risk 
of other autoimmune diseases.41, 42 Overlapping genetic variants may form the 
basis of a disturbed immune system, and together with environmental factors 
and other, more distinct genetic factors, form a ‘bad hand of cards’ that leads to 
the development of AAV.
The results of this meta-analysis support a role for the intricate relationship 
among alpha-1-antitrypsin and ANCA, the MHC system and other inflammatory 
processes in the pathogenesis of AAV. The association between SERPINA1 and 
AAV supports the concept that ANCA are important in AAV pathogenesis. Alpha-
1-antitrypsin is coded by SERPINA1 and is a major inhibitor of PR3. It has been 
hypothesised that lower levels of alpha-1-antitrypsin, resulting from the presence 
of the Z and S alleles of SERPINA1, lead to increased levels of circulating PR3 and 
possibly trigger the synthesis of anti-PR3-ANCA.43 This hypothesis implies that 
the association of AAV with alpha-1-antitrypsin deficiency is restricted to PR3-
ANCA positive patients; however, in this meta-analysis, the association between 
the Z allele of SERPINA1 was present in both PR3-ANCA-positive and MPO-
ANCA-positive patients and in both c-ANCA-positive and p-ANCA-positive 
patients. Another hypothesis is that patients with AAV and alpha-1-antitrypsin 
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deficiency have a reduced ability to bind PR3 released by previously activated 
neutrophils, thus promoting PR3-mediated proteolytic vessel damage.
As noted, 20 genetic variants in the MHC region were associated with 
AAV in this meta-analysis. We, therefore, confirm an important role for the 
MHC region, but because of linkage disequilibrium, were unable to determine 
the nature of this association, that is, whether it represents single or multiple 
independent associations. Both GWAS showed that the SNP association signal in 
the MHC region was fully accounted for by HLA-DPB1, dramatically diminishing 
the associations of other SNPs in this region.15, 16 The results of our meta-analysis 
also support a role for other inflammatory processes in the pathogenesis of AAV, 
with the associations with CTLA-4 and PTPN22 suggesting a role for a threshold 
of activation or suppression of T cells.
The different subtypes generally grouped under the umbrella term AAV have 
profound differences in ANCA specificities3 and clinical outcomes.4 The results 
of this meta-analysis indicate that these different AAV subtypes also have distinct 
genetic backgrounds, as previously shown in a GWAS.15 Moreover, we found 
significant associations in opposite directions for the different AAV subgroups. 
Significant associations of the same SNP in opposite directions for different types 
of autoimmune diseases have been described before and could be indicative of 
different mechanisms of disease.44 Larger studies are required to investigate this 
issue further in AAV.
The subdivision of AAV based on ANCA serotype had the stronger genetic 
basis in our meta-analysis; in 76% of the genetic variants, subdivision based 
on ANCA serotype resulted in higher ORs than subdivision based on clinical 
diagnosis. The results of these analyses should, however, be interpreted with 
caution because of the limited number of studies included in some of the analyses 
and need to be validated in other studies. Although until now the concept of a 
single disease spectrum has resulted in similar treatment strategies in patients 
with AAV, our limited results suggest that syndrome-specific therapeutics based 
on ANCA serotype strategies may be considered.
Our study has some limitations. First, in some of our analyses, the number 
of subjects or studies was limited; this limitation was especially the case in the 
subgroup analyses. Second, publication bias is an issue of concern in all meta-
analyses. Authors might omit non-significant genetic associations and report only 
those associations that reach statistical significance. However, none of the tests 
performed to assess funnel plot asymmetry in this meta-analysis were significant. 
Furthermore, the studies included in this meta-analysis show heterogeneity 
with respect to clinical diagnosis, ANCA serotype, disease characteristics, 
ethnicity and study design. The clinical heterogeneity was accompanied by 
statistical heterogeneity for 16 of the 140 included genetic variants. However, 
there is no fully accepted statistical measure that precisely determines clinical 
heterogeneity.27 To account for heterogeneity, random-effects models were 
49
Chapter II - Genetic variants in ANCA-associated vasculitis: a meta-analysis
performed where possible.25 Nevertheless, estimates reported in this study 
should be interpreted with caution, especially when statistical heterogeneity 
was present or when a small number of studies and/or relatively small groups 
of participants were included. Finally, it should be kept in mind that the genetic 
associations identified do not imply causality. While they provide insight into 
pathogenicity and suggest the involvement of certain pathways, these may not 
represent therapeutic targets.
In summary, this meta-analysis identified 33 genetic variants, in or near 15 
genes, associated with AAV. Moreover, we showed genetic distinctions among 
the different AAV subtypes, supporting the concept that these subtypes may 
represent distinct autoimmune syndromes. These subtypes are most likely driven 
by ANCA serotype and not by clinical diagnosis.
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We investigated whether ENT involvement is associated with renal biopsy 
findings and renal function in patients with ANCA-associated vasculitis (AAV).
Methods 
Newly diagnosed AAV patients derived from three international, multicentre 
trials were included. To investigate an association between ENT involvement 
and estimated glomerular filtration rate (eGFR) at diagnosis and 5-year follow-
up, we performed multivariable regression analyses including clinical and 
histopathological parameters. To investigate whether our findings are specific 
to ENT involvement, we performed comparable analyses between eGFR and 
other early disease manifestations (arthralgia/arthritis, cutaneous and lung 
involvement).
Results 
One hundred and eighty-five of the 414 patients had ENT involvement. The mean 
presenting eGFR of patients with and without ENT involvement was 39.16 and 
23.88 ml/min/1.73m2, respectively (P<0.001). Mean eGFR increased by 6.76 
ml/min/1.73m2 with each added ENT symptom (P = 0.007). Patients with ENT 
involvement had less interstitial fibrosis and tubular atrophy and a prognostically 
more favourable histopathological class on renal biopsy examination. Multivariable 
regression analyses correcting for clinical and histopathological parameters 
showed that ENT involvement is associated with both baseline and 5-year follow-
up eGFR. There were no associations between baseline and 5-year follow-up 
eGFR and arthralgia/arthritis, cutaneous or lung involvement, suggesting that 
our findings are specific to ENT involvement.
Conclusion 
The presence of ENT involvement in AAV patients is associated with 
prognostically favourable renal biopsy findings and better renal function. These 
results indicate that there may be different phenotypes of AAV defined by ENT 
involvement.
57
Chapter III - Renal function and ENT involvement in ANCA-associated vasculitis
Introduction
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are 
the major clinical subtypes of ANCA-associated vasculitis (AAV)1. Establishing 
an early diagnosis of AAV is complicated by the diversity and lack of specificity 
of symptoms AAV patients present with, introducing both patient and doctor 
delay2. To what extent clinical outcome of AAV depends on early recognition of 
the disease is largely unknown; however, it seems likely that early diagnosis and 
treatment can prevent progressive organ damage, particularly the occurrence of 
end-stage renal disease (ESRD).
The presence of ENT involvement may be an early sign of AAV3. ENT 
involvement occurs in ~53% of AAV patients 4 and is reflected in symptoms 
such as hearing loss, otalgia, (bloody) rhinorrhoea, otorrhoea, sinusitis, nasal 
crusting and recurrent otitis media2. The presence of ENT involvement is closely 
associated with the presence of PR3-ANCA and is observed much less often in 
MPO-ANCA-positive patients.
Approximately 80% of AAV patients will develop renal involvement during 
their disease course5-7, which in a considerable proportion of patients will lead to 
ESRD and/or death8-10. Previously we found that patients with MPO-ANCA have 
more chronic lesions in their renal biopsy than patients with PR3-ANCA, which 
may reflect the association of a more smouldering disease with MPO-ANCA and 
a more active disease with PR3-ANCA3.
Recent data from a genome-wide association study (GWAS) indicate that 
within AAV, distinct subtypes may be recognized11. Positivity for either MPO-
ANCA or PR3-ANCA was found to be the most important indicator of these 
subtypes, supporting the hypothesis that PR3-ANCA vasculitis and MPO-ANCA 
vasculitis are distinct autoimmune syndromes.
The diagnosis of AAV is based on a combination of clinical symptoms, ANCA 
serology and histological findings. This combination of findings may also form 
the basis for a patient profile with respect to outcome and may be representative 
of certain distinct AAV phenotypes12, 13. One factor of interest is the presence or 
absence of ENT involvement, because the absence of ENT involvement has been 
shown to increase mortality risk in AAV patients14-19. In this study we focused 
on ENT involvement in AAV patients in relation to renal biopsy findings and 
renal outcome. In addition, we performed a subgroup analysis based on ANCA 
serotype, because of the well-known association of ENT disease and PR3-ANCA. 
We hypothesized that ENT involvement in AAV is associated with fewer chronic 
lesions in the renal biopsy and better renal outcome.
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Methods
Study population and clinical parameters
Patients were recruited from 62 hospitals located in 15 countries. All patients 
were enrolled in three international, prospective multicentre trials conducted by 
the European Vasculitis Society (EUVAS): CYCAZAREM (Cyclophosphamide 
Versus Azathioprine During Remission For Generalised Vasculitis), CYCLOPS 
(Daily Oral Versus Pulse Cyclophosphamide During The Induction Phase For 
Generalised Vasculitis) and MEPEX (Plasma Exchange Versus Methylprednisolone 
For Severe Renal Vasculitis)20-22. Inclusion and exclusion criteria for all trials 
are described elsewhere20-22. Local research ethics committees approved the 
studies and all patients provided informed consent. All trials were performed in 
accordance with the Declaration of Helsinki. Disease definitions were adopted 
from the 1994 Chapel Hill Consensus Conference23and previous European Union 
studies24, 25. All patients had been newly diagnosed as having GPA or MPA as 
determined by local physicians. Only patients with generalized AAV and available 
BVAS data were included in this study26. The four-variable Modification of Diet 
in Renal Disease was used to determine the estimated glomerular filtration rate 
(eGFR) in all patients, including the patients with ESRD27.
ENT involvement was assessed at trial entry and was defined as present 
if patients had at least one of the ENT items scored using the BVAS. These 
items included nasal obstruction, bloody nasal discharge, nasal crusts, sinus 
involvement, conductive hearing loss, sensorineural hearing loss, hoarseness/
stridor, granulomatous sinusitis and subglottic inflammation26. When ENT 
involvement was suspected, this was confirmed by local ENT specialists.
To assess whether associations with renal function are related to ENT 
involvement or are confounded by reduced diagnostic delay in patients with ENT 
symptoms, we did comparative analyses investigating associations between eGFR 
and other organ manifestations that are likely to reduce diagnostic delay in a 
similar fashion, specifically looking at cutaneous involvement, lung involvement 
and arthralgia/arthritis as scored by the BVAS. Cutaneous involvement included 
cutaneous infarcts, purpura, other skin vasculitis, ulcers, gangrene and multidigit 
gangrene26. Lung involvement included persistent cough, dyspnoea or wheeze, 
haemoptysis/haemorrhage, massive haemoptysis, respiratory failure and nodules 
or cavities, pleural effusion/pleurosity or infiltrate on chest radiology26.
Histopathological parameters
Paraffin sections of diagnostic renal biopsies stained with silver, periodic acid-
Schiff, haematoxylin and eosin and trichrome were examined. Sections were 
reviewed by two of five participating pathologists (I.M.B., F.F., L.H.N., R.W. or 
J.A.B.). Both pathologists, blinded to patient data and the other observer’s results, 
scored the biopsies separately and according to a previously standardized protocol 
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and the histopathological classification of ANCA-associated glomerulonephritis 
(AAGN)28-30. Discrepancies between observers were resolved during central 
reviews to achieve consensus for each biopsy.
A predefined set of histopathological parameters, including interstitial fibrosis 
and tubular atrophy (IFTA), interstitial infiltrate, tubulitis and histopathological 
class, were included in multivariable analyses. In analyses including the 
histopathological classification, only biopsies containing a minimum of seven 
whole glomeruli were included.
Statistical analysis
Student’s t-test was used to investigate an association between baseline and 5-year 
follow-up eGFR and overall ENT involvement. Student’s t-test was also used 
to investigate an association between baseline eGFR and individual BVAS ENT 
subitems. A chi-squared test was used to investigate the association between 
ANCA subtype and the distribution of ENT symptoms. A chi-squared test 
for trend (linear-by-linear association) was used to investigate the association 
between histological parameters and ENT involvement. Linear regression analysis 
was used to explore the relationship between the number of ENT symptoms and 
eGFR at presentation. A quadratic term analysis was not significant, therefore 
a linear model was considered appropriate for this analysis. Seven patients were 
positive for five ENT symptoms, but because including these patients violated the 
linearity of the model, these patients were excluded from the analysis.
Correlations of ENT involvement, age, PR3-ANCA, tubulitis, interstitial 
infiltrate, IFTA and histopathological class according to the AAGN classification 
with baseline and 5-year follow-up eGFR were assessed using Pearson’s or 
Spearman’s correlation test as appropriate. Along with ENT involvement, the 
following entry parameters were selected for inclusion in the multivariable 
model investigating baseline eGFR: age, PR3-ANCA, IFTA, tubulitis, interstitial 
infiltrate and histopathological class according to the AAGN classification. 
ENT involvement, age, PR3-ANCA, IFTA, tubulitis, interstitial infiltrate and 
protocolized treatment received during the trial period were included in a model 
investigating 5-year follow-up eGFR. Histopathological class was not included 
in this model, as including this parameter strongly reduced the number of 
patients that could be included in the analysis. Analysis of covariance (ANCOVA) 
investigating 5-year follow-up eGFR was performed by including baseline eGFR 
in the model. In prespecified sensitivity analyses, the same models were used 
to investigate the effect of ENT involvement on baseline and 5-year follow-
up eGFR in patients only positive for PR3-ANCA. Multicollinearity statistics 
demonstrated no multicollinearity in the multivariable regression analyses 
performed, indicating that it was legitimate to perform these analyses. We did not 
include diagnosis (GPA or MPA) in the analyses, as diagnosis is often dependent 
on ENT involvement (patients with ENT involvement are often diagnosed as GPA 
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and patients without ENT involvement are often diagnosed as MPA). Correcting 
for diagnosis would mask the effect of ENT involvement.
Since renal biopsies were not available for all patients, including the predefined 
histopathological parameters limited the number of patients included in the 
analysis. This was particularly true for histopathological class since biopsies 
needed to contain at least seven whole glomeruli. To be able to include all 
patients we therefore created three models. The first model included only 
clinical data: ENT involvement, age and PR3-ANCA. In the second model we 
added the following histopathological parameters: tubulitis, interstitial infiltrate 
and IFTA. The third model included all of the above parameters as well as the 
histopathological class.
To investigate whether possible associations with renal function are specific 
to ENT involvement and not confounded by reduced diagnostic delay in patients 
with ENT involvement, we performed comparable analyses between baseline 
and 5-year follow-up eGFR and other early disease manifestations - specifically 
arthralgia/ arthritis, cutaneous involvement and lung involvement. 
A P-value of <0.05 was considered significant. All analyses were performed 
using SPSS version 20.0 (IBM, Armonk, NY, USA).
Results
Patients
A total of 414 patients with generalized AAV recruited from the CYCAZAREM20, 
CYCLOPS22 and MEPEX21 trials were included in this study. All 149 patients 
from the CYCLOPS trial were included. From the CYCAZAREM and MEPEX 
trials, 149 of the 155 and 116 of the 137 patients were included, respectively. 
Exclusion of 27 patients was based on incomplete data about the presence or 
absence of ENT involvement. Diagnostic renal biopsies were obtained from 199 
patients, of which 152 contained a minimum of seven whole glomeruli. Two 
patients did not have renal involvement at trial entry. Both patients were included 
in the CYCAZAREM trial because of other disease manifestations that were 
considered to be life-threatening. Baseline eGFR of these patients was 102 and 
118 ml/min/1.73m2.
ENT involvement
Of the 414 patients included in the study, 185 (45%) presented with ENT 
involvement. Detailed clinical data at baseline of patients with and without 
ENT involvement are provided in Table 1. ENT involvement was associated with 
higher eGFR, younger age, diagnosis of GPA and PR3-ANCA positivity. ENT 
symptoms as scored using the BVAS are outlined in supplementary Table S1. Nasal 
obstruction, bloody nasal discharge and nasal crusting were the most common 
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symptoms. In patients with ENT involvement, the distribution of symptoms 
was similar in PR3-ANCAand MPO-ANCA-positive patients (supplementary 
Table S2).






eGFR, mL/min/1.73 m2 (±SD) 39.16 (±33.11) 23.88 (±20.05) <0.001
Gender, male / female 111 / 74 122 / 107 0.17
Age, years (SD) 56.49 (14.90) 60.89 (12.87) 0.001
Diagnosis, n (%)
   Granulomatosis with polyangiitis







   PR3-ANCA
   MPO-ANCA
   Double positive











   CYCAZAREM
   CYCLOPS








ANCA-serotype data was available for 412 of the 414 patients. Patients with and without ENT involve-
ment are referred to as ENT positive and ENT negative, respectively. ENT, ear-, nose-, and throat; 
eGFR, estimated glomerular filtration rate; ANCA, anti-neutrophil cytoplasm antibody; PR3, protein-
ase 3; MPO, myeloperoxidase.
ENT involvement and baseline eGFR
The mean baseline eGFR of patients with and without ENT involvement was 
39.16 (S.D. 33.11) and 23.88 (S.D. 20.05) ml/min/1.73m2, respectively. The 
presence of overall ENT involvement was associated with higher eGFR [P<0.001 
(95% CI 10.09, 20.46)]. Regarding specific ENT symptoms, the presence of 
nasal obstruction, bloody nasal discharge, nasal crusting, granulomatous sinusitis 
and conductive hearing loss was significantly associated with higher eGFR 
(supplementary Table S3). Moreover, the more ENT symptoms a patient had, 
the higher the eGFR was at presentation; average eGFR increased by 6.76 (95% 
CI 1.86-11.67) ml/min/1.73m2 with each additional ENT symptom (P = 0.007; 
Fig. 1).
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Figure 1. Increasing numbers of ENT symptoms are associated with increasing eGFR at 
diagnosis.
On average, eGFR increased 6.76 (95% CI 1.86 – 11.67) mL/min/1.73 m2 with each additional 
ENT symptom (p=0.007). Data are presented as mean ± SEM. ENT, ear-, nose-, and throat; 
eGFR, estimated glomerular filtration rate.
ENT involvement and renal histology
The absence of IFTA in the renal biopsy was associated with ENT involvement 
(P<0.001; Table 2). Seventeen patients (20%) with ENT involvement had no 
IFTA in their renal biopsy, compared with four patients (4%) without ENT 
involvement. Nineteen patients (23%) with ENT involvement had severe IFTA in 
their renal biopsy, compared with 45 patients (39%) without ENT involvement. 
Furthermore, there was an association between histopathological class in the 
AAGN classification30 and ENT involvement (P = 0.04; Table 2). Nineteen 
patients (30%) with ENT involvement had a focal class renal biopsy, compared 
with 16 patients (18%) without ENT involvement. Six patients (9%) with ENT 
involvement had a sclerotic class renal biopsy, compared with 13 patients (15%) 
without ENT involvement. Residuals analysis showed that the focal and sclerotic 
classes contributed most to the chi-square statistic.
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   None
   Focal interstitial fibrosis / small foci of tubular atrophy
   Diffuse interstitial fibrosis / extensive foci of tubular atrophy
< 0.001
17 (20) 4 (4)
48 (57) 66 (57)
19 (23) 45 (39)
Histopathological classification of AAGN*, n (%)
   Focal
   Crescentic
   Mixed
   Sclerotic
0.04
19 (30) 16 (18)
32 (50) 42 (48)
7 (11) 17 (19)
6 (9) 13 (15)
Interstitial infiltrates**, n (%)
   None
   Mild
   Moderate
   Severe
0.18
9 (11) 4 (3)
32 (39) 48 (42)
32 (39) 45 (39)
9 (11) 18 (16)
Tubulitis, n (%)
   Absent
   Present
29 (34) 36 (31) 0.63
55 (66) 79 (69)
*Only biopsies with a minimum of seven whole glomeruli were included in this analysis (n=152). 
**Data available for 197 patients. Renal biopsy specimens were available for 199 patients. Patients 
with and without ENT involvement are referred to as ENT positive and ENT negative, respectively. 
ENT, ear-, nose-, and throat; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil 
cytoplasm antibody-associated glomerulonephritis.
ENT involvement is associated with higher eGFR independently of 
PR3-ANCA
Univariate analyses showed a correlation between baseline eGFR and ENT 
involvement, age, PR3-ANCA, tubulitis, interstitial infiltrate, IFTA and 
histopathological class (supplementary Table S4). ENT involvement was 
independently associated with higher baseline renal function in all three 
multivariable linear regression models (Table 3; supplementary Table S5). In 
addition to ENT involvement, age, tubulitis, interstitial infiltrate, IFTA and 
histopathological class were independently associated with eGFR. In this model 
including ENT involvement, PR3-ANCA is not associated with eGFR. To 
investigate whether a strong association between ENT involvement and PR3-
ANCA is the reason why PR3-ANCA is not associated with eGFR in this model, 
we conducted the multivariable model excluding ENT involvement. In this 
analysis, PR3-ANCA was not associated with eGFR (data not shown). Moreover, 
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we also performed a stratified analysis in which we started with ENT disease 
and then investigated the effect of ANCA specificity on eGFR in patients both 
with and without ENT involvement. In these analyses, PR3-ANCA was again 
not associated with eGFR (data not shown). Both findings contradict that an 
association between ENT involvement and PR3-ANCA is the reason why PR3-
ANCA is not significantly associated with eGFR.
A prespecified subgroup analysis that included only PR3-ANCA-positive 
patients revealed that ENT involvement was also independently associated with 
baseline eGFR in this subgroup of patients. In addition to ENT involvement, age, 
tubulitis, interstitial infiltrate and histopathological class were independently 
associated with baseline eGFR (Table 3).
ENT involvement is associated with higher eGFR independently of GPA 
diagnosis
Because of the strong association between ENT involvement and GPA diagnosis, 
it was not possible to include both parameters in the same multivariable linear 
regression model. To investigate the possibility of ENT involvement being a 
surrogate for the GPA phenotype instead of being independently associated with 
eGFR, we therefore conducted the multivariable regression analysis including 
only GPA patients. ENT involvement was independently associated with 
baseline eGFR in this analysis (supplementary Table S6), indicating that ENT 
involvement is not a surrogate for the GPA phenotype but is associated with eGFR 
independently of GPA diagnosis. In addition to ENT involvement, age, interstitial 
infiltrate, IFTA and histopathological class were independently associated with 
eGFR. PR3-ANCA was not associated with eGFR.
ENT involvement and renal function at 5-year follow-up
Data on renal function at 5-year follow-up were available for 81 and 72 patients 
with and without ENT involvement, respectively. Univariate analyses showed 
a correlation between 5-year follow-up eGFR and ENT involvement, age, 
interstitial infiltrate, IFTA and histopathological class (supplementary Table 
S4). As shown in Fig. 2, eGFR increased in patients both with and without 
ENT involvement during follow-up. Patients with ENT involvement had a better 
eGFR at 5-year follow-up compared with patients without ENT involvement. 
Mean eGFR at 5-year follow-up was 54.58 (S.D. 25.43) and 44.02 (S.D. 20.01) 
ml/min/1.73m2 in patients with and without ENT involvement, respectively (P 
= 0.005). Multivariate analysis showed that ENT involvement, age and IFTA 
were independently associated with eGFR at 5-year follow-up (Table 3). PR3-
ANCA was not associated with 5-year follow-up eGFR. When adding baseline 
eGFR to the multivariate model, ENT involvement was no longer associated 
with 5-year follow-up eGFR (supplementary Table S7). This finding implies that 
ENT involvement is not associated with an accelerated increase in eGFR, but that 
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patients with ENT involvement start with a higher presenting eGFR and preserve 
this advantage during the 5-year follow-up. A prespecified subgroup analysis 
including only PR3-ANCA-positive patients revealed that ENT involvement is 
also associated with 5-year follow-up eGFR in this subgroup of patients (Table 
3). Also in this subgroup of PR3-ANCA-positive patients, ENT involvement is 
no longer associated with 5-year follow-up eGFR when adding baseline eGFR to 
the model (supplementary Table S7).
Figure 2. Patients with ENT involvement have significantly better eGFR at diagnosis and 
5-year follow-up.
Data are presented as mean ± SEM. ENT, ear-, nose-, and throat; eGFR, estimated glomerular 
filtration rate.
Cutaneous involvement, arthralgia/arthritis and lung involvement are not 
associated with baseline and 5-year follow-up eGFR
To investigate whether the higher eGFR in patients with ENT involvement is 
specific for ENT involvement or is attributable to less diagnostic delay in these 
patients, we analysed the relationship between eGFR and cutaneous involvement, 
arthralgia/arthritis and lung involvement, as these symptoms are likewise 
expected to reduce diagnostic delay. Of the 414 included patients, 98 (24%) 
had cutaneous involvement, 162 (39%) had arthralgia/arthritis and 207 (50%) 
had lung involvement. Multivariable linear regression analyses demonstrated 
no association between cutaneous involvement, arthralgia/arthritis or lung 
involvement and baseline eGFR (Table 4; supplementary Table S8). In all three 
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models, age, tubulitis, interstitial infiltrate, IFTA and histopathological class were 
associated with eGFR. Multivariable linear regression analyses also demonstrated 
no association between cutaneous involvement, lung involvement or arthralgia/
arthritis and eGFR at 5-year follow-up (supplementary Table S9).
Discussion
Our study demonstrates that AAV patients with ENT involvement have a 
higher eGFR at diagnosis and 5-year follow-up than AAV patients without 
ENT involvement. Specifically, nasal obstruction, bloody nasal discharge, nasal 
crusting, granulomatous sinusitis and conductive hearing loss were associated 
with higher eGFR. Moreover, the number of ENT symptoms was related to renal 
function, with eGFR increasing with each added ENT symptom. Patients with 
ENT involvement had less IFTA and less chronic damage in their renal biopsies. 
We also found that renal histology of AAV patients with ENT involvement had 
features associated with better renal prognosis compared with renal histology 
of AAV patients without ENT involvement. In the multivariable analysis, 
PR3-ANCA was no longer associated with eGFR when including histological 
parameters in the model. This finding indicates an association between ANCA 
serotype and renal histological findings, as previously described3. Interestingly, 
we found that ENT involvement is associated with renal function independently 
of GPA diagnosis and PR3-ANCA.
Our findings can be explained by two possible mechanisms. It is possible that 
through ENT involvement, patients are diagnosed earlier with AAV. Therefore, 
in patients with ENT involvement, renal function may still be relatively preserved 
at presentation. Alternatively, the presence or absence of ENT involvement may 
represent different phenotypes of AAV. We will discuss a number of features that 
are either in favour or against these two notions.
Clinically overt ENT symptoms may lead to an earlier diagnosis of AAV by 
reducing patient and possibly doctor delay, as previously proposed3. This may 
explain the relatively preserved renal function in patients with ENT involvement. 
However, in our study, manifestations of the skin, lung and arthralgia/arthritis 
that would supposedly reduce patient and/or doctor delay were not associated 
with baseline and 5-year follow-up eGFR. Generalized symptoms (such as fever) 
have been shown to occur earlier in the disease than manifestations of the skin, 
lung and arthralgia/arthritis31. However, these symptoms were not associated 
with a higher eGFR in this cohort (data not shown). This lack of distinctiveness 
is probably due to the large proportion of patients with general symptoms at 
diagnosis (91% in our cohort).
Even though a number of studies have investigated diagnostic delay in AAV31-33, 
to our knowledge, very few studies have investigated diagnostic delay for specific 
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organ involvement. Recently Poulton et al.34 showed that AAV patients with 
ENT involvement were more likely to experience a delay in diagnosis because 
both physicians and patients focused on the more common causes of the ENT 
symptoms instead of regarding them as signs of vasculitis. Even though there 
was a risk of recall bias in this study, the authors tried to minimize this by 
interviewing patients within 5 years after diagnosis. Bligny et al.18 showed that 
patients with ENT involvement have better survival than patients without ENT 
involvement. They argued that the better prognosis was likely related to different 
pathogenic routes and not to earlier diagnosis and treatment, as 13 of the 15 
patients without ENT involvement had lung involvement, which can lead to 
earlier diagnosis. Interestingly, in AAV patients with ENT involvement, ENT 
symptoms mostly start within 12 months after diagnosis35. Considering these 
findings, the argument that ENT involvement is an easily recognizable sign of 
vasculitis that can lead to early recognition and better eGFR does not appear to 
hold.
A recently published GWAS provided support for the concept that PR3-ANCA 
vasculitis and MPO-ANCA vasculitis are distinct autoimmune syndromes11. 
Single nucleotide polymorphisms were shown to be associated more strongly with 
PR3-ANCA and MPO-ANCA than with the clinical syndromes MPA and GPA. 
In general, AAV patients with ENT involvement are likely to be PR3-ANCA 
positive and AAV patients without ENT involvement are likely to be MPO-ANCA 
positive2. In our multivariable analyses, ENT involvement overruled ANCA 
subtype in relation to the preservation of baseline and 5-year follow-up renal 
function, and in a prespecified subgroup analysis consisting of only PR3-ANCA-
positive patients, ENT involvement was still associated with higher baseline and 
5-year follow-up eGFR. Both findings indicate that ENT involvement is associated 
with a favourable renal profile independent of ANCA serotype and may be an 
important factor in the determination of different phenotypes of AAV.
One limitation of our study is that no data about the time from onset of 
symptoms to diagnosis of AAV were available. However, low reliability of a 
patient’s interpretation of symptoms that may or may not have been attributable 
to AAV makes it hard and perhaps not desirable to use these data in an analysis. 
One strength of our study is the large number of patients we were able to include 
due to a large European collaboration. Moreover, renal biopsies were available 
for a large proportion of patients. Because our patients were recruited from 
three randomized controlled trials, clinical data were accurately documented 
prospectively.
Our study demonstrates that ENT involvement itself is an important clinical 
parameter of AAV, first because it is closely related to renal histology and 
outcome, and second because it may be a determinant of different phenotypes 
in AAV. Taking the findings of the GWAS into consideration, it is possible that 
within the subdivision of PR3-ANCA vasculitis and MPO-ANCA vasculitis, 
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AAV patients can be further categorized as ENT positive or ENT negative. Just 
as in SLE, where presenting symptoms in relation to clinical outcome have been 
compared to a hand of cards, in AAV, PR3-ANCA positivity together with the 
presence of ENT involvement may be representative of a relatively good hand 
of cards. Regarding future diagnostic and classification criteria for AAV, we 
suggest that the presence or absence of ENT should be taken into account as an 
important clinical parameter.
Key messages
-- ENT involvement in ANCA-associated vasculitis patients is associated with 
higher baseline and 5-year follow-up estimated glomerular filtration rate.
-- ENT involvement in ANCA-associated vasculitis patients is associated with 
prognostically favourable findings on renal biopsy examination.
-- The presence or absence of ENT involvement may define different phenotypes 
of ANCA-associated vasculitis.
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Abstract
Purpose of review 
This review discusses the findings of studies validating the histopathological 
classification of antineutrophil cytoplasmic antibody (ANCA)-associated 
glomerulonephritis, which was devised in 2010 by an international working group 
of pathologists and nephrologists in collaboration with the European Vasculitis 
Society.
Recent findings 
So far, eight studies have validated the histopathological classification of ANCA-
associated glomerulonephritis. The studies came from Japan, China, Australia, the 
United States, the Netherlands, and Turkey. These validation studies confirmed 
that the histopathological classification of ANCA-associated glomerulonephritis 
is of predictive value for renal outcome. This was especially the case for patients 
with either a focal or sclerotic-class renal biopsy, whereas the crescentic and 
mixed classes showed different results in the validation studies. These differences 
could be due to differences in patient populations or therapy, inter-rater reliability 
and lack of inclusion of tubulointerstitial lesions in the classification. Therapy is 
known to influence renal outcome, but due to the retrospective design of the 
to-date performed validation studies, this parameter could not be fully accounted 
for in these validation studies. Inter-rater reliability among three histopathologists 
was investigated in one study and was moderate.
Summary 
The histopathological classification of ANCA-associated glomerulonephritis 
predicts renal outcome during follow-up, especially in patients with a focal or 
sclerotic-class renal biopsy. A large international validation study is currently 
being performed.
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Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic 
autoimmune disease affecting small and middle-sized blood vessels1•. Microscopic 
polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are the major 
clinical syndromes of ANCA-associated vasculitis, whereas renal limited vasculitis 
(RLV) and eosinophilic GPA (EGPA) occur less frequently2. Approximately 
90% of ANCA-associated vasculitis patients have circulating antibodies against 
proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA. These antibodies 
probably play a pathogenic role in the disease process and have recently been 
shown to represent genetically distinct subsets of patients with ANCA-associated 
vasculitis3••, 4•, 5••, 6, 7••. Renal involvement is a common and severe feature of 
ANCA-associated vasculitis, leading to end-stage renal failure (ESRF) and even 
death in a considerable number of patients8-10.
ANCA-associated glomerulonephritis may show a variety of lesions, of which 
crescentic and focal necrotizing glomerulonephritis are the most prominent11. 
Clinicopathologic studies have demonstrated that the presence or absence of 
specific pathologic lesions in the renal biopsy is of important prognostic value 
for renal outcome, independently of baseline estimated glomerular filtration 
rate (eGFR). A high percentage of normal glomeruli is the strongest histological 
predictor of a favorable renal outcome; a high percentage of globally sclerotic 
glomeruli is associated with a worse renal outcome12–14. The percentage of cellular 
crescents is associated with recovery of renal function, irrespective of baseline 
eGFR13. Tubulointerstitial lesions, especially tubular atrophy, are associated with 
a worse renal outcome12–14.
In 2010, the histopathological classification of ANCA-associated 
glomerulonephritis was devised by an international working group of 
pathologists and nephrologists in collaboration with the European Vasculitis 
Society (EUVAS)15. This review discusses the findings of studies validating the 
histopathological classification of ANCA-associated glomerulonephritis.
The histopathological classification of antineutrophil 
cytoplasmic antibody associated glomerulonephritis
The histopathological classification of ANCA-associated glomerulonephritis 
is built around glomerular pathology and encompasses four classes: focal, 
crescentic, mixed, and sclerotic-class renal biopsies15. The focal class is defined 
by the predominance of normal glomeruli (≥50%), the crescentic class by the 
predominance of cellular crescentic glomeruli (≥50%), and the sclerotic class 
by the predominance of globally sclerotic glomeruli (≥50%). The mixed class 
represents a heterogeneous glomerular phenotype in which no glomerular 
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feature predominates. A flowchart through which renal biopsies can be evaluated 
according to this classification system is depicted in Fig. 1. Tubulointerstitial 
lesions were not included in the classification system because these lesions did 
not improve the predictive value of the classification system in a first validation 
study incorporated in the publication by Berden et al.15, and only increased its 
complexity.
Figure 1. Classification system flowchart
Biopsies are scored for glomerular lesions in the following order: globally sclerotic glomeruli, 
normal glomeruli and cellular crescentic glomeruli. Biopsies that do not fit into one of these 
classes will automatically be included in the mixed class. Reprinted, with permission from the 
Journal of the American Society of Nephrology.15
Baseline characteristics of the 100 patients of European descent included in the 
validation study incorporated in the publication by Berden et al. are depicted in 
Table 1. The phenotypical order of focal, crescentic, mixed, and sclerotic-class 
renal biopsies corresponded to the eGFR at baseline and at 1 and 5-year follow-up 
(Table 2). In addition, the histopathological classification and the baseline eGFR 
were the only independent predictors for eGFR at both 1 and 5 year follow-up 
in a multivariable analysis taking patient age, treatment, baseline eGFR, and 
the histopathological classification of ANCA-associated glomerulonephritis 
into account. The percentage of patients who developed ESRF increased with 
ascending class.
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Validation of the histopathological classification 
of antineutrophil cytoplasmic antibody-associated 
glomerulonephritis
So far, eight studies from Japan, China, Australia, the United States, the 
Netherlands, and Turkey have validated the histopathological classification of 
ANCA-associated glomerulonephritis16–23. Five of these studies included more 
than 100 patients16,19–21,23. The distributions of diagnoses and ANCA serotype 
varied and are depicted in Table 1. We will review these validation studies below.
Validation of the classification system in the Asian population
Four validation studies came from Asia, three of which were from Japan and one 
from China16–19. All these studies had a predominance of MPO-ANCA-positive 
patients. The diagnosis of GPA or MPA was equally distributed in two studies17,19. 
Two other studies consisted of 95 and 100% of MPA patients, respectively16,18. 
At baseline, eGFR levels in all four studies showed a similar distribution over the 
four classes, with the best eGFR levels for patients with a renal biopsy classified 
as focal class and worst levels for patients with a renal biopsy classified as sclerotic 
class. In all these studies, patients with renal biopsies classified as crescentic and 
mixed class showed intermediate eGFR levels. The outcome with respect to 
renal function during follow-up in relation to the histopathological class varied 
somewhat amongst the studies as discussed below in detail. This may have been 
influenced by the different end-points of the studies.
Iwakiri et al.16 reported a significant relationship between the four 
histopathological classes and eGFR at baseline and 1-year follow-up, which 
was greatly determined by a relatively good eGFR in patients with a focal-class 
renal biopsy (Tables 1 and 2). A renal survival curve over 120 months showed a 
distribution pattern similar to that of the validation study in the publication by 
Berden et al., with patients with focal and sclerotic-class renal biopsies having the 
best and worst renal survival, respectively. There was no significant difference 
in the eGFR of patients with renal biopsies classified as crescentic or mixed 
class. The authors comment that discrimination between these two classes was 
hindered because, in their cohort, both the proportion of normal and sclerotic 
glomeruli was higher in the mixed class than in the crescentic-class renal biopsies.
Togashi et al.17 reported that the phenotypical order of focal, crescentic, mixed 
and sclerotic class corresponded to the severity of renal function impairment at 
baseline and 1 and 5-year follow-up in a cohort of Japanese MPO-ANCA-positive 
patients (Tables 1 and 2). However, at all time points, the eGFR of patients with 
crescentic and mixed-class renal biopsies was similar. Overall, renal survival 
was relatively good with only five of the 54 patients developing ESRF during the 
5-year follow-up. Of the patients developing ESRF, two patients had a crescentic 
and three patients had a sclerotic-class renal biopsy.
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Muso et al.18 focused on baseline eGFR and the development of ESRF in a 
Japanese cohort (Tables 1 and 2). The phenotypical order of focal, crescentic, 
mixed, and sclerotic-class renal biopsies corresponded to the order of severity 
of renal function impairment at baseline. At 5-year follow-up, the risk of 
ESRF development was not increased in patients with focal and mixed-class 
renal biopsies. Patients with a renal biopsy classified as sclerotic had a highly 
increased risk to develop ESRF. Patients with focal, mixed and crescentic-class 
renal biopsies had similar renal survival curves, particularly after 10 months of 
follow-up.
Chang et al.19 validated the histopathological classification of ANCA-associated 
glomerulonephritis in a Chinese cohort (Table 1). The phenotypical order of focal, 
crescentic, mixed, and sclerotic-class renal biopsies corresponded to the order 
of severity of renal function impairment at baseline (Table 2). Renal survival 
was best for patients with a focal-class renal biopsy and worst for patients with a 
sclerotic-class renal biopsy. Comparing patients with a mixed and crescentic-class 
renal biopsy, 5-year renal survival was 72 and 60%, respectively. The authors 
stated that the patients with a mixed-class ANCA-associated glomerulonephritis 
in this cohort had relatively milder lesions than patients with a mixed-class 
ANCA-associated glomerulonephritis in the Berden et al. cohort, with more 
normal glomeruli, fewer sclerosed glomeruli and fewer glomeruli with fibrous 
crescents. In addition, tubulointerstitial lesions were not independent predictors 
of ESRF in a multivariable analysis taking the histopathological classification of 
ANCA-associated glomerulonephritis into account.
Summarizing the data from the Asian studies, we conclude that all studies 
show a clear tendency for eGFR at baseline being related to the phenotypical 
order of focal, crescentic, mixed, and sclerotic-class renal biopsies. Patients 
with a focal-class renal biopsy had the best eGFRs and patients with a sclerotic-
class renal biopsy had the worst eGFRs. Follow-up data varied in time periods 
and whether ESRF or eGFR was chosen as the end-point. It may be tentatively 
concluded that there was no clear-cut difference in the outcome of patients 
with crescentic and mixed-class renal biopsies. In some studies, there was a 
tendency for patients in the mixed-class to have a slightly better renal outcome 
than patients in the crescentic class. The Asian studies differed from the studies 
in the Caucasian population which we discuss below, in terms of ANCA-serotype 
distribution, diagnosis distribution, and a patient population from the Asian race.
Validation of the classification system in the Caucasian population
The largest validation study reported so far came from a Dutch cohort consisting 
of 164 patients with an equal distribution of PR3-ANCA and MPO-ANCA 
patients (Table 1)20. There was only one patient with a renal biopsy classified as 
being in the sclerotic class, therefore this class could not be part of the analysis. 
The histopathological classification of ANCA-associated glomerulonephritis 
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predicted eGFR at both 1 and 2-year follow-up (Table 2). At both time points, 
eGFR differed significantly between patients with a focal and crescentic-class 
renal biopsy, and between patients with a focal and mixed-class renal biopsy, but 
not between patients with a crescentic and mixed-class renal biopsy. In addition, 
5-year renal survival was significantly higher in patients with a focal-class renal 
biopsy than in patients with a crescentic or mixed-class renal biopsy, whereas 
renal survival in these two latter groups was similar. Subdividing the crescentic 
and mixed-class renal biopsies on the basis of more or less than 25% normal 
glomeruli in the renal biopsy showed that patients with more than 25% normal 
glomeruli had a significantly better renal survival.
A recently published study by Ford et al.21 is the only study so far which 
investigated the inter-rater reliability of the classification system, showing 
variability among three histopathologists scoring 145 renal biopsies (k=0.46). 
Good agreement was found for classifying the sclerotic class (k=0.70), but only 
moderate agreement for classifying the focal, crescentic, and mixed classes 
(k=0.47, k=0.23, and k=0.51, respectively). There was no significant difference 
in ANCA subtype between patients in the different classification groups (Table 
2). Most tubulointerstitial lesions were found in the sclerotic class. Renal function 
at presentation was best in patients with a focal or mixed-class renal biopsy, 
and worst in patients with a sclerotic or crescentic-class renal biopsy. At 1-year 
follow-up, eGFR declined in the phenotypical order of focal, crescentic, mixed, 
and sclerotic-class renal biopsies. Patients with a sclerotic-class renal biopsy 
had a significantly increased risk of ESRF development or death compared with 
patients with a focal, crescentic, or mixed-class renal biopsy. When taking ESRF 
development or death as outcome, there was no difference in outcome between 
patients with focal, crescentic or mixed-class renal biopsies. A drawback of this 
study is that no minimum amount of glomeruli was required in the renal biopsies.
Ellis et al.22 performed a validation study in 76 patients from the United 
States. Diagnosis and ANCA serotype were equally distributed in this cohort 
(Table 1). Renal function at baseline was best in patients with a renal biopsy 
classified as focal and did not differ between patients with renal biopsies classified 
as crescentic, mixed, or sclerotic (Table 2). At both 1 and 2-year follow-up, 
renal function was best in patients with a focal-class renal biopsy, worst in 
patients with a sclerotic-class renal biopsy, and intermediate in patients with a 
crescentic or mixedclass renal biopsy. In contrast to the study by Ford et al., this 
study showed that patients in the crescentic class were significantly more often 
c-ANCA-positive with a GPA phenotype. Renal survival at 1-year follow-up did 
not differ significantly between the classes, but the histopathological class was an 
independent predictor of eGFR at 1-year follow-up in linear regression analyses.
Unlu et al.23 reported a study in Turkish patients that was not primarily 
focused on the validation of the histopathological classification for ANCA-
associated glomerulonephritis, but evaluated the classification system with dialysis 
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as outcome in a subanalysis (Table 1). The classification system did predict for 
dialyses requirement in the log-rank test, but not in the Cox regression model 
(Table 2). Similar to the study performed by Ford et al., in this study, no minimum 
amount of glomeruli was required in the renal biopsies.
Points of consideration and future perspectives
The studies validating the histopathological classification of ANCA-associated 
glomerulonephritis show that the classification system predicts clinical outcome, 
in particular, in patients with either a focal or sclerotic-class renal biopsy. There 
are conflicting outcomes with respect to the crescentic and the mixed-class 
renal biopsies. In a number of studies, the outcome of patients with a crescentic-
class renal biopsy is similar to that of patients with a mixed-class renal biopsy. 
In other studies, patients with focal and crescentic-class renal biopsies seem to 
have similar outcomes. There is some evidence that the proportion of normal 
glomeruli is an important determinator of outcome and is taken as a parameter 
to subcategorize the classes. Whether additionally, the variation of study results 
is due to differences in patient populations, moderate inter-rater reliability, or 
other factors is currently unknown. Only one study investigated inter-rater 
reliability, showing moderate variability among histopathologists. In particular, 
the mixed-class renal biopsies may be ‘suffering’ from an ‘identity crisis’, as 
exemplified in Fig. 2. This figure shows that biopsies in this class may indeed 
show mixed findings as their denominator suggests, in which either an acute 
or chronic phenotype predominated. This may have important consequences 
for renal outcome if different phenotypes prevail in different studies. Renal 
outcome is also greatly influenced by the therapy a patient receives. However, 
due to the retrospective design of all to-date performed validation studies, it 
was not possible to fully account for this parameter in these studies. Another 
important issue is the influence of interstitial lesions on outcome, in addition to 
the classes which are primarily based on glomerular lesions. In a recent review by 
Haas et al.24, it was questioned whether the lack of inclusion of tubulointerstitial 
changes would affect the value of the classification system. It was also questioned 
whether the classification system identified specific lesions most likely to respond 
to one or more immunosuppressive agents. These issues are being addressed in 
a large international validation study, which is currently being performed and 
incorporates histopathological, clinical, and therapeutical data.
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Figure 2. Different phenotypes of mixed class ANCA-associated glomerulonephritis
Hypothetical example of how mixed class biopsies may represent quite different phenotypes of 
ANCA-associated glomerulonephritis in terms of activity and chronicity.
Conclusion
In general, validation studies supported the predictive value of the 
histopathological classification of ANCA-associated glomerulonephritis for renal 
outcome. This was especially the case in patients with a focal or sclerotic-class 
renal biopsy, whereas the crescentic and mixed classes showed different results 
in the validation studies. These differences could be due to differences in patient 
populations or therapy, moderate inter-rater reliability, and lack of inclusion of 
tubulointerstitial lesions in the classification system. To address these issues, a 
large international validation study is currently being performed.
Key points
-- The histopathological classification of ANCA-associated glomerulonephritis 
predicts renal outcome during follow-up, especially in patients with either a 
focal or sclerotic-class renal biopsy.
-- There are conflicting outcomes with respect to the crescentic and the mixed-
class renal biopsies.
-- This could be due to differences in patient populations or therapy, moderate 
inter-rater reliability, and lack of inclusion of tubulointerstitial lesions in the 
classification system.
-- A large international validation study is currently being performed to address 
these issues.
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To investigate the incidence of malignancies during longitudinal follow-up of 
patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), 
and to examine the effect of immunosuppressive therapy on malignancy risk in 
these patients.
Methods 
The study population consisted of patients with histopathologically confirmed 
AAV, diagnosed between 1991 and 2013 at a large university hospital. The mean 
duration of followup was 10 years. Malignancy incidence was assessed using the 
Dutch National Pathology Database. Incidence rates from the Netherlands Cancer 
Registry were used to compare malignancy incidence in the AAV cohort to that 
in the general Dutch population.
Results 
Thirty-six of 138 patients with AAV developed a total of 85 malignancies 
during a mean followup of 9.7 years. The sex-, age-, and calendar year-adjusted 
malignancy risk was 2.21-fold higher (95% confidence interval [95% CI] 1.64-
2.92) than that in the general population. Non-melanoma skin cancers occurred 
most frequently (standardized incidence ratio 4.23 [95% CI 2.76-6.19]). The 
incidence rates of other malignancies were not significantly increased. Malignancy 
risk was associated with the duration of cyclophosphamide (CYC) therapy and, 
interestingly, was not increased in patients who had received CYC for <1 year.
Conclusion 
Patients with AAV have a higher risk of malignancy than the general population, 
but this risk is accounted for solely by non-melanoma skin cancers. Over the 
years, the risk of other malignancies – specifically bladder and hematologic 
malignancies – has decreased in patients with AAV. This finding reflects ongoing 
efforts to reduce CYC exposure by developing new treatment regimens.
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Introduction
The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides 
(AAVs), including granulomatosis with polyangiitis (Wegener’s) (GPA) and 
microscopic polyangiitis (MPA), are small-to-medium vessel vasculitides that 
affect multiple organs and are life-threatening when untreated1. The availability 
of immunosuppressive therapy has dramatically improved prognosis in patients 
with AAV. Before the introduction of immunosuppressive therapy for this 
disorder, the mortality rate within 1 year after diagnosis was 80%. Currently, 
the remission rate is 90%2-4. Moreover, the life expectancy of patients with AAV 
who survive 5 years after diagnosis approaches that of the general population4, 5. 
As a result, attention has shifted to the long-term complications experienced by 
patients with AAV. Malignancies have been shown to be the second most common 
cause of death >1 year after diagnosis4. In previous studies, the incidence of 
malignancies among patients with AAV has been shown to be increased compared 
to the general population6-12. This was particularly the case for bladder cancer, 
malignant lymphomas, leukemia, and non-melanoma skin cancers (NMSCs).
The results of earlier studies of malignancy risk in AAV must be interpreted 
in light of a number of factors. First, in previous studies, except for one 
published in 19926, followup was limited to ∼5 years7, 9, 10, 13. Second, in some 
studies information on malignancy incidence was based on patient or physician 
questionnaires, which may have introduced reporting bias. Most importantly, 
the observation period in most studies dated from the 1960s to the 1990s6-8, 
13. In recent years, immunosuppressive therapy regimens have changed, based 
on efforts to reduce exposure to steroids and cyclophosphamide (CYC)14-16. 
Therefore, previous data on malignancy incidence mostly reflect risks associated 
with therapy regimens that are no longer used.
In the current study, we investigated the incidence of malignancies in 138 
patients with AAV treated with current immunosuppressive therapy regimens, 
who were followed up for a mean of 10 years. Specifically, we examined the 
effect of duration of CYC exposure on the risk of malignancy in these patients. 
A nationwide histology database was used to assess the incidence of malignancy 
in this cohort.
Patients and methods
Study population and data collection
This study was conducted in accordance with the ethical principles stated in the 
Declaration of Helsinki.
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We enrolled patients with histopathologically confirmed AAV diagnosed at 
Leiden University Medical Center between 1991 and 2013. Patients with 
coexisting autoimmune diseases were excluded. Definitions provided in the 
2012 revised International Chapel Hill Consensus Conference Nomenclature of 
Vasculitides17 were used. Of the 138 patients enrolled, 134 (97%) had undergone 
renal biopsy in which AAV was confirmed histopathologically (i.e., crescentic 
and/or necrotizing glomerulonephritis with few or no immune deposits detected 
by immunofluorescence and/or electron microscopy). In the 4 patients who did 
not undergo renal biopsy, the biopsies showing AAV originated from the lung 
(3 patients), the ear/nose/throat (ENT) (3 patients), and the skin (2 patients). 
All 4 of these patients had a clinical diagnosis of GPA, and all exhibited ANCA 
positivity. Twenty of the 138 patients in the study were negative for ANCA or had 
an unknown ANCA serotype; AAV in these patients was confirmed histologically 
by renal biopsy findings as defined above. Seven of these patients also had a second 
biopsy from another organ showing AAV (skin [4 patients], lung [2 patients], and 
ENT region [1 patient]).
Primary malignancies were identified via the Dutch National Pathology 
Database, a nationwide histopathology and cytopathology network and registry 
in The Netherlands. The database includes data from all pathology laboratories18. 
The cohort was linked to the Central Population Registry to obtain information on 
death and emigration. The observation time started on the date of AAV diagnosis 
and ended on the date of death, the date of last followup, or on May 1, 2013, 
whichever occurred first. We retrieved medical records to collect information on 
sex, date of birth, clinical diagnosis (GPA/MPA), ANCA serotype, renal function 
at diagnosis, renal transplantation, renal transplantation date (when applicable), 
and use of immunosuppressive medication (type and duration).
Standardized incidence ratio calculation
Malignancy occurrence in our cohort was compared to that in the general 
population by determining standardized incidence ratios (SIRs), calculated 
as the observed number of malignancies divided by the expected number of 
malignancies. To obtain the most accurate value, SIRs were calculated with 
matching for sex, age (5-year age groups), and calendar-year period (1-year 
time periods). The observed number of malignancies was the total number of 
malignancies that occurred in the cohort. If a patient developed multiple NMSCs, 
only the first NMSC was taken into account in the analyses. The expected 
number of malignancies was defined as the person-years at risk multiplied by the 
national cancer incidence rate data provided by the Netherlands Cancer Registry. 
Subgroup analyses were performed for the following variables: sex, age at study 
entry (dichotomous according to the median value), renal transplantation, clinical 
diagnosis, ANCA serotype, followup duration, and history of malignancy before 
AAV diagnosis. Moreover, we considered that the landmark European Vasculitis 
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Society (EUVAS) trial Cyclophosphamide versus Azathioprine as Remission 
Maintenance Therapy for ANCA-Associated Vasculitis (CYCAZAREM), 
published in 200319, led to a drastic reduction in CYC exposure in patients 
with AAV. Consequently, we performed separate subgroup analyses of patients 
diagnosed before 2003 and patients diagnosed in or after 2003, to investigate 
whether this change in immunosuppressive therapy regimen had an effect on 
malignancy risk.
Statistical analysis
Student’s t-test and the chi-square test were used to assess the significance of 
differences in baseline characteristics of patients who did and those who did not 
develop malignancies. Survival rates were analyzed by log rank test. Malignancy-
free survival time was calculated with the Kaplan-Meier method; the observation 
time started at AAV diagnosis and ended at the date of the first malignancy 
diagnosis, death, or May 1, 2013, whichever occurred first. SIRs and 95% 
confidence intervals (95% CIs) were calculated with an exact Poisson regression 
analysis, which allowed incorporation of patients with multiple malignancies, 
assuming a Poisson distribution of the observed number of cases20-22. For all 
subgroup analyses, exact Poisson regression models were performed to calculate 
the relative risk. P values less than 0.05 were considered significant.
Results
Patient characteristics
A total of 138 patients with histopathologically confirmed AAV were included 
in the study. Of the 117 patients (85%) with available clinical diagnoses, 79 
(68%) had a diagnosis of GPA and 38 (32%) had a diagnosis of MPA; none had 
a diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Of 
the 128 patients (93%) with available data on ANCA serotype, 55 (43%) were 
positive for proteinase 3 (PR3)-ANCA; 47 (37%) for myeloperoxidase (MPO)-
ANCA, and 5 (4%) for both PR3-ANCA and MPO-ANCA; 11 patients (9%) 
were positive for ANCA but with no available data on whether they were PR3-
ANCA or MPO-ANCA positive, and 10 patients (8%) were negative for ANCA. 
The mean ± SD age at AAV diagnosis was 59.3 ± 14.8 years, and did not differ 
significantly between patients who did and those who did not develop malignancy 
during followup. Fourteen patients had a history of malignancy occurrence prior 
to the AAV diagnosis. No malignancy diagnosed prior to the AAV diagnosis 
metastasized during the followup period. Additional demographic and clinical 
data are summarized in Table 1.
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Mean age at diagnosis, years (SD) 59.3 (14.8) 58.9 (15.6) 60.7 (12.0) 0.533
Male, n (%) 87 (63) 62 (61) 25 (69) 0.355
Clinical diagnosis, n (%) 0.753
   GPA 79 (57) 56 (55) 23 (64)
   MPA 38 (28) 28 (27) 10 (28)
   Unknown 21 (15) 18 (18) 3 (8)
ANCA-serotype, n (%) 0.079
   PR3-ANCA 55 (40) 35 (34) 20 (56)
   MPO-ANCA 47 (34) 39 (38) 8 (22)
   ANCA-negative 10 (7) 7 (7) 3 (8)
   PR3- and MPO-ANCA positive 5 (4) 5 (5) 0 (0)
   ANCA positive1 11 (8) 9 (9) 2 (6)
   Unknown 10 (7) 7 (7) 3 (8)
Mean baseline serum creatinine, 
μl/l (SD)
337.0 (303.6) 332.5 (279.1) 348.0 (361.0) 0.813
Renal transplantation, n (%) 10 (7) 8 (8) 2 (6) 0.649
Previous history of malignancy, 
n (%)
14 (10) 11 (11) 3 (8) 0.675
Organ involvement, n (%)2
   Cutaneous 36 (31) 21 (25) 15 (46) 0.044
   Eyes 35 (30) 21 (25) 14 (42) 0.075
   Ear, nose, and throat 78 (67) 53 (63) 25 (76) 0.276
   Chest 61 (52) 45 (54) 16 (49) 0.683
   Cardiovascular 7 (6) 6 (7) 1 (3) 0.671
   Gastrointestinal 16 (14) 13 (16) 3 (9) 0.551
   Kidney 138 (100) 0 (0) 138 (100) N/A
   Nervous system 32 (27) 25 (30) 7 (21) 0.490
Deaths, n (%) 56 (41) 39 (38) 17 (47) 0.2553
The study population consisted of 138 patients with histologically confirmed antineutrophil cytoplas-
mic antibody (ANCA)–associated vasculitis (AAV). Data on clinical diagnosis and ANCA serotype 
were available for 117 patients and 128 patients, respectively. Except where indicated otherwise, 
values are the number (%). GPA = granulomatosis with polyangiitis (Wegener’s); MPA = microscopic 
polyangiitis.
1 Patients who were ANCA positive, but with no information in the medical records regarding whether 
they were positive for proteinase 3 (PR3)–ANCA or myeloperoxidase (MPO)–ANCA.
2 All 138 patients had renal involvement; data on involvement of other organs were available for 117
patients.
3 P = 0.044 versus patients with no malignancy occurrence.
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Observed malignancies
Thirty-six patients developed malignancies (total of 85 malignancies) during 
the followup period (mean 9.7 years, median 8.0 years; 1,339 person-years). Of 
these malignancies, 61 were NMSCs, and they occurred in a total of 22 patients. 
The NMSCs included 42 basal cell carcinomas and 19 squamous cell carcinomas. 
In addition, 3 colon carcinomas, 3 breast carcinomas, 3 prostate carcinomas, 
2 lung carcinomas, 2 soft tissue sarcomas, 2 unknown primary malignancies, 
and a variety of malignancies that occurred only once were observed (Table 2). 
Malignancy-free survival at 2, 5, and 10 years of followup was 99%, 84%, and 
80%, respectively (Figure 1).
Figure 1. Years of malignancy-free survival in patients with antineutrophil cytoplasmic an-
tibody-associated vasculitis (AAV) (solid line) compared to the age-and sex-matched general 
population (dashed line).
Comparison with the general population
The sex-, age-, and calendar year–adjusted malignancy risk among the AAV 
patients in this cohort was 2.21-fold higher than the risk in the general population 
(95% CI 1.64-2.92) (Table 2). This increased risk was attributable solely to an 
increased risk of developing NMSC (SIR 4.23 95% CI 2.76-6.19). We observed 
only 1 bladder carcinoma and 1 non-Hodgkin’s lymphoma in the cohort. These 
incidences were not significantly increased compared to the general population, 
with SIRs of 1.43 (95% CI 0.04-7.96) and 1.37 (95% CI 0.03-7.63), respectively. 
The risk of developing any of the other reported malignancies was also not 
increased compared to that in the general population (Table 2).
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Table 2. SIRs calculated for malignancies overall and per observed malignancy
Malignancy type PY N malignancies SIR 95% CI p-value
All malignancies 1339 85 2.21 1.64 – 2.92 <0.001
     NMSC 1339 61 4.23 2.76 – 6.19 <0.001
     Non-NMSC 1339 24 1.46 0.93 – 2.17 0.095
By malignancy
     Breast carcinoma 1339 3 2.04 0.42 – 5.96 0.367
   Colon carcinoma 1339 3 1.85 0.38 – 5.41 0.444
   Prostate carcinoma 795 3 0.99 0.20 – 2.89 1.000
   Lung carcinoma 1339 2 0.75 0.23 – 3.30 0.993
   Soft tissue sarcomas 1339 2 7.69 0.93 – 27.79 0.057
   Unknown primary malignancy 1339 2 3.92 0.47 – 14.17 0.187
   Brain carcinoma 1339 1 5.56 0.14 – 30.95 0.329
   Parotis carcinoma 1339 1 33.33 0.84 – 185.72 0.059
   Bladder carcinoma 1339 1 1.43 0.04 – 7.96 1.000
   Uterus carcinomas 544 1 4.00 0.10 – 22.29 0.442
   Non-Hodgkin lymphoma 1339 1 1.37 0.03 – 7.63 1.000
   Renal cell carcinoma 1339 1 2.44 0.06 – 13.59 0.672
   Chondrosarcoma 1339 1 28.57 0.72 – 159.19 0.068
   Esophageal cancinoma 1339 1 2.70 0.07 – 15.06 0.602
   Melanoma 1339 1 1.92 0.05 – 10.71 0.811
The analysis encompassed 1,339 person-years (except for the sex-specific malignancies prostate 
carcinoma [795 person-years] and uterus carcinoma [544 person-years]). Standardized incidence ratio 
(SIR) (ratio of observed to expected malignancies) was adjusted for sex, age (5-year age groups), and 
calendar time period (1-year time periods). 95% CI = 95% confidence interval; NMSC = non-melano-
ma skin cancer.
Malignancy risk by clinical diagnosis and ANCA subtype
We performed prespecified subgroup analyses with stratification by sex, age, 
followup duration, clinical diagnosis, ANCA subtype, history of malignancy 
before AAV diagnosis, diagnosis and treatment initiation before or after 
publication of the CYCAZAREM trial (2003), and renal transplantation (Table 
3). The risk of malignancy became increased compared to the general population 
after the duration of AAV exceeded 5 years (Table 3).
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Analysis of the clinical diagnosis and ANCA serotype subgroups showed a 
significantly increased malignancy risk in patients with GPA and/or with PR3-
ANCA compared to the general population, but not in patients with MPA and/
or MPO-ANCA. However, within the AAV cohort, the malignancy risk was not 
significantly different between those who had GPA and/or were positive for PR3-
ANCA and those who had MPA and/or were positive for MPO-ANCA (Table 3).
Malignancy risk in patients with a history of malignancy before AAV diag-
nosis
Fourteen of the 138 patients had a history of malignancy before AAV diagnosis 
and 124 did not. The total number of malignancies that developed in these 2 
groups during followup were 5 and 80, respectively. SIRs were similar between 
patients with and patients without a history of malignancy before the AAV 
diagnosis (Table 3).
Malignancy risk before and after publication of the CYCAZAREM trial in 
2003
Eighty-three of the 138 AAV patients were diagnosed before 2003, and 55 in or 
after 2003 (Table 3). The mean ± SD duration of CYC therapy was 14.5 ± 17.4 
months and 5.1 ± 4.1 months in patients diagnosed before 2003 and patients 
diagnosed in or after 2003, respectively (P < 0.001). The 83 patients diagnosed 
before 2003 developed a total of 73 malignancies, which resulted in a 2.43-
fold increase in malignancy risk compared to the general population (95% CI 
1.76-3.26). The 55 patients diagnosed in or after 2003 developed a total of 12 
malignancies; the malignancy risk in these patients was not significantly increased 
compared to the general population (SIR 1.34 [95% CI 0.49-2.92]).
Malignancy risk in patients with renal transplants
Ten patients (7%) underwent renal transplantation during followup. The 
mean ± SD time from AAV diagnosis to renal transplantation was 6.7 ± 4.8 years. 
Two of the 10 patients with renal transplants developed a total of 7 malignancies, 
during a mean ± SD followup of 12.8 ± 4.8 years. These malignancies included 
3 squamous cell carcinomas, 2 basal cell carcinomas, 1 prostate carcinoma, 
and 1 parotid carcinoma. Malignancy risk compared to the general population 
was significantly increased among patients with AAV who had undergone renal 
transplantation (SIR 3.33 [95% CI 1.08-7.78]) as well as those who had not 
undergone transplantation (SIR 2.17 [95% CI 1.59-2.91]). We did not observe 
a significant effect of transplantation on malignancy risk in these subgroups 
(P = 0.495); however, since only 10 patients in the cohort had undergone 
transplantation, this subanalysis was presumably not sufficiently powered to 
detect a significant difference.
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Effects of immunosuppressive therapy on malignancy risk
Data on immunosuppressive therapy were available for 117 patients (85%) (Table 
4). All 117 patients received prednisolone, 110 (94%) received CYC, 62 (53%) 
received azathioprine (AZA), and 24 (21%) received mycophenolate mofetil 
(MMF) at some time during their disease. Moreover, 4 patients (3%) received 
methotrexate, and 5 patients (4%) received rituximab. The mean ± SD duration 
of CYC therapy was 17.6 ± 17.9 months and 8.0 ± 11.8 months, respectively, in 
patients who did and those who did not develop a malignancy during followup 
(P = 0.001) (Table 4).








Ever treatment, n (%)
   Prednisolone 117 (100) 84 (100) 33 (100) N/A
   Cyclophosphamide 110 (94) 80 (95) 30 (91) 0.374
   Azathioprine 62 (53) 43 (51) 19 (58) 0.533
   Mycophenolate mofetil 24 (21) 20 (24) 4 (12) 0.159
Mean duration, months 
(SD)
   Prednisolone 37.7 (42.3) 29.7 (39.2) 58.1 (43.7) 0.001
   Cyclophosphamide 10.7 (14.4) 8.0 (11.8) 17.6 (17.9) 0.001
   Azathioprine 18.5 (31.4) 14.2 (28.3) 29.5 (36.5) 0.017
   Mycophenolate mofetil 7.6 (21.1) 7.5 (16.7) 7.8 (29.9) 0.943
Some of the patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV) received 
consecutive treatments with cyclophosphamide and/or azathioprine and/or mycophenolate mofetil (47 
patients received cyclophosphamide and azathioprine, 8 patients received cyclophosphamide and myco-
phenolate mofetil, 1 patient received azathioprine and mycophenolate mofetil, and 13 patients received 
cyclophosphamide, azathioprine, and mycophenolate mofetil).
NA = not applicable (analyses on prednisolone were not possible as all patients were treated with this 
immunosuppressant).
The duration of CYC exposure was directly associated with malignancy risk (Table 5). The malignan-
cy risk in patients with AAV who had received CYC for <1 year was not significantly different from 
that in the general population. Patients treated with CYC for 12–24 months and those treated for >24 
months showed increased malignancy risks, with SIRs of 3.83 (95% CI 1.98–6.70) and 4.67 (95% CI 
2.55–7.83), respectively.
The duration of CYC exposure was directly associated with malignancy risk 
(Table 5). The malignancy risk in patients with AAV who had received CYC 
for, 1 year was not significantly different from that in the general population. 
Patients treated with CYC for 12–24 months and those treated for >24 months 
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showed increased malignancy risks, with SIRs of 3.83 (95% CI 1.98–6.70) and 
4.67 (95% CI 2.55–7.83), respectively. 
The risk of malignancy in patients treated with CYC and corticosteroids 
was not different from that in patients treated with AZA or MMF maintenance 
therapy following CYC treatment (SIR 2.62 [95% CI 1.53–4.19] and SIR 2.02 
[95% CI 1.29–3.01], respectively). The average duration of CYC treatment was 
14 months in patients treated with CYC and corticosteroids and 10 months in 
patients who received other immunosuppressive agents for maintenance therapy 
after CYC treatment (P = 0.234).









SIR (95% CI) SIR
p-value
RR (95% CI) RR
p-value
0 – 6 months 65 15 1.52 (0.78 – 2.64) 0.212
6 – 12 months 21 14 1.82 (0.79 – 3.59) 0.156 1.20 (0.43 – 3.19) 0.847
12 – 24 months 16 30 3.83 (1.98 – 6.70) <0.001 2.53 (1.04 – 6.17) 0.040
> 24 months 15 18 4.67 (2.55 – 7.83) <0.001 3.08 (1.31 – 7.32) 0.008
Standardized incidence ratio (SIR) (ratio of observed to expected malignancies) depicts malignancy 
risk compared to the general population. Relative risk (RR) depicts malignancy risk compared to the 
referent group. 95% CI = 95% confidence interval.
Discussion
This is the first published study to investigate malignancy incidence in relation 
to current therapy regimens in a cohort of patients with AAV followed up for 
a long period (mean 10 years). During this period, the risk of malignancy was 
2.21-fold higher in patients with AAV compared to the general population. This 
increased risk was attributable solely to the occurrence of NMSC. There was 
no increased risk for all other reported malignancies compared to the general 
population. In particular, there was no increased risk of bladder cancer, leukemia, 
or malignant lymphomas, in contrast to data presented in previous reports6–11,13. 
In our cohort, risk of malignancy was directly associated with the duration of 
CYC therapy. Interestingly, malignancy risk was not increased among patients 
who had been exposed to CYC for <1 year.
Previous studies on malignancy risk in AAV showed 2.4-33-fold increases 
in the risk of developing bladder cancer, 3.2-5.9-fold increases in the risk of 
developing leukemia, and 1.1-11-fold increases in the risk of developing malignant 
lymphomas12. Followup periods in those studies were ∼5 years7,9–11 or were 
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not reported8, 13, except in the case of one study conducted from 1967 to 1990 
with a median followup of 8 years6. As noted, patients in our AAV cohort had 
no increased risk of developing any of these malignancies after a mean followup 
period of 10 years. Only 1 patient in our cohort, who received CYC for 4 years, 
developed bladder carcinoma (9 years after AAV was diagnosed). In addition, 
there was 1 non-Hodgkin’s lymphoma (which occurred 13 years after the AAV 
diagnosis). This patient was treated with CYC for 4.5 years and AZA for 3.8 
years.
The discrepancies between our findings and those of previous studies likely 
reflect the changes in AAV treatment regimens over the years. Most previous 
studies were conducted from the 1960s to the 1990s6-8, 13. Since that time, large, 
international therapeutic trials have been conducted14-16, 19, which resulted in 
dramatic reductions in exposure to CYC. A previous 5-year followup study 
of patients initially recruited in those trials demonstrated no increased risk of 
bladder or hematologic malignancies compared to the general population10. Our 
study validates those results and, moreover, shows that even after 10 years of 
followup, the risk of developing these malignancies is not increased.
The followup period of our study (1991–2013) overlaps publication of the 
reports of the therapeutic trials conducted by the EUVAS14-16, 19. In the landmark 
EUVAS CYCAZAREM study published in 2003, it was concluded that early 
withdrawal of CYC and substitution of AZA at the time of remission did not 
increase relapse rates in patients with AAV, and that the duration of exposure to 
CYC therefore could be safely reduced by switching to maintenance therapy at 
the time of remission achievement19. In our cohort, the mean duration of CYC 
therapy was ∼3 times longer in patients diagnosed before 2003 compared to 
patients diagnosed in or after 2003. Interestingly, we found that the malignancy 
risk compared to the general population is significantly increased among AAV 
patients diagnosed before 2003, but not among those diagnosed later. This 
indicates that the reduction in CYC exposure over time has resulted in a decrease 
in malignancy risk among patients with AAV.
Apart from increased malignancy risk induced through immunosuppressive 
therapy regimens, it has been suggested that an increased risk of malignancy 
may arise from chronic stimulation of the immune system due to vasculitis23. 
Moreover, more severe disease with greater disease activity is generally associated 
with longer duration of immunosuppressive therapy; thus, it is difficult to separate 
disease-related and therapy-related effects on malignancy risk. Our finding of a 
high incidence of malignancies only after 5 years of followup (i.e., after longer 
exposure to immunosuppressive therapy) suggests that this therapy may have an 
important effect on the development of malignancies, because intrinsic disease-
associated malignancies would be more likely to occur within the first 5 years. 
Moreover, we found that the malignancy risk in patients with AAV decreased 
after reduction of CYC exposure, which clearly indicates a dose-dependent effect.
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Subgroup analyses demonstrated a significantly increased malignancy risk among 
patients with GPA and/or PR3-ANCA positivity, but not among patients with 
MPA and/or MPO-ANCA positivity. Possible explanations for this could be that 
patients with GPA and/or PR3-ANCA positivity had superior survival or a higher 
risk of relapses and need for more immunosuppressive treatment compared to 
patients with MPA and/or MPO-ANCA positivity. Further analyses demonstrated 
that survival was not different between patients with GPA and/or PR3-ANCA 
positivity and patients with MPA and/or MPO-ANCA positivity (data not shown). 
However, the duration of CYC treatment was significantly longer among patients 
with PR3-ANCA positivity than among those with MPO-ANCA positivity (mean 
14 months and 8 months, respectively). This finding further supports the notion 
that immunosuppressive treatment exposure increases malignancy risk in patients 
with AAV.
Currently, immunosuppressive therapy for AAV seems to be complicated by 
the occurrence of NMSC. It has been suggested that AZA might accelerate NMSC 
development by sensitizing the skin cell genome to ultraviolet A radiation24. 
Previous studies have shown an association between AZA exposure and the 
occurrence of NMSC in patients with transplants, myasthenia, autoimmune 
inflammatory rheumatic diseases, and inflammatory bowel disease25-29. Our 
data imply that there is also an association between AZA and NMSC in patients 
with AAV (Table 4). In contrast, we found no difference in the occurrence of 
NMSC between patients treated with CYC alone and those treated with AZA 
following CYC therapy, despite similar durations of CYC exposure. However, our 
analysis may not have been sufficiently powered to detect a significant difference. 
Although mortality associated with NMSCs is low, their impact should not be 
underestimated because they can cause significant morbidity. Our results support 
the notion that patients with AAV who receive immunosuppressive therapy should 
undergo regular skin cancer screening and be advised to protect themselves 
against ultraviolet radiation exposure30.
One limitation of this study is the fact that the clinical data were collected 
retrospectively. However, for most patients these data were accessible and 
recorded punctually. Moreover, the analysis was confined to a Dutch patient 
population, which should be taken into account in comparing our results with 
those from the previous multicenter European study10. Finally, the limited 
number of patients included in this study could have resulted in insufficient power 
to detect significant differences, particularly in the subgroup analyses. One of 
the strengths of the study is the long followup period. This is the first study on 
malignancy risk in patients with AAV with a mean followup duration as long as 10 
years. Moreover, the diagnosis of AAV was confirmed histologically in all of our 
patients. Finally, no malignancy in our patient cohort could have been missed, due 
to the accurate data reporting through the Dutch National Pathology Database.
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In conclusion, the results of this 10-year followup study indicate that patients 
with AAV have a higher risk of NMSC than the general population. There was 
no increased risk of bladder cancer, leukemia, or malignant lymphomas, as was 
previously reported in patients with AAV. With current treatment regimens, 
CYC treatment appears to be safe for up to 1 year without causing an increase 
in malignancy risk. Longer exposure to CYC increased the risk of malignancy 
occurrence. Our results demonstrate that with treatment regimens currently in 
use for AAV, the risk of developing bladder and hematologic malignancies is lower 
than with previous standard regimens, underscoring the success of international 
efforts to find less cytotoxic treatment regimens for the disease. However, other 
toxicities associated with current therapies, e.g., in terms of infertility and 
infection, remain a concern. Quite recently, rituximab was introduced as part 
of AAV treatment regimens, showing success and with the promise of further 
reducing malignancy risk in AAV patients16, 31, 32. Continued efforts aimed at 
developing additional safe and effective therapies for AAV are, nevertheless, still 
warranted.
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Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) treated with cyclophosphamide have an increased malignancy risk 
compared with the general population. We investigated whether treatment with 
rituximab instead of cyclophosphamide has decreased the malignancy risk in 
patients with AAV.
Methods 
The study included patients with AAV treated at a tertiary vasculitis referral 
centre between 2000 and 2014. The malignancy incidence in these patients was 
compared with the incidence in the general population by calculating standardised 
incidence ratios (SIRs), adjusted for sex, age and calendar year. Malignancy 
incidence was compared between rituximab-treated and cyclophosphamide-
treated patients.
Results 
Of the 323 included patients, 33 developed a total of 45 malignancies during a 
mean follow-up of 5.6 years. This represented a 1.89-fold increased (95% CI 
1.38 to 2.53) malignancy risk, and a non-significantly increased risk if non-
melanoma skin cancer was excluded (SIR, 1.09; 95% CI 0.67 to 1.69). The risk 
of non-melanoma skin cancer was 4.58-fold increased (95% CI 2.96 to 6.76). 
Cyclophosphamide-treated patients had an increased malignancy risk compared 
with the general population (SIR, 3.10; 95% CI 2.06 to 4.48). In contrast, 
rituximab-treated patients had a malignancy risk similar to the general population 
(SIR, 0.67; 95% CI 0.08 to 2.43). The malignancy risk in cyclophosphamide-
treated patients was 4.61-fold higher (95% CI 1.16 to 39.98) than in rituximab-
treated patients.
Conclusions 
The malignancy risk in patients with AAV was lower in rituximab-treated patients 
than in cyclophosphamide-treated patients. Notably, rituximab treatment was 
not associated with an increased malignancy risk compared with the general 
population. Rituximab could therefore be a safe alternative to cyclophosphamide 
in the treatment of AAV.
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Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a 
systemic autoimmune disease that affects small-sized to medium-sized blood 
vessels in multiple organs. AAV comprises granulomatosis with polyangiitis 
(formerly Wegener’s granulomatosis), microscopic polyangiitis and eosinophilic 
granulomatosis with polyangiitis (formerly Churg-Strauss syndrome).1 
Autoantibodies against proteinase 3 (PR3-ANCA) and myeloperoxidase (MPO-
ANCA) assist in the diagnosis of AAV, but patients can also be negative for 
ANCA.2 Although the introduction of cyclophosphamide therapy for AAV 
has improved patient survival considerably,3, 4 the carcinogenic effects of 
cyclophosphamide put patients at increased risk of developing malignancies. 
Several studies have reported increased malignancy risks in patients with AAV 
who were treated with cyclophosphamide compared with the general population, 
especially for non-melanoma skin cancer, bladder cancer, malignant lymphoma 
and leukaemia.5–12 Moreover, two studies found a dose–response association 
between cyclophosphamide and malignancy risk.8, 13 These results are restricted 
to patients with granulomatosis with polyangiitis and microscopic polyangiitis, 
and the malignancy risk in patients with eosinophilic granulomatosis with 
polyangiitis has not been investigated in detail before.
International efforts have been devoted to find less cytotoxic regimens for 
the treatment of AAV. In particular, the cumulative cyclophosphamide doses 
have been lowered,14, 15 and rituximab has emerged as a promising substitute 
for cyclophosphamide.16, 17 The initial findings from randomised controlled 
trials showed similar treatment efficacy in patients treated with either 
cyclophosphamide or rituximab.18–20 However, concerns were raised about a 
possible higher malignancy rate in patients treated with rituximab.21 ,22 Notably, 
the trials focused on treatment efficacy; thus, their results regarding malignancy 
incidence should be interpreted in light of their small sample sizes and the short 
follow-up of a maximum of 24 months.
This study investigated the long-term malignancy risk in 323 patients with 
AAV. This is, to our knowledge, the first study to compare the long-term 




The study included patients with AAV (granulomatosis with polyangiitis, 
microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis) who 
were treated at the Vasculitis and Lupus Clinic at Addenbrooke’s Hospital, 
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Cambridge, UK, between 2000 and 2014. The diagnosis was established 
according to the European Medicines Agency algorithm.23 Follow-up began 
on the date of diagnosis and ended on the date of death, the date the patient 
was lost to follow-up or on 1 July 2015, whichever occurred first. Follow-up 
surveillance was performed at Addenbrooke’s Hospital. This study was conducted 
in accordance with the ethical principles stated in the Declaration of Helsinki.
Clinical data
The following data were obtained from the medical records of the patients: 
demographic characteristics, diagnosis, date of diagnosis, ANCA serotype, 
organ involvement, therapy regimen, renal transplantation and the occurrence of 
malignancies. Patients with incomplete or missing medical records were excluded 
from further analyses. The cumulative doses of cyclophosphamide and rituximab 
during follow-up were determined. For subgroup analysis, patients were 
categorised according to their cyclophosphamide and/or rituximab exposure into 
the following categories: patients treated only with cyclophosphamide, patients 
treated only with rituximab, patients treated with both cyclophosphamide and 
rituximab, or patients who were not treated with either cyclophosphamide 
or rituximab. In all categories, the treatment may also have included other 
immunosuppressive agents, such as glucocorticoids, azathioprine, mycophenolate 
mofetil, methotrexate and/or tumour necrosis factor (TNF)-α inhibitors.
Standardised incidence ratio calculations
Standardised incidence ratios (SIRs) were calculated to compare the malignancy 
incidence between the study cohort and the general UK population, expressing 
the malignancy risk relative to the general population and matching for sex, age 
and calendar year. The SIR is the observed number of malignancies divided by 
the expected number of malignancies. The observed number of malignancies 
was the total number of primary invasive malignancies. The expected number 
of malignancies was the number of person-years at risk in our cohort multiplied 
by the malignancy incidence rates in the general UK population as obtained 
from the Office for National Statistics and matched for sex, 5-year age group and 
1-year calendar time period.24 Since the malignancy incidence rates were available 
until 2013, the malignancy incidence rate in 2013 was extrapolated to 2014 and 
2015. The SIR was calculated for malignancies at all sites, for all malignancies 
except non-melanoma skin cancers and for each malignancy site as reported in the 
study population. SIRs were stratified by sex, age category at diagnosis (younger 
than the median age of 59 years vs 59 years or older), clinical diagnosis, ANCA 
serotype, renal transplantation and follow-up duration. Moreover, SIRs were 
compared in different treatment categories and according to the cumulative doses 
of cyclophosphamide and rituximab.
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Statistical analyses
Student’s t-test, the χ2 test, Fisher’s exact test and the one-way analysis of variance 
(ANOVA) test were used to compare the characteristics of different subgroups 
(SPSS statistical software, V.23). SIR values were compared between subgroups 
by calculating relative risks (RRs). Exact Poisson regression analysis was used to 
calculate 95% CIs for the SIR and RR values assuming a Poisson distribution of 
the observed number of cases (SAS software, V.9.3; SAS Institute).25–27 p Values 
less than 0.05 were considered significant in all analyses.
Results
Patient characteristics
The characteristics of the 323 patients with AAV included in this study are shown 
in table 1. The mean (SD) age at diagnosis was 56.4 (16.1) years, and the mean 
follow-up was 5.6 (3.2) years (1802 person-years). A total of 160 (49%) patients 
were diagnosed with microscopic polyangiitis; 109 patients (34%) were diagnosed 
with granulomatosis with polyangiitis; and 54 patients (17%) were diagnosed 
with eosinophilic granulomatosis with polyangiitis. Finally, 12 patients (4%) 
underwent renal transplantation, and 39 patients (12%) died during follow-up.
Malignancy occurrence
Of the 323 patients, 33 developed a total of 45 malignancies during follow-up. 
The sex, age and calendar year-adjusted malignancy risk was 1.89-fold higher 
in the patients with AAV than in the general population (95% CI 1.38 to 2.53) 
(table 2). There were 13 different malignancy types, with non-melanoma skin 
cancer occurring most frequently (10 basal cell carcinomas and 15 squamous cell 
carcinomas). The SIR for non-melanoma skin cancer was significantly increased 
(SIR, 4.58; 95% CI 2.96 to 6.76), while the risk for all malignancies excluding 
non-melanoma skin cancer was comparable to that of the general population 
(SIR, 1.09; 95% CI 0.67 to 1.69) (table 2).
Malignancy occurrence in the subgroups
The SIR for overall malignancy risk was stratified by gender, age, clinical diagnosis, 
ANCA serotype, renal transplantation and follow-up duration (supplementary 
table S1). Patients with eosinophilic granulomatosis with polyangiitis had the 
highest malignancy risk (SIR, 2.75; 95% CI 1.19 to 5.40), followed by those with 
granulomatosis with polyangiitis (SIR, 2.20; 95% CI 1.20 to 3.68) and those 
with microscopic polyangiitis (SIR, 1.59; 95% CI 1.01 to 2.38). Transplanted 
patients had a higher malignancy risk (SIR, 4.31; 95% CI 1.17 to 11.04) than 
patients who did not undergo renal transplantation (SIR, 1.79; 95% CI 1.29 to 
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2.43). The treatment duration and cumulative doses of cyclophosphamide and 
rituximab in subgroups are shown in supplementary table S2.







SIR (95% CI)† p 
Value†
All sites 45 23.80 1.89 (1.38 to 2.53) <0.001
Non-melanoma skin 




20 18.33 1.09 (0.67 to 1.69) 0.76
Lung 4 2.61 1.53 (0.42 to 3.92) 0.53
Breast 3 2.82 1.06 (0.22 to 3.11) 1.00
Colon or rectum 3 1.98 1.52 (0.31 to 4.44) 0.63
Prostate 2 2.74 0.73 (0.09 to 2.64) 0.97
Bladder 1 0.65 1.53 (0.04 to 8.57) 0.96
Pancreas 1 0.52 1.94 (0.05 to 10.81) 0.81
Testis 1 0.04 24.66 (0.62 to 137.41) 0.08
Ovary 1 0.39 2.54 (0.06 to 14.14) 0.65
Melanoma 1 0.66 1.52 (0.04 to 8.49) 0.96
Tongue 1 0.07 13.70 (0.35 to 76.34) 0.14
Central nervous system 1 0.25 3.94 (0.10 to 21.95) 0.45
Kidney 1 0.49 2.03 (0.05 to 11.32) 0.78
*SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group) 
and calendar time period (per 1-year calendar time period).
†Calculated by exact Poisson regression analysis.
SIR, standardised incidence ratio.
Effects of cyclophosphamide and rituximab on malignancy risk
Patients treated only with cyclophosphamide had a 3.10-fold higher (95% CI 2.06 
to 4.48) malignancy risk than the general population (table 3), and a 1.14-fold 
higher (95% CI 0.49 to 2.25) malignancy risk if non-melanoma skin cancer was 
excluded. Patients treated only with rituximab had no increased malignancy risk 
compared with the general population (SIR, 0.67; 95% CI 0.08 to 2.43), which 
was similar if non-melanoma skin cancer was excluded (SIR, 0.88; 95% CI 0.11 
to 3.19). The malignancy risk in patients treated only with cyclophosphamide 
was 4.61-fold higher (95% CI 1.16 to 39.98) than in patients treated only with 
rituximab and was 3.05-fold higher (95% CI 1.40 to 7.35) than in patients treated 
with both cyclophosphamide and rituximab (table 4). The mean cumulative 
cyclophosphamide dose was lower in patients treated only with cyclophosphamide 
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than in patients treated with both cyclophosphamide and rituximab (7.3 g 
vs 11.1 g; p=0.002). The duration of follow-up was longer for patients who 
received rituximab than for patients who did not receive rituximab (p<0.001). 
In terms of mean organ involvement, the disease extent did not differ between 
the treatment groups (p=0.07) (table 3). Patients treated with cyclophosphamide 
received azathioprine maintenance therapy more frequently than those treated 
with rituximab (81% vs 42%; p<0.001). The SIR of malignancy for patients 
receiving a combination of cyclophosphamide and azathioprine was 3.20 (95% CI 
2.05 to 4.76; p<0.001), whereas patients receiving a combination of rituximab 
and azathioprine expressed a comparable malignancy risk to that of the general 
population (SIR, 1.52; 95% CI 0.18 to 5.50; p=0.38).
Table 4. Relative risks (RR) according to treatment category
Treatment* RR (95% CI)† p Value†
Only cyclophosphamide versus only rituximab 4.61 (1.16 to 39.98) 0.03
Only cyclophosphamide versus both 3.05 (1.40 to 7.35) 0.003
Only cyclophosphamide versus none 1.48 (0.60 to 4.36) 0.52
*The ‘only cyclophosphamide’ group was treated with cyclophosphamide but not with rituximab. The 
‘only rituximab’ group was treated with rituximab but not with cyclophosphamide. ‘Both’ indicates 
a group that received cyclophosphamide and rituximab. ‘None’ indicates a group that did not receive 
cyclophosphamide or rituximab. Other immunosuppressive drugs were also administered in all of the 
groups.
†RR represents the risk of malignancy compared with the reference group. Calculated by exact Pois-
son regression analysis.
Effects of cumulative cyclophosphamide and rituximab doses on malignancy 
risk
The mean (SD) cumulative cyclophosphamide and rituximab doses were 9.1 
(9.0) g and 5.9 (3.4) g, respectively. The highest cyclophosphamide dose was 
108 g, given intermittently for 7.6 years, during a follow-up period of 8.1 years, 
in which the patient experienced no relapses. The highest rituximab dose was 
18 g, given intermittently over 6.1 years, during a follow-up period of 9.1 years, 
in which one relapse occurred. A positive dose–response relationship was found 
between cyclophosphamide therapy and the overall malignancy risk (table 5), and 
between cyclophosphamide therapy and the risk of non-melanoma skin cancer 
(supplementary table S3). The opposite relationship was found for patients treated 
with rituximab: the higher the cumulative rituximab dose, the lower the overall 
malignancy risk (table 5), and the lower the risk of non-melanoma skin cancer 
(supplementary table S3). Patients who did not receive rituximab had a 2.86-fold 
higher (95% CI 1.98 to 3.99) malignancy risk than the general population. No 
increased risk was observed when patients had a cumulative rituximab dose below 
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6.0 g (SIR, 1.41; 95% CI 0.57 to 2.90). A total of 83 patients received more than 
6.0 g rituximab, and these patients had a non-significantly lower malignancy 
risk than the general population (SIR, 0.45; 95% CI 0.09 to 1.32) and a 6.32-
fold lower (95% CI 1.99 to 32.15) malignancy risk than patients who did not 
receive rituximab (table 5). The cumulative cyclophosphamide and rituximab 
doses individually received by the patients who developed a malignancy during 
follow-up are shown in supplementary table S4.









SIR (95% CI)† SIR
p value†




 0 89 8 1.37 (0.59–2.70) 0.47 1 (reference)
 0.1–20 207 31 1.91 (1.30–2.71) 0.001 1.39 (0.63–3.50) 0.52
 20–108 16 5 5.06 (1.64–11.82) 0.007 3.69 (0.95–12.78) 0.06
Rituximab
 0 167 34 2.86 (1.98–3.99) <0.001 1 (reference)
 0.1–6 70 7 1.41 (0.57–2.90) 0.47 0.49 (0.18–1.13) 0.11
 6–18 83 3 0.45 (0.09–1.32) 0.10 0.16 (0.03–0.50) <0.001
*SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group) 
and calendar time period (per 1-year calendar time period). SIR represents the malignancy risk 
compared with the general population, and the RR represents the malignancy risk compared with the 
reference group.
†Calculated by exact Poisson regression analysis.
RR, relative risk; SIR, standardised incidence ratio.
Discussion
This study compared the malignancy risks in patients with AAV treated 
with rituximab versus cyclophosphamide. Strikingly, patients treated with 
cyclophosphamide had a 4.61-fold higher risk than those treated with rituximab. 
In patients treated with cyclophosphamide, the malignancy risk was 3.10-fold 
higher than in the general population; in contrast, patients treated with rituximab 
did not show an increased risk compared with the general population. Patients 
treated with both rituximab and cyclophosphamide (N=114) had a lower 
malignancy risk than those treated with only cyclophosphamide, even though 
the mean cyclophosphamide dose was lower in the latter group. In addition, 
119
Chapter VI - Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
there was a non-significant trend towards an inverse dose–response relationship 
between the cumulative rituximab dose and malignancy risk: the more rituximab 
a patient received, the lower the malignancy risk, with the risk actually falling 
below the risk in the general population if more than a cumulative dose of 6.0 g 
was given. The relative risk for developing a malignancy was more than six times 
lower in patients who had received a cumulative dose of rituximab of more than 
6.0 g than in patients who had not received rituximab at all.
Interestingly, our findings – although the number of patients was relatively 
low – may point towards the possibility that rituximab has a protective role 
in the development of malignancies. This hypothesis is underlined by data 
showing a trend of an inverse dose–response relationship, and by the difference 
in malignancy development of the combined treatment group (i.e., patients 
receiving both cyclophosphamide and rituximab). Depletion of B cells due to 
rituximab may increase antitumour immunity, as was demonstrated in mouse 
models in which B-cell-deficient mice are resistant to the development of certain 
malignancies.28, 29 The enhanced antitumour immune response in these mice is 
probably caused by decreased IL-10 production by B cells, leading to enhancement 
of the antitumour effects of cytotoxic T cells.28 There is emerging evidence 
that regulatory B cells are the main mediators of this mechanism.30 In humans, 
the hypothesis that rituximab enhances the antitumour immune response is 
supported by the trend towards a lower risk of developing a second primary 
malignancy in patients with non-Hodgkin’s lymphoma treated with rituximab-
containing chemotherapy compared with patients treated with chemotherapy 
that does not include rituximab.31, 32 However, clarification of the effects of B-cell 
depletion on antitumour immunity in humans requires further investigation.
The increased risks of bladder and haematological malignancies that have 
been previously reported for patients treated with cyclophosphamide did not 
materialise in this study, possibly reflecting the ongoing efforts to reduce 
cumulative cyclophosphamide doses.11 In accordance with two recent studies, 
only the risk of non-melanoma skin cancer was increased in the current study.9, 
11 To prevent the development of these lesions, all patients were given written 
information concerning the risks of non-melanoma skin cancer. Moreover, they 
were advised to avoid ultraviolet radiation, to use sunscreens and to promptly 
report skin lesions. Of the patients who developed non-melanoma skin cancer 
despite these preventative measures, the majority had received azathioprine 
as maintenance therapy before the occurrence of this malignancy. Therefore, 
the previously reported association between non-melanoma skin cancer and 
azathioprine exposure is confirmed in our study.33–37 However, in our study, only 
the combination of cyclophosphamide and azathioprine treatment was associated 
with an increased malignancy risk. In contrast, patients treated with rituximab 
and azathioprine had a malignancy risk similar to the general population. 
Lowering cyclophosphamide and azathioprine exposure will most likely decrease 
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the malignancy risk. For patients with AAV who receive azathioprine, especially 
those who received cyclophosphamide as induction therapy, regular skin cancer 
screening should be started to control and prevent the development of non-
melanoma skin cancers. Moreover, patients should be advised as to how to protect 
themselves against ultraviolet radiation.38
Previous studies that investigated the malignancy risk in patients with AAV 
were restricted to patients with granulomatosis with polyangiitis and microscopic 
polyangiitis, and did not include patients with eosinophilic granulomatosis 
with polyangiitis. Eosinophilic granulomatosis with polyangiitis has a lower 
incidence than granulomatosis with polyangiitis and microscopic polyangiitis, 
and it is treated similarly.39 The 54 patients with eosinophilic granulomatosis 
with polyangiitis who were included in this study had a 2.75-fold increased 
malignancy risk compared with the general population. We therefore recommend 
that clinicians monitor patients with eosinophilic granulomatosis with polyangiitis 
for malignancies as carefully as patients with granulomatosis with polyangiitis 
and microscopic polyangiitis.
One limitation of this study is its retrospective design. However, it excluded 
patients with unclear or missing data. A second limitation is the relative short 
follow-up, with a mean of 5.6 years. Longer follow-up studies are now required 
to validate our findings. A third limitation of this study is the relatively small 
number of patients, particularly in the subgroup analyses. This could explain the 
non-significance of the inverse dose–response relationship between rituximab 
and malignancy risk. This relationship merits further investigation in larger 
studies. Finally, the study involved just one medical centre, so the findings may 
not be generalisable to other settings. One strength of this study is the large study 
population, in which, for the first time, the malignancy risk was evaluated in 
patients treated with rituximab during long-term follow-up. This is also the first 
study to analyse the malignancy risk in patients with eosinophilic granulomatosis 
with polyangiitis. Another strength of our study is the calculation of cumulative 
cyclophosphamide and rituximab doses. Finally, the calculation of sex, age and 
calendar-year period-matched SIRs ensured reliable comparisons between our 
cohort and the general population.
In conclusion, we demonstrated that patients with AAV who are treated with 
rituximab have a decreased burden of malignancy, which surpasses expectations 
from clinical trials data.18, 19 Moreover, our results suggest that rituximab may 
protect against the occurrence of malignancies, a possibility that should be 
explored in further detail using larger cohort populations. Patients with AAV 
treated with rituximab had a strikingly lower malignancy risk than those treated 
with cyclophosphamide and no increased malignancy risk compared with the 
general population. Therefore, the rituximab dose currently used in clinical 
practice could be a safe alternative to cyclophosphamide in the treatment of AAV.
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More than 150 years after the publication of the first case-report of a patient with, 
what is now considered to be, antineutrophil cytoplasmic antibodies (ANCA)-
associated vasculitis, considerable progress has been made in the understanding 
of the pathogenesis, the diagnostic approach, and the treatment of this disease.1 
Research in ANCA-associated vasculitis has come a long way. However, the 
heart of the matter is still unsolved, as the exact nature of this complex disease 
and, consequently, the most appropriate disease classification system and optimal 
treatment strategies are still not unravelled. In this thesis, several aspects of 
ANCA-associated vasculitis concerning genetics, clinical and histopathological 
classification, and long-term outcome were investigated.
Genetics and disease classification
Despite the considerable progress made in recent decades, the pathophysiology of 
ANCA-associated vasculitis is still not fully unravelled. Amongst others, genetic 
factors are believed to contribute to the pathogenesis of this complex disease.2 
In Chapter 2 of this thesis we conducted a meta-analysis to investigate the 
genetic variants that are most likely associated with ANCA-associated vasculitis. 
To increase the validity of our meta-analysis, we included raw data from a large 
genome-wide association study (GWAS).3 This study provides the first complete 
and comprehensive overview of all genetic variants investigated in ANCA-
associated vasculitis in at least two independent studies.
Thirty-three genetic variants, located in or near 15 genes, were found to be 
associated with ANCA-associated vasculitis. The genetic variants were located in 
or near the following genes: CD226, CTLA-4, FCGR2A, HLA-B, HLA-DP, HLA-DQ , 
HLA-DR, HSD17B8, IRF5, PTPN22, RING1/RXRB, RXRB, STAT4, SERPINA1, and 
TLR9. The results of this meta-analysis confirm that genetic factors contribute 
to the pathogenesis of ANCA-associated vasculitis. In particular, they support a 
role for the major histocompatibility complex (MHC), the innate and adaptive 
immune system, and several inflammatory processes in the pathogenesis of this 
complex disease; the identified genetic factors could potentially result in altered 
HLA mediated antigen presentation, inadequate T- and B-lymphocyte activation, 
and abnormal target antigen structure and/or function. The mechanisms whereby 
and the extent to which these genetic variants directly cause disease requires 
further investigation.
Most importantly, the results of our meta-analysis provide clear evidence of 
a genetic susceptibility that differed between granulomatosis with polyangiitis 
(GPA) and microscopic polyangiitis (MPA) patients and between proteinase 3 
(PR3)-ANCA positive and myeloperoxidase (MPO)-ANCA positive patients. 
Moreover, the associations were primary aligned with ANCA-serotype rather 
than with the clinically defined syndromes: in 76% of the genetic variants, 
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subdivision based on ANCA-serotype resulted in higher odds ratios than 
subdivision based on clinical diagnosis.
Considerable debate surrounds the classification of ANCA-associated 
vasculitis. GPA and MPA have overlapping clinical features, and while patients 
with typical characteristics are easy to classify, many patients are allocated 
inconsistently even by experienced clinicians. Moreover, even though the Chapel 
Hill Consensus Conference (CHCC) and European Medicines Agency (EMA) 
classification systems use identical names for the ANCA-associated vasculitis 
disease categories, a study performed by Lionaki et al. demonstrated substantial 
discrepancies between the two classification systems in the allocation of patients 
to these categories: 78% of patients classified as having MPA using the CHCC 
system were considered to have GPA by the EMA system.4 The authors argued 
that this resulted in part from differences in disease definitions. For instance, the 
EMA system over-represents the diagnostic category of GPA because, according 
to the American College of Rheumatology criteria, essentially any upper 
respiratory involvement is considered to be GPA.5 Overall, the inconsistencies 
between clinicians and between the classification systems and the lack of 
diagnostic criteria make the use of the terms GPA and MPA less accurate and 
less predictive of outcome.
Interestingly, a number of clinical studies demonstrated that disease course, 
treatment response, and patient outcome align more closely with ANCA-serotype 
than with clinical diagnosis. Lionaki et al. demonstrated that ANCA-serotype is 
closely associated with clinical features and the relative frequency of organ system 
involvement.4 ANCA-serotype was shown to be more strongly associated with 
relapse than clinical diagnosis, and patients with PR3-ANCA positive GPA were 
shown to have a significantly different disease course than patients with MPO-
ANCA positive GPA.4, 6 Unizony et al. investigated treatment response in patients 
enrolled in the Rituximab in ANCA-associated Vasculitis (RAVE) trial according 
to both clinical diagnosis (GPA versus MPA) and ANCA-serotype (PR3-ANCA 
versus MPO-ANCA).7 Treatment response did not differ between GPA and MPA 
patients. In contrast, treatment response did differ between PR3-ANCA positive 
and MPO-ANCA positive patients: PR3-ANCA positive patients were shown to 
respond better to rituximab than to the combination of cyclophosphamide and 
azathioprine. These findings have led to the following question: is it the name 
of the disease or is it the serotype that is more important with respect to disease 
classification and individual patient prognosis?
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Our genetic findings taken together with the clinical findings discussed previously 
underscore the need to account for ANCA-serotype in the classification of 
ANCA-associated vasculitis. Arguments to incorporate ANCA-serotype in the 
classification of ANCA-associated vasculitis include:
-- Distinct genetic subsets correlate more strongly with ANCA-serotype than 
with clinical classification
-- ANCA-serotype correlates better with clinical features than clinical 
classification
-- ANCA-serotype is more reproducible and reliable than clinical classification
-- ANCA-serotype better reflects the disease mechanism
However, there are problems with using only ANCA-serotype to classify 
patients. For example, using current assays, 5-10% of ANCA-associated 
vasculitis patients are ANCA-negative.8-13 Moreover, better understanding of 
the granuloma formation in ANCA-associated vasculitis may reveal therapies that 
specifically target this component of the disease, which requires acknowledging 
this phenotype. Therefore, for now, a classification system based primarily on 
ANCA-serotype with subsequent subdivision based on clinical diagnosis – e.g. 
PR3-ANCA positive GPA – may be the best way to characterize patients until 
we truly understand the similarities and differences in the pathogenesis of the 
ANCA-associated vasculitides. This will provide practical classification criteria 
better aligned to patient phenotype, treatment responses, and outcomes, and 
will allow logical design and testing of future therapies.
In Chapter 3, we focused on ear, nose, and throat (ENT) involvement and 
ANCA-serotype with respect to renal histology at diagnosis and renal outcome. 
Previously, Hauer et al. demonstrated that MPO-ANCA positive vasculitis 
patients have more chronic lesions in their renal biopsies than PR3-ANCA 
positive vasculitis patients. The authors hypothesized that this finding may reflect 
an association of MPO-ANCA with a clinical phenotype of smouldering disease.14 
This could be indicative of different disease mechanisms in PR3-ANCA vasculitis 
and MPO-ANCA vasculitis, in line with the results presented in Chapter 2. 
However, PR3-ANCA positivity is also closely correlated with ENT disease.15, 
16 Thus, another hypothesis for the fewer chronic lesions in the renal biopsies of 
PR3-ANCA positive patients is that the clinically overt ENT manifestations in 
these patients lead to earlier diagnosis of ANCA-associated vasculitis by reducing 
patient’s and/or doctor’s delay.
In our study, patients with ENT involvement had fewer chronic lesions in 
their renal biopsies and better renal function at diagnosis and 5-year follow-
up than patients without ENT involvement. Our results suggest that this is 
not caused by earlier diagnosis due to the clinically overt ENT symptoms: in 
the same patients, other manifestations that would also have reduced patient 
and/or doctor’s delay, such as lung involvement, cutaneous manifestations, and 
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arthralgia/arthritis, were not associated with renal histology or renal outcome. 
To exemplify this point further; a study by Bligny et al. reported higher survival 
in ANCA-associated vasculitis patients with ENT involvement than patients 
without ENT involvement.17 The authors argued that this is not likely caused by 
earlier diagnosis and treatment, as 87% of patients without ENT involvement had 
lung involvement, which, theoretically, also would have led to earlier diagnosis. 
Interestingly, a study by Poulton et al. even demonstrated an increased diagnostic 
delay in ANCA-associated vasculitis patients with ENT involvement.18 The 
authors argued that both physicians and patients focused on the more common 
causes of the ENT symptoms instead of regarding them as signs of vasculitis. As 
could be expected, patients with skin manifestations often had a prompt diagnosis 
of ANCA-associated vasculitis.18
In our study, ENT involvement overruled ANCA-serotype in the 
multivariable analysis and was still associated with better renal outcome in a 
sub-analysis including only PR3-ANCA positive patients. Thus, independent 
of ANCA-serotype, ENT involvement itself seems to be associated with better 
renal histology and outcome. The findings of this study can be viewed in the 
context of the two distinct pathological features in GPA, namely: vasculitis, 
which is predominantly localized in the kidneys, and granulomatosis, which 
predominantly involves the airways.19 The clinical heterogeneity of GPA reflects a 
spectrum of manifestations ranging from predominantly vasculitic disease at one 
end to predominantly granulomatous disease at the other. Thus, in our study, the 
patients with ENT involvement could have had a predominantly granulomatous 
disease, while the patients without ENT involvement had a predominantly 
vasculitic disease. In this light, the better renal prognosis in the patients with 
ENT involvement could be representative of the more benign renal course of 
‘granulomatous GPA’ compared to ‘vasculitic GPA’.
The pathological pathways leading to vasculitis or granuloma formation are 
hypothesized to be different. Immunological studies indicate that these two 
distinct pathological features correspond to different T cell immune responses; 
i.e. a T helper cell 1 (Th1)-type response in granulomatous disease and a Th2-
type response in vasculitic disease.20-22 Further studies are needed to adequately 
assess the potential prognostic value of ENT involvement, which, in turn, might 
provide further insight into the pathogenesis of GPA.
Histopathological classification of ANCA-associated 
glomerulonephritis
The histopathological classification of ANCA-associated glomerulonephritis was 
devised by an international working group of renal pathologists and nephrologists 
with the aim of further adding to the prognostication of patients with ANCA-
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associated glomerulonephritis.23 Thus far, 21 validation studies, consisting of 
cohorts from Asia, North-America, Australia, and Europe, have investigated 
the prognostic value of the classification system.24-44 Chapter 4 reviews the 
findings of these validation studies and puts them into a broader perspective. In 
general, the studies confirmed the predictive value of the classification system 
for renal outcome in the focal and sclerotic classes. However, several studies 
showed conflicting results with respect to the crescentic and mixed classes.24-37
A number of factors may have contributed to the inconsistent results between 
the validation studies. As indicated by their denominator, biopsies in the mixed 
class may indeed show mixed lesions in which either an acute or chronic phenotype 
can predominate. Therefore, differences in the compositions of the mixed classes 
in the various validation studies may have contributed to the different outcomes 
reported for this class. It could be argued that, in its current form, this class is 
too heterogeneous to have a straightforward predictive value in the classification 
system. A second explanation for the inconsistent results between the validation 
studies might be a problem of definitions; the crescentic class was originally 
defined as the predominance of cellular crescents, however, this definition 
may have lacked important details leading to inter-observer discrepancies 
among pathologists.23, 29 Differences in patient population and treatment most 
probably also contributed to the variable results between the validation studies. 
Unfortunately, due to their retrospective design, it was not possible to fully 
account for treatment in most of the validation studies. A number of validation 
studies suggested that inclusion of tubulointerstitial parameters could increase 
the predictive value of the classification system. In contrast, Berden et al. argued 
that inclusion of tubulointerstitial parameters does not add meaningfully to the 
predictive value of the classification system and only increases its complexity.23
Currently ongoing studies that aim at the optimization of the histopathological 
classification of ANCA-associated glomerulonephritis are discussed in the ‘Future 
perspectives’ section of this chapter.
Treatment and outcome
Over the last decades, the introduction of immunosuppressive treatment has 
improved the prognosis of patients with ANCA-associated vasculitis dramatically. 
Maintenance of remission, on the other hand, still represents a challenge, 
necessitating prolonged immunosuppressive treatment.45 Despite the clear 
success of conventional immunosuppressive therapies, their long-term side effects 
jeopardize outcomes. One of the long-term side effects of immunosuppressive 
treatment is the occurrence of malignancies.46
Chapter 5 reports the results of the first 10-year follow-up study investigating 
malignancy risk in patients with ANCA-associated vasculitis treated with current 
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treatment regimens. In these patients, overall malignancy risk was 2.21 times 
increased compared to the general population. This increased malignancy 
risk was attributable solely to the increased risk of non-melanoma skin cancer 
(NMSC). Importantly, in contrast to previous studies,47 in our study the risks of 
bladder cancer, lymphomas, and leukaemia were not increased. These findings 
most likely reflect the decrease in cyclophosphamide exposure in the treatment 
of ANCA-associated vasculitis in the last decade.8-10, 13
The close relationship between disease activity and immunosuppressive 
treatment exposure makes it difficult to distinguish disease-related from 
treatment-related effects on malignancy risk. Nonetheless, a subgroup analysis 
– based on year of diagnosis and subsequent treatment – demonstrated that 
malignancy risk was no longer significantly increased after the major reduction 
in cyclophosphamide exposure that resulted from the publication of the 
CYCAZAREM trial.10 Moreover, malignancy risk was directly correlated to the 
duration of cyclophosphamide treatment.
In summary, the data reported in Chapter 5 demonstrate the effectiveness 
of international efforts to reduce toxicity in the treatment of ANCA-associated 
vasculitis. Despite the advances achieved, the road towards treatment modalities 
with less adverse effects in terms of, amongst others, infection risk, infertility, 
and malignancy occurrence in patients with prolonged cyclophosphamide 
exposure, is still long. Recently, rituximab was successfully introduced in the 
treatment of ANCA-associated vasculitis with the aim of, amongst others, further 
reducing these adverse treatment effects.13, 48, 49
Chapter 6 reports the first study that compares the long-term malignancy 
risks between rituximab-based and cyclophosphamide-based treatment in 
ANCA-associated vasculitis. Strikingly, malignancy risk was 4.61 fold increased 
in patients treated with cyclophosphamide compared to patients treated 
with rituximab. Malignancy risk was 3.10 fold increased in patients treated 
with cyclophosphamide compared to the general population. This increased 
malignancy risk was again solely attributable to the occurrence of NMSC. In 
contrast, malignancy risk was not increased in patients treated with rituximab. 
Interestingly, patients treated with both rituximab and cyclophosphamide had a 
lower malignancy risk than patients treated with cyclophosphamide alone, despite 
the mean cumulative cyclophosphamide dose being lower in the latter group. 
In addition, there was a trend towards an inverse dose-response relationship 
between the cumulative rituximab dose and malignancy risk, i.e., the more 
rituximab a patient received, the lower the malignancy risk. Notably, patients 
who cumulatively received more than 6.0g rituximab had a lower malignancy 
risk than the general population. This effect was observed for both haematological 
and non-haematological malignancies.
These findings hint towards the possibility that rituximab has an inhibitory 
effect on (haematological and non-haematological) malignancy occurrence. B cell 
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depletion – the mechanism of action of rituximab – was shown to increase anti-
tumour immunity in murine models.50, 51 This enhanced anti-tumour immune 
response is hypothesized to be caused by decreased IL-10 production by B 
regulatory cells, leading to enhancement of the anti-tumour effects of cytotoxic 
T cells.50 In humans, the hypothesis that rituximab enhances the anti-tumour 
immune response is supported by the trend towards a lower risk of developing a 
second primary (non-haematological) malignancy in patients with non-Hodgkin 
lymphoma treated with rituximab-containing chemotherapy, compared to 
patients treated with conventional chemotherapy not including rituximab.52, 53 
Clearly, elucidation of the effects of B-cell depletion on anti-tumour immunity 
requires further investigation.
In conclusion, the results of the study reported in Chapter 6 demonstrate 
that patients with ANCA-associated vasculitis treated with rituximab have a 
decreased burden of malignancy, surpassing expectations from clinical trial 
data.54, 55 Moreover, our results suggest that rituximab may have an inhibitory 
effect on malignancy occurrence. Therefore, regarding the occurrence of 
malignancies, rituximab seems a superior alternative to cyclophosphamide in 
the treatment of ANCA-associated vasculitis.
Future perspectives
Despite the major advances made in the understanding of the pathogenesis, the 
diagnostic approach, and the treatment of ANCA-associated vasculitis, many 
questions are still unanswered and new questions arise every day. The results of 
the meta-analysis presented in this thesis confirm that genetic factors contribute 
to the pathogenesis of ANCA-associated vasculitis. However, functional 
studies remain to be performed to establish the precise role of these genetic 
variants and their effects on the disease process. Future studies in genetics and 
epigenetics will likely not only lead to a deeper understanding of the pathogenesis 
of ANCA-associated vasculitis, but perhaps also to a personalised medicine 
approach to clinical management and therapeutic target selection. In systemic 
lupus erythematosus, researchers have developed a personalized transcriptional 
immunomonitoring approach that enables patient stratification based on 
molecular networks best correlating with disease progression.56 The development 
of such a personalized transcriptional immunomonitoring approach in ANCA-
associated vasculitis would create some order in this complex heterogeneous 
disease, bringing patient-tailored treatment one step closer.
The genetic differences between PR3-ANCA vasculitis and MPO-ANCA 
vasculitis indicate that future genetic and clinical studies should be sufficiently 
powered to allow for independent analysis of PR3-ANCA positive and MPO-
ANCA positive patients. Currently, a GWAS including GPA and MPA patients 
133
Chapter VII - Summary and general discussion
is being conducted that is sufficiently powered to investigate genetic associations 
in the PR3-ANCA and MPO-ANCA subgroups independently.57 Moreover, an 
ongoing GWAS is investigating whether there are genetic differences between 
MPO-ANCA positive and MPO-ANCA negative patients with eosinophilic 
granulomatosis with polyangiitis (EGPA).57 Preliminary results of this GWAS 
point towards profound differences in the pathogenesis of these two EGPA 
subtypes and suggest a number of therapeutic approaches that might be effective 
in EGPA.
Current treatment strategies in ANCA-associated vasculitis do not take into 
account specific patient and disease characteristics. However, genetic and clinical 
data suggest that treatment should be tailored to specific parameters. Possible 
parameters that, now or in the future, could be taken into consideration for 
refining treatment, in the form of patient-tailored therapy, are: genetic markers, 
ANCA-serotype, severity scores, and scores and/or markers predicting relapse. 
A step in this direction is set by the identification of altered gene expressions 
that can predict treatment response in MPA patients.58 The MAINRITSAN 
2 trial (ClinicalTrials.gov NCT01731561) is currently investigating treatment 
response in rituximab treatment according to a fixed administration protocol 
versus individually tailored rituximab treatment based on ANCA-status and 
peripheral blood CD19 lymphocyte reappearance. In refractory rheumatoid 
arthritis, similar parameters (rheumatoid factor, anti-CCP antibodies, and serum 
IgG concentration) were shown to predict treatment response to rituximab.59
Presently, we are stepping into a new therapeutic era with targeted therapies 
– e.g. monoclonal antibodies such as rituximab – that could further improve 
the treatment of ANCA-associated vasculitis. This is a field for ongoing and 
future trials that investigate the optimal dosing and duration of rituximab both 
as induction and maintenance treatment. The currently ongoing RITAZAREM 
trial (ClinicalTrials.gov NCT01697267) will provide the largest trial dataset 
for the use of rituximab as remission-induction treatment for ANCA-associated 
vasculitis. This trial compares rituximab and azathioprine maintenance treatment 
following rituximab induction-treatment, and explores whether prolonged 
B-cell depletion leads to sustained treatment-free remission after treatment 
discontinuation. Although the first studies, as demonstrated in this thesis, 
indicate that rituximab treatment has resulted in less morbidity in the long run, 
more long-term follow-up studies with longer follow-up are warranted.
Moreover, it becomes more and more apparent that the burden of 
corticosteroids is responsible for a substantial part of the treatment-related adverse 
events in ANCA-associated vasculitis. Several ongoing studies are investigating 
different dosing regimens of steroids regarding efficacy and safety. The currently 
ongoing PEXIVAS trial (ClinicalTrials.gov NCT00987389) is the largest trial 
conducted in ANCA-associated vasculitis thus far and has recruited more than 
700 patients from over 100 centres over the world. This 2-by-2 trial addresses the 
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effect of a reduced cumulative dosing regimen of glucocorticoids and the effect 
of adjuvant plasma exchange in patients with severe ANCA-associated vasculitis.
Regarding histology, future studies might answer the question whether renal 
biopsy findings will be directly useful to guide therapeutic decision-making. 
A large international validation study of the histopathological classification of 
ANCA-associated glomerulonephritis in which histopathological, clinical, and 
therapeutic data are being incorporated is currently being conducted. Moreover, 
the biopsies included in the 21 previously performed validation studies are now 
being collected with the aim of re-evaluating them by a group of experienced 
pathologists. The aim of these studies is to evaluate the predictive value of 
the classification system, formulate clearer and more concise definitions, and 
possibly also revise the histopathological classification of ANCA-associated 
glomerulonephritis.
Overall, the vasculitis patient and research communities can be optimistic 
about the future of research in ANCA-associated vasculitis and the potential for 
this work to unravel the puzzle of this complex disease and, most importantly, 
to improve the lives of patients with ANCA-associated vasculitis.
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Vasculitis betekent letterlijk: ontsteking van bloedvaten. Ontstekingen van 
bloedvaten kunnen overal in het lichaam voorkomen. In de meeste gevallen 
leiden zij, afhankelijk van de ernst van de ontstekingen, in meer of mindere 
mate tot functieverlies van de betrokken organen. Dit proefschrift gaat specifiek 
over vasculitis die gekenmerkt wordt door de aanwezigheid van anti-neutrofiele 
cytoplasmatische antilichamen (ANCA) in het bloed van patiënten. ANCA zijn 
afweerstoffen die gericht zijn tegen componenten in het celvocht (cytoplasma) 
van bepaalde typen witte bloedcellen (neutrofiele granulocyten en monocyten). 
De klassieke eiwitten waar ANCA zich tegen richten zijn proteïnase 3 (PR3) en 
myeloperoxidase (MPO).
ANCA-geassocieerde vasculitis omvat de volgende ziektebeelden:
-- granulomatose met polyangiitis (GPA, voorheen de ziekte van Wegener 
genoemd);
-- microscopische polyangiitis (MPA);
-- eosinofiele granulomatose met polyangiitis (EGPA, voorheen Churg-Strauss-
syndroom genoemd).
De meeste patiënten met GPA hebben PR3-ANCA in het bloed en de meeste 
patiënten met MPA hebben MPO-ANCA in het bloed. Ongeveer de helft van 
de EGPA patiënten heeft MPO-ANCA in het bloed, de andere helft heeft 
geen ANCA in het bloed. ANCA lijken een rol te spelen bij het ontstaan van 
ANCA-geassocieerde vasculitis; onder bepaalde omstandigheden activeren 
ANCA witte bloedcellen. Deze geactiveerde witte bloedcellen veroorzaken de 
bloedvatontstekingen.
Patiënten met ANCA-geassocieerde vasculitis hebben vaak ‘algemene’ klachten 
zoals malaisegevoel en gewichtsverlies. Daarnaast zijn vaak het keel-, neus- en 
oorgebied (KNO-gebied), de longen en de nieren van deze patiënten aangedaan. 
De ziekte kan zich ook manifesteren in de gewrichten, het zenuwstelsel en het 
maagdarmstelsel. Bij het uitblijven van een behandeling overlijden de meeste 
patiënten met ANCA-geassocieerde vasculitis kort na het stellen van de 
diagnose. Zonder behandeling is één jaar na de diagnose nog slechts één op de 
vijf patiënten in leven. De behandeling van ANCA-geassocieerde vasculitis bestaat 
uit ontstekingsremmende en afweeronderdrukkende medicijnen. Hoewel deze 
behandeling op korte termijn erg effectief is, keert de ziekte bij ongeveer de helft 
van de patiënten na verloop van tijd terug. Bovendien hebben deze medicijnen 
ernstige bijwerkingen waar patiënten zelfs aan kunnen overlijden.
Ongeveer 150 jaar geleden werd in de wetenschappelijke literatuur de eerste 
patiënt met ANCA-geassocieerde vasculitis beschreven. Sindsdien is de kennis 
omtrent het ziekteproces en de behandeling van dit complexe ziektebeeld 
aanzienlijk toegenomen. Vraagstukken omtrent de oorzaak van ANCA-
geassocieerde vasculitis, de meest geschikte ziekteclassificatiesystemen en de 
meest optimale behandelstrategieën vormen de focus van de huidige studies naar 
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ANCA-geassocieerde vasculitis. De studies die in dit proefschrift zijn beschreven 
onderzoeken:
-- de genetische achtergrond van ANCA-geassocieerde vasculitis;
-- de klinische en histopathologische classificaties van ANCA-geassocieerde 
vasculitis;
-- het ontstaan van maligniteiten (kankergezwellen) als gevolg van de behandeling 
van ANCA-geassocieerde vasculitis.
Genetica en ziekteclassificatie
Het ziekteproces waardoor ANCA-geassocieerde vasculitis ontstaat, is complex 
en nog niet volledig ontrafeld. Wetenschappers veronderstellen dat onder meer 
genetische factoren een rol spelen bij het ontstaan van ANCA-geassocieerde 
vasculitis. In hoofdstuk 2 van dit proefschrift wordt de genetische achtergrond 
van ANCA-geassocieerde vasculitis onderzocht. In de afgelopen jaren hebben 
verschillende onderzoeksgroepen over de wereld een groot aantal studies 
uitgevoerd naar de genetische achtergrond van ANCA-geassocieerde vasculitis. 
Veel van deze studies zijn echter uitgevoerd met relatief kleine aantallen 
patiënten en controles. Hierdoor zijn de resultaten van deze studies soms lastig 
te interpreteren en/of onbetrouwbaar. Hoofdstuk 2 beschrijft een meta-
analyse van de genetische associatiestudies die zijn uitgevoerd bij patiënten met 
ANCA-geassocieerde vasculitis. Een meta-analyse is een statistische methode 
om resultaten van verschillende studies samen te voegen om zo tot een meer 
robuust resultaat te komen. Om de validiteit van de meta-analyse te vergroten zijn 
tevens ruwe data uit een grote Europese genoomwijde associatiestudie (GWAS) 
geïncludeerd. GWAS is een relatief nieuwe methode voor wetenschappers om 
genen te identificeren die betrokken zijn bij een bepaalde ziekte. Door middel 
van deze methode onderzoeken wetenschappers het genoom op kleine variaties, 
genaamd single nucleotide polymorphisms (SNPs), die vaker voorkomen bij 
mensen met een bepaalde ziekte dan bij mensen zonder deze ziekte.
De genetische varianten die in de meta-analyse significant geassocieerd waren 
met ANCA-geassocieerde vasculitis liggen in of dicht bij de volgende genen: 
CD226, CTLA-4, FCGR2A, HLA-B, HLA-DP, HLA-DQ , HLA-DR, HSD17B8, IRF5, 
PTPN22, RING1/RXRB, RXRB, STAT4, SERPINA1 en TLR9. De resultaten van 
deze meta-analyse bevestigen dat genetische factoren bijdragen aan het ontstaan 
van ANCA-geassocieerde vasculitis. In het bijzonder ondersteunen zij een rol 
voor het major histocompatibility complex (MHC), het aangeboren en adaptieve 
immuunsysteem en verschillende ontstekingsprocessen in het ontstaan van 
deze complexe ziekte. Verder onderzoek naar het werkingsmechanisme van 
bovenstaande genen zal hopelijk niet alleen leiden tot nieuwe inzichten in de 
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ontstaanswijze, maar ook tot nieuwe aangrijpingspunten voor de therapie van 
ANCA-geassocieerde vasculitis.
De meta-analyse gepresenteerd in hoofdstuk 2 toont genetische verschillen 
tussen patiënten met GPA en patiënten met MPA. Eveneens toont de meta-
analyse genetische verschillen tussen patiënten met PR3-ANCA in het bloed en 
patiënten met MPO-ANCA in het bloed. De genetische verschillen tussen de 
ANCA-serotypes (PR3-ANCA en MPO-ANCA) waren groter dan de genetische 
verschillen tussen de klinische diagnosen (GPA en MPA). Deze bevinding 
impliceert dat PR3-ANCA-vasculitis en MPO-ANCA-vasculitis genetisch 
verschillende ziektebeelden zijn. Op grond van de sterke overeenkomsten 
in hun klinische en histologische manifestaties worden GPA en MPA tot op 
heden beschouwd als verschillende entiteiten binnen hetzelfde ziektebeeld. 
Niettemin wordt steeds meer duidelijk dat er opvallende verschillen tussen 
deze ziektebeelden zijn. Zo hebben GPA / PR3-ANCA-positieve patiënten een 
groter risico op een terugkeer van de ziekte dan MPA / MPO-ANCA-positieve 
patiënten. Daarnaast is behandeling met het relatief nieuwe geneesmiddel 
rituximab effectiever bij patiënten met PR3-ANCA dan bij patiënten met MPO-
ANCA. Deze verschillen hebben geleid tot de vraag of de verschillende entiteiten 
binnen ANCA-geassocieerde vasculitis verschillende uitingen van eenzelfde 
ziektebeeld zijn of dat zij juist verschillende ziektebeelden representeren.
De sterke genetische verschillen tussen PR3-ANCA- en MPO-ANCA-
positieve patiënten tezamen met de klinische verschillen tussen deze patiënten 
wijzen erop dat PR3-ANCA-vasculitis en MPO-ANCA-vasculitis verschillende 
ziektebeelden zijn. Dit onderstreept de noodzaak voor de incorporatie van het 
ANCA-serotype in de classificatie van ANCA-geassocieerde vasculitis. Deze 
nieuwe classificatie zal in de toekomst hopelijk leiden tot de ontwikkeling van 
meer specifieke therapeutische strategieën.
Hoofdstuk 3 van dit proefschrift richt zich op het voorkomen van KNO-
betrokkenheid en het ANCA-serotype in relatie tot renale betrokkenheid bij 
ANCA-geassocieerde vasculitis. Eerder onderzoek heeft aangetoond dat patiënten 
met MPO-ANCA-vasculitis meer chronische laesies in het nierbiopt hebben 
dan patiënten met PR3-ANCA-vasculitis. Dit kan enerzijds – in lijn met de 
bevindingen uit hoofdstuk 2 van dit proefschrift – duiden op verschillende 
ziektemechanismen in PR3-ANCA-vasculitis en MPO-ANCA-vasculitis. 
Anderzijds komen KNO-manifestaties – onder andere recidiverende bloedneuzen 
en gehoorverlies – vaker voor bij ANCA-geassocieerde vasculitispatiënten die 
PR3-ANCA-positief zijn. Het is mogelijk dat de PR3-ANCA-positieve patiënten 
door de klinisch aanwezige KNO-manifestaties vroeger gediagnosticeerd en 
behandeld worden dan MPO-ANCA-positieve patiënten. Dit zou een verklaring 
kunnen zijn voor de prognostisch gunstigere nierbiopten van de PR3-ANCA-
positieve patiënten.
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Vierhonderdenveertien patiënten met ANCA-geassocieerde vasculitis afkomstig 
uit 62 ziekenhuizen in 15 landen namen deel aan de studie gepresenteerd in 
hoofdstuk 3 van dit proefschrift. In vergelijking met patiënten zonder KNO-
manifestaties hadden patiënten mét KNO-manifestaties minder chronische laesies 
in de nierbiopten en een betere nierfunctie tijdens de diagnose en 5 jaar na de 
diagnose. Andere manifestaties die ook tot een snellere diagnose kunnen leiden, 
zoals gewrichtsklachten, vasculitis van de huid en vasculitis van de longen (zich 
onder andere uitend door het opgeven van bloed), waren niet geassocieerd met 
de nierfunctie tijdens de diagnose en 5 jaar na de diagnose. Hieruit volgt dat de 
betere renale uitkomsten bij patiënten met KNO-betrokkenheid waarschijnlijk 
niet worden veroorzaakt doordat deze patiënten vroeger gediagnosticeerd en 
behandeld worden. KNO-betrokkenheid was nog steeds geassocieerd met de 
nierfunctie in een subgroep-analyse waarin alleen PR3-ANCA positieve patiënten 
waren geïncludeerd. KNO-betrokkenheid lijkt dus een belangrijke klinische 
parameter te zijn die, onafhankelijk van ANCA-serotype, geassocieerd is met 
een betere nierfunctie.
De histopathologische classificatie van ANCA-geassocieerde 
glomerulonefritis
Bij circa 80 tot 90 procent van de patiënten met ANCA-geassocieerde vasculitis 
zijn de nieren betrokken bij het ziekteproces. Dat juist de nieren zo vaak aangetast 
worden door de vasculitis is niet verwonderlijk. Het filtreersysteem van de 
nieren bestaat namelijk uit kluwens van kleine bloedvaatjes, de glomeruli. Bij de 
patiënten waarbij de nieren betrokken zijn bij het ziekteproces ontsteken deze 
bloedvaatjes. Hierdoor kunnen de nieren op den duur schadelijke afvalstoffen 
niet meer uitscheiden en hopen deze stoffen zich in het lichaam op. Bij ernstige 
nierfunctiestoornissen is nierfunctievervangende therapie in de vorm van dialyse 
of niertransplantatie op den duur noodzakelijk.
In 2010 werd de histopathologische classificatie van ANCA-geassocieerde 
glomerulonefritis (ziektemanifestaties van vasculitis in de nier) ontwikkeld 
door een internationale werkgroep van nefropathologen en nefrologen. De 
histopathologische classificatie heeft als voornaamste doel het bijdragen aan 
een betere inschatting van de prognose van patiënten met ANCA-geassocieerde 
glomerulonefritis. Het classificatiesysteem is opgebouwd rondom glomerulaire 
pathologie en onderscheidt vier categorieën:
-- De focale categorie; in deze categorie zijn minimaal 50 procent van de 
glomeruli niet aangetast door vasculitis.
-- De crescentische categorie; in deze categorie tonen minimaal 50 procent van 
de glomeruli cellulaire crescents.
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-- De gemengde categorie; in deze categorie is geen van de karakteristieke 
afwijkingen dominant.
-- De sclerotische categorie; in deze categorie zijn minimaal 50 procent van de 
glomeruli globaal gescleroseerd (verlittekend).
Een validatiestudie toonde aan dat deze categorieën in de genoemde volgorde 
geassocieerd zijn met oplopende ernst van nierfunctieverlies op de lange termijn.
Tot op heden is de histopathologische classificatie van ANCA-geassocieerde 
glomerulonefritis gevalideerd in 21 studies afkomstig uit Azië, Noord-
Amerika, Australië en Europa. In hoofdstuk 4 worden de bevindingen uit 
deze validatiestudies bediscussieerd en in breder perspectief geplaatst. De 
resultaten van deze studies bevestigen de voorspellende waarde van de focale en 
sclerotische categorieën voor de nierfunctie op de lange termijn. De verschillende 
validatiestudies toonden echter bij de crescentische en gemengde categorieën 
tegenstrijdige resultaten. In sommige studies hadden de patiënten met een 
nierbiopt in de crescentische categorie betere renale uitkomsten dan patiënten 
met een nierbiopt in de gemengde categorie. In andere studies was dit andersom 
en hadden patiënten met een nierbiopt in de gemengde categorie een betere 
nierfunctie. De gemengde categorie in haar huidige vorm lijkt dan ook te divers 
van aard te zijn om een voorspellende waarde voor de nierfunctie op de lange 
termijn te hebben.
Behandeling en langetermijnuitkomst
Zoals hiervoor besproken is behandeling van ANCA-geassocieerde vasculitis van 
levensbelang. Zonder behandeling is één jaar na de diagnose slechts één op de 
vijf patiënten in leven. Bij de behandeling van ANCA-geassocieerde vasculitis 
wordt onderscheid gemaakt tussen de initiële therapie om de vasculitis te 
onderdrukken (inductietherapie) en de therapie om de vasculitis onderdrukt 
te houden (onderhoudstherapie). De inductietherapie bestaat klassiek uit het 
afweeronderdrukkend medicijn cyclofosfamide in combinatie met prednison 
(een corticosteroïde). De onderhoudstherapie bestaat uit azathioprine of 
methotrexaat waarbij de prednison wordt afgebouwd en waar mogelijk wordt 
gestopt. Azathioprine en methotrexaat zijn afweeronderdrukkende medicijnen 
die milder zijn dan cyclofosfamide. Met deze behandeling is 90 procent van 
de patiënten met ANCA-geassocieerde vasculitis één jaar na het stellen van de 
diagnose nog in leven.
De behandeling van ANCA-geassocieerde vasculitis is erg effectief maar gaat 
helaas ook gepaard met ernstige complicaties. Een mogelijke complicatie van 
het langdurig gebruik van afweeronderdrukkende medicijnen is het optreden 
van maligniteiten. In hoofdstuk 5 van dit proefschrift werd het risico op 
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maligniteiten onderzocht bij patiënten met ANCA-geassocieerde vasculitis die 
zijn behandeld met cyclofosfamide. De patiënten met ANCA-geassocieerde 
vasculitis hadden een tweemaal hoger risico op het ontwikkelen van maligniteiten 
ten opzichte van leeftijdsgenoten uit de algemene bevolking. Het risico op 
maligniteiten hield direct verband met de cumulatieve dosis cyclofosfamide 
die een patiënt kreeg; hoe meer cyclofosfamide, des te hoger het risico op het 
ontwikkelen van een maligniteit. Alleen het risico op het ontwikkelen van 
basaalcelcarcinomen en plaveiselcelcarcinomen van de huid was verhoogd. In 
tegenstelling tot oudere studies was in de studie gepresenteerd in hoofdstuk 5 
het risico op blaaskanker, leukemie en lymfomen niet verhoogd. Deze vooruitgang 
is waarschijnlijk het resultaat van internationale inspanningen (onder andere 
door middel van het uitvoeren van grote internationale klinische trials) om de 
behandeling van ANCA-geassocieerde vasculitis effectiever en veiliger te maken. 
Dit werd onder andere verwezenlijkt door een sterke verlaging van de totale dosis 
cyclofosfamide bij de behandeling van ANCA-geassocieerde vasculitis.
Cyclofosfamide blijft echter nog altijd ongunstige bijwerkingen hebben, met 
risico’s op onder andere infecties, onvruchtbaarheid en, bij patiënten met veel 
cyclofosfamidegebruik, maligniteiten. In de wetenschappelijke wereld wordt 
dan ook voortdurend gezocht naar nieuwere en veiligere therapieën. Onlangs is 
rituximab met succes geïntroduceerd in de behandeling van ANCA-geassocieerde 
vasculitis. Twee klinische trials (RITUXVAS en RAVE) demonstreerden dat 
rituximab effectief is in de behandeling van ANCA-geassocieerde vasculitis en 
relatief weinig bijwerkingen heeft. Deze studies leidden echter wel tot zorgen 
over een mogelijk verhoogd risico op maligniteiten bij de ANCA-geassocieerde 
vasculitispatiënten die met rituximab werden behandeld.
Hoofdstuk 6 beschrijft de eerste langetermijnstudie waarin het risico 
op maligniteiten wordt onderzocht bij patiënten met ANCA-geassocieerde 
vasculitis die worden behandeld met rituximab. Patiënten die werden behandeld 
met cyclofosfamide hadden een ruim vier en een half maal hoger risico op 
het ontwikkelen van maligniteiten ten opzichte van de patiënten die werden 
behandeld met rituximab. Het risico op maligniteiten was bij de patiënten die 
werden behandeld met cyclofosfamide ruim 3 maal hoger ten opzichte van 
leeftijdsgenoten uit de algemene bevolking. Daarentegen hadden de patiënten 
die werden behandeld met rituximab geen verhoogd risico op het ontwikkelen 
van maligniteiten ten opzichte van leeftijdsgenoten uit de algemene bevolking. 
De cumulatieve dosis cyclofosfamide hield – net zoals in de studie beschreven 
in hoofdstuk 5 – ook in deze studie direct verband met het risico op het 
ontwikkelen van maligniteiten. Concluderend laten de resultaten van de studie 
gepresenteerd in hoofdstuk 6 zien dat, wat betreft het risico op maligniteiten, 
rituximab een veiliger alternatief is dan cyclofosfamide in de behandeling van 
ANCA-geassocieerde vasculitis.
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Toekomstperspectieven
De resultaten uit dit proefschrift tonen aan dat genetische factoren betrokken 
zijn bij het ontstaan van ANCA-geassocieerde vasculitis. Vervolgstudies zullen de 
precieze rol van deze genetische varianten in het ziekteproces moeten vaststellen. 
Deze (epi)genetische studies zullen hopelijk niet alleen leiden tot diepere inzichten 
in het ontstaan van ANCA-geassocieerde vasculitis, maar ook tot therapie gericht 
op specifieke karakteristieken van de individuele patiënt (personalized medicine).
Daarnaast tonen de resultaten uit dit proefschrift ook aan dat PR3-
ANCA vasculitis en MPO-ANCA vasculitis verschillende genetische 
achtergronden hebben. Deze bevinding onderstreept de noodzaak voor een 
nieuw classificatiesysteem van ANCA-geassocieerde vasculitis. Dit nieuwe 
classificatiesysteem behoort primair gebaseerd te zijn op ANCA-serotype in plaats 
van klinische diagnose. In dit classificatiesysteem zal dus gesproken worden van 
PR3-ANCA vasculitis en MPO-ANCA vasculitis in plaats van GPA en MPA. 
De genetische verschillen tussen patiënten met PR3-ANCA en MPO-ANCA 
impliceren ook dat toekomstige genetische en klinische studies zodanig opgezet 
moeten worden dat afzonderlijke analyse van deze patiëntengroepen zinvol is.
Bij de behandeling van ANCA-geassocieerde vasculitis wordt momenteel 
een deel van de specifieke patiënt- en ziektekenmerken buiten beschouwing 
gelaten. De resultaten van genetische en klinische studies impliceren echter dat 
het afstemmen van de behandeling op specifieke patiënt- en ziekteparameters 
tot betere behandelresultaten zal leiden. Mogelijke parameters die, nu of in de 
toekomst, in aanmerking komen voor het realiseren van ‘therapie op maat’ zijn: 
genetische markers, ANCA-serotype (PR3-ANCA of MPO-ANCA), scores die 
de ziekte-ernst weergeven en markers die een terugval voorspellen.
De resultaten uit dit proefschrift suggereren dat rituximab veelbelovend is in 
de behandeling van ANCA-geassocieerde vasculitis. De langetermijneffecten van 
rituximab bij patiënten met ANCA-geassocieerde vasculitis zijn echter onbekend 
en zullen door middel van vervolgstudies onderzocht moeten worden. Daarnaast 
wordt steeds duidelijker dat corticosteroïden verantwoordelijk zijn voor een 
substantieel deel van de, aan therapie gerelateerde, complicaties die patiënten 
met ANCA-geassocieerde vasculitis ervaren. Toekomstige studies zullen dan 
ook verschillende doseringsschema’s met betrekking tot de werkzaamheid en 
veiligheid van corticosteroïden moeten onderzoeken. Tot slot zullen toekomstige 
studies ook moeten uitwijzen of bevindingen in het nierbiopt van patiënten met 
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
CD226 rs763361 (T)
   GPA 3 2021/17898 1.19 (1.11 – 1.28) <0.001
   MPA 1 156/5366 1.04 (0.83 – 1.31) 0.739
   EGPA 1 119/1226 1.19 (0.91 – 1.56) 0.208
   PR3-ANCA 2 764/6592 1.22 (1.09 – 1.36) <0.001
   MPO-ANCA 2 199/6592 1.20 (0.99 – 1.46) 0.066
CTLA-4 (AT)86
   GPA 3 210/432 0.44 (0.34 – 0.57) <0.001
   MPA 2 93/311 0.87 (0.60 – 1.25) 0.450
   PR3-ANCA 1 62/200 0.71 (0.47 – 1.09) 0.122
   MPO-ANCA 2 92/311 0.94 (0.65 – 1.35) 0.733
CTLA-4 (AT)102
   GPA 2 93/309 0.94 (0.45 – 1.94) 0.856
   MPA 2 93/311 0.86 (0.51 – 1.45) 0.574
   PR3-ANCA 1 62/200 0.87 (0.41 – 1.87) 0.722
   MPO-ANCA 2 92/311 0.69 (0.26 – 1.81) 0.456
CTLA-4 (AT)104
   GPA 2 93/309 0.84 (0.55 – 1.27) 0.398
   MPA 2 93/311 0.87 (0.58 – 1.29) 0.474
   PR3-ANCA 1 62/200 0.42 (0.22 – 0.79) 0.007
   MPO-ANCA 2 92/311 0.85 (0.57 – 1.26) 0.412
CTLA-4 (AT)106
   GPA 2 93/309 1.69 (0.67 – 4.25) 0.264
   MPA 2 93/311 0.64 (0.28 – 1.46) 0.287
   PR3-ANCA 1 62/200 1.83 (0.60 – 5.55) 0.289
   MPO-ANCA 2 92/311 0.53 (0.22 – 1.30) 0.168
CTLA-4 (AT)108
   GPA 2 93/309 0.40 (0.12 – 1.35) 0.141
   MPA 2 93/311 0.75 (0.36 – 1.54) 0.431
   PR3-ANCA 1 62/200 0.30 (0.07 – 1.28) 0.103
   MPO-ANCA 2 92/311 0.66 (0.31 – 1.41) 0.291
CTLA-4 (AT)110
   GPA 2 93/309 0.55 (0.18 – 1.74) 0.311
   MPA 2 93/311 0.26 (0.05 – 1.36) 0.109
   PR3-ANCA 1 62/200 0.56 (0.16 – 1.94) 0.359
   MPO-ANCA 2 92/311 0.26 (0.05 – 1.38) 0.113
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
CTLA-4 (AT)116
   GPA 2 93/309 0.66 (0.17 – 2.60) 0.553
   MPA 2 93/311 0.41 (0.05 – 3.38) 0.408
   PR3-ANCA 1 62/200 0.21 (0.01 – 3.72) 0.288
   MPO-ANCA 2 92/311 0.69 (0.12 – 3.98) 0.673
CTLA-4 (AT)118
   GPA 2 93/309 0.32 (0.06 – 1.68) 0.176
   MPA 2 93/311 0.31 (0.06 – 1.69) 0.175
   PR3-ANCA 1 62/200 0.11 (0.01 – 1.81) 0.121
   MPO-ANCA 2 92/311 0.44 (0.10 – 1.97) 0.283
CTLA-4 (AT)122
   GPA 2 93/309 1.32 (0.26 – 6.80) 0.742
   MPA 2 93/311 1.57 (0.48 – 5.19) 0.456
   PR3-ANCA 1 62/200 0.35 (0.02 – 6.62) 0.487
   MPO-ANCA 2 92/311 3.69 (1.40 – 9.71) 0.008
CTLA-4 (AT)124
   GPA 2 93/309 1.69 (0.67 – 4.25) 0.264
   MPA 2 93/311 0.64 (0.28 – 1.46) 0.287
   PR3-ANCA 1 62/200 1.83 (0.60 – 5.55) 0.289
   MPO-ANCA 2 92/311 0.53 (0.22 – 1.30) 0.168
CTLA-4 (AT)126
   GPA 2 93/309 1.43 (0.47 – 4.35) 0.526
   MPA 2 93/311 0.38 (0.08 – 2.11) 0.266
   PR3-ANCA 1 62/200 0.21 (0.01 – 3.72) 0.288
   MPO-ANCA 2 92/311 0.54 (0.12 – 2.46) 0.428
CTLA-4 (AT)128
   GPA 2 93/309 0.39 (0.07 – 2.14) 0.278
   MPA 2 93/311 1.27 (0.39 – 4.20) 0.694
   PR3-ANCA 1 62/200 0.29 (0.04 – 2.25) 0.235
   MPO-ANCA 2 92/311 1.29 (0.39 – 4.28) 0.674
CTLA-4 rs231775 (G)
   GPA 2 510/5994 1.05 (0.92 – 1.20) 0.430
   MPA 2 252/5994 1.17 (0.97 – 1.40) 0.100
   PR3-ANCA 1 326/5365 1.00 (0.85 – 1.18) 0.983
   MPO-ANCA 1 167/5365 0.96 (0.77 – 1.21) 0.747
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
CTLA-4 rs3087243 (A)
   GPA 3 1561/7855 0.80 (0.73 – 0.87) <0.001
   MPA 2 358/5886 0.79 (0.68 – 0.92) 0.003
   PR3-ANCA 1 478/5257 0.81 (0.71 – 0.93) 0.003
   MPO-ANCA 1 264/5257 0.96 (0.80 – 1.15) 0.658
FCAR rs16986050 (G)
   GPA 2 1029/5891 0.92 (0.80 – 1.05) 0.214
   MPA 1 394/5365 0.93 (0.69 – 1.26) 0.647
   PR3-ANCA 1 326/5365 1.13 (0.93 – 1.38) 0.211
   MPO-ANCA 1 167/5365 1.00 (0.75 – 1.33) 0.988
FCGR2A rs1801274 (C)
   GPA 5 1082/5969 0.99 (0.94 – 1.05) 0.827
   MPA 4 800/5766 0.97 (0.81 – 1.15) 0.698
   PR3-ANCA 4 883/5820 0.91 (0.79 – 1.03) 0.138
   MPO-ANCA 4 844/5969 0.80 (0.67 – 0.95) 0.011
FCGR3A rs396991 (G)
   GPA 1 91/154 1.30 (0.89 – 1.91) 0.172
   MPA 1 50/303 0.65 (0.39 – 1.07) 0.090
   PR3-ANCA 1 91/154 1.30 (0.89 – 1.91) 0.172
   MPO-ANCA 1 50/303 0.65 (0.39 – 1.07) 0.090
FCGR3B (NA1)
   GPA 3 865/667 0.93 (0.80 – 1.08) 0.343
   MPA 2 75/200 1.52 (1.03 – 2.25) 0.035
   PR3-ANCA 2 143/254 1.07 (0.79 – 1.45) 0.664
   MPO-ANCA 2 121/403 1.19 (0.86 – 1.64) 0.287
GHSR rs509035 (A)
   GPA 2 1198/6595 1.05 (0.96 – 1.16) 0.292
   MPA 1 262/5259 1.00 (0.82 – 1.20) 0.966
   PR3-ANCA 1 478/5259 1.05 (0.91 – 1.21) 0.521
   MPO-ANCA 1 264/5259 0.83 (0.68 – 1.01) 0.057
HLA-A2
   GPA 5 380/7796 0.96 (0.81 – 1.14) 0.633
   c-ANCA 1 16/96 0.90 (0.37 – 2.23) 0.826
HLA-A11
   GPA 5 380/7702 0.61 (0.41 – 0.90) 0.014
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   MPA 1 23/405 2.97 (1.19 – 7.41) 0.020
   c-ANCA 1 16/472 0.71 (0.17 – 3.03) 0.644
HLA-A24
   GPA 3 108/1223 0.94 (0.56 – 1.60) 0.830
   c-ANCA 1 16/472 0.75 (0.34 – 1.65) 0.476
HLA-A26
   GPA 3 108/1223 1.24 (0.61 – 2.54) 0.550
   MPA 1 23/405 2.49 (1.00 – 6.18) 0.049
   c-ANCA 1 16/472 2.36 (1.00 – 5.60) 0.051
HLA-A31
   GPA 3 108/1223 1.02 (0.43 – 2.44) 0.969
   c-ANCA 1 16/472 1.55 (0.46 – 5.24) 0.479
HLA-A32
   GPA 3 108/1223 1.62 (0.74 – 3.54) 0.231
   c-ANCA 1 16/472 2.07 (0.61 – 7.04) 0.246
HLA-B35
   GPA 4 349/7095 0.62 (0.44 – 0.89) 0.010
   c-ANCA 1 16/472 0.80 (0.19 – 3.40) 0.757
HLA-B39
   GPA 2 67/523 0.65 (0.11 – 3.68) 0.622
   c-ANCA 1 16/472 0.86 (0.11 – 6.51) 0.887
HLA-B44
   GPA 3 108/1223 1.53 (0.96 – 2.44) 0.072
   c-ANCA 1 16/472 2.50 (0.85 – 7.40) 0.098
HLA-B51
   GPA 2 67/523 1.03 (0.46 – 2.32) 0.943
   c-ANCA 1 16/472 1.87 (0.64 – 5.49) 0.255
HLA-B55
   GPA 2 67/523 1.07 (0.40 – 2.88) 0.887
   c-ANCA 1 16/472 7.35 (2.33 – 23.14) 0.001
HLA-B60
   GPA 2 57/1172 1.98 (0.77 – 5.09) 0.154
   c-ANCA 1 16/472 1.19 (0.28 – 5.13) 0.814
HLA-B62
   GPA 2 57/1172 2.27 (1.05 – 4.90) 0.036
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   c-ANCA 1 16/472 2.21 (0.83 – 5.91) 0.114
HLA-Cw1
   GPA 2 68/523 1.28 (0.59 – 2.77) 0.534
   c-ANCA 1 16/472 1.45 (0.58 – 3.58) 0.426
HLA-Cw3
   GPA 2 68/523 1.36 (0.79 – 2.33) 0.267
   c-ANCA 1 16/472 1.40 (0.65 – 3.01) 0.384
HLA-Cw7
   GPA 2 68/523 0.96 (0.57 – 1.62) 0.877
   c-ANCA 1 16/472 0.50 (0.12 – 2.10) 0.340
HLA-DPA1 rs9277341 
(C)
   GPA 2 1032/2200 0.35 (0.30 – 0.41) <0.001
   c-ANCA 1 578/1820 0.27 (0.22 – 0.33) <0.001
HLA-DPB1*0101
   GPA 1 148/89 0.17 (0.05 – 0.63) 0.008
   PR3-ANCA        2 183/139 0.45 (0.20 – 0.99) 0.048
   MPO-ANCA 1 22/50 1.01 (0.29 – 3.48) 0.986
HLA-DPB1*0201
   GPA 2 283/458 0.67 (0.45 – 0.99) 0.042
   MPA 1 50/77 1.38 (0.75 – 2.52) 0.298
   EGPA 1 102/369 0.93 (0.57 – 1.51) 0.759
   PR3-ANCA        1 148/89 0.44 (0.21 – 0.91) 0.027
   MPO-ANCA 1 50/77 1.38 (0.75 – 2.52) 0.298
HLA-DPB1*0301
   GPA 3 774/918 0.23 (0.16 – 0.32) <0.001
   MPA 1 119/460 0.67 (0.37 – 1.21) 0.186
   EGPA 2 167/829 0.47 (0.29 – 0.75) 0.001
   PR3-ANCA        2 183/139 0.19 (0.09 – 0.39) <0.001
   MPO-ANCA 1 22/50 1.71 (0.74 – 3.94) 0.210
   ANCA negative 1 27/369 0.58 (0.21 – 1.65) 0.311
HLA-DPB1*0401
   GPA 3 774/918 2.89 (2.50 – 3.35) <0.001
   MPA 1 119/460 1.09 (0.80 – 1.49) 0.597
   EGPA 2 167/829 1.08 (0.85 – 1.36) 0.548
225
I. Supplementary data Chapter II
Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   PR3-ANCA        2 183/139 3.93 (2.75 – 5.62) <0.001
   MPO-ANCA 1 22/50 1.43 (0.67 – 3.02) 0.351
   ANCA negative 1 27/369 1.26 (0.73 – 2.20) 0.407
HLA-DPB1*0402
   GPA 2 283/458 1.13 (0.82 – 1.55) 0.439
   EGPA 1 102/369 1.15 (0.75 – 1.75) 0.533
   PR3-ANCA        2 183/139 1.11 (0.69 – 1.77) 0.674
   MPO-ANCA 1 22/50 0.94 (0.31 – 2.85) 0.913
HLA-DPB1*0501
   GPA 1 148/89 0.20 (0.01 – 4.93) 0.324
   PR3-ANCA        2 183/139 1.11 (0.26 – 4.76) 0.886
   MPO-ANCA 1 22/50 1.14 (0.10 – 12.91) 0.916
HLA-DPB1*0601
   GPA 1 148/89 0.60 (0.08 – 4.29) 0.610
   PR3-ANCA        2 183/139 1.12 (0.23 – 5.51) 0.887
   MPO-ANCA 1 22/50 6.93 (0.28 – 173.53) 0.239
HLA-DPB1*0901
   GPA 1 148/89 1.81 (0.07 – 44.73) 0.716
   PR3-ANCA        2 183/139 0.98 (0.27 – 3.62) 0.978
   MPO-ANCA 1 22/50 0.91 (0.17 – 4.85) 0.907
HLA-DPB2 rs3130215 
(A)
   GPA 3 1135/7249 1.37 (0.88 – 2.13) 0.160
   MPA 1 156/5366 1.33(1.06 – 1.66) 0.013
   PR3-ANCA 1 326/5366 0.65 (0.55 – 0.77) <0.001
   MPO-ANCA 1 167/5366 1.27 (1.02 – 1.58) 0.032
HLA-DQB1*02
   GPA 2 83/141 0.91 (0.53 – 1.55) 0.720
   PR3-ANCA        1 32/91 0.98 (0.45 – 2.14) 0.954
HLA-DQB1*0302
   GPA 1 32/91 0.94 (0.36 – 2.49) 0.905
   PR3-ANCA        2 67/141 1.03 (0.54 – 1.98) 0.924
   MPO-ANCA 1 22/50 1.06 (0.37 – 2.99) 0.917
HLA-DQB1*0303
   GPA 1 32/91 2.97 (0.72 – 12.23) 0.132
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   MPA 1 50/77 2.11 (1.14 – 3.90) 0.018
   PR3-ANCA 2 67/141 0.79 (0.31 – 2.05) 0.634
   MPO-ANCA 2 72/127 1.91 (1.12 – 3.26) 0.017
HLA-DQB1*04
   GPA 2 83/141 1.63 (0.52 – 5.11) 0.404
   PR3-ANCA 1 32/91 1.74 (0.40 – 7.50) 0.457
HLA-DQB1*0501
   GPA 1 32/91 0.77 (0.32 – 1.88) 0.568
   PR3-ANCA 2 67/141 1.05 (0.58 – 1.91) 0.865
   MPO-ANCA 1 22/50 2.05 (0.84 – 4.97) 0.113
HLA-DQB1*0602
   GPA 1 32/91 0.89 (0.38 – 2.05) 0.779
   PR3-ANCA 2 67/141 0.80 (0.42 – 1.54) 0.504
   MPO-ANCA 1 22/50 0.35 (0.08 – 1.63) 0.181
HLA-DQ7
   GPA 1 32/91 0.43 (0.16 – 1.16) 0.095
   MPA 1 23/405 0.66 (0.34 – 1.30) 0.234
   PR3-ANCA 2 67/141 0.98 (0.58 – 1.66) 0.940
   MPO-ANCA 1 22/50 1.26 (0.57 – 2.77) 0.569
HLA-DR1
   GPA 6 413/6002 0.76 (0.58 – 1.00) 0.054
   MPA 4 223/6020 1.12 (0.72 – 1.74) 0.612
   EGPA 3 128/5924 0.82 (0.53 – 1.26) 0.360
   PR3-ANCA 3 157/560 0.57 (0.38 – 0.86) 0.008
   MPO-ANCA 3 133/734 0.78 (0.49 – 1.25) 0.297
HLA-DR2
   GPA 4 301/6132 1.36 (1.08 – 1.72) 0.010
   EGPA 1 14/113 1.40 (0.45 – 4.39) 0.561
   PR3-ANCA 1 35/90 1.34 (0.63 – 2.86) 0.442
   MPO-ANCA 1 22/90 1.03 (0.39 – 2.69) 0.958
   c-ANCA 1 16/472 0.33 (0.08 – 1.38) 0.128
HLA-DR3
   GPA 5 368/5802 1.24 (1.00 – 1.56) 0.056
   MPA 2 38/518 0.45 (0.17 – 1.14) 0.092
   EGPA 2 116/482 0.70 (0.43 – 1.13) 0.139
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   PR3-ANCA 3 157/560 1.29 (0.90 – 1.86) 0.170
   MPO-ANCA 2 69/469 0.85 (0.49 – 1.48) 0.574
HLA-DR4
   GPA 7 425/6424 1.32 (1.09 – 1.60) 0.004
   MPA 2 66/5555 1.50 (0.98 – 2.30) 0.060
   EGPA 4 176/6246 1.70 (1.23 – 2.34) 0.001
   PR3-ANCA 3 157/560 0.98 (0.71 – 1.36) 0.917
   MPO-ANCA 2 69/202 2.51 (1.46 – 4.32) 0.001
   c-ANCA 1 16/472 0.72 (0.27 – 1.88) 0.498
HLA-DR5
   GPA 3 285/5660 0.76 (0.54 – 1.06) 0.102
   MPA 1 23/405 1.59 (0.80 – 3.15) 0.182
   EGPA 1 14/113 1.24 (0.34 – 4.46) 0.746
   PR3-ANCA 1 35/90 0.85 (0.30 – 2.42) 0.756
   MPO-ANCA 1 22/90 0.52 (0.12 – 2.38) 0.402
HLA-DR6
   GPA 4 301/6132 0.45 (0.33 – 0.62) <0.001
   MPA 1 30/5442 0.29 (0.09 – 0.92) 0.035
   EGPA 2 26/5555 0.19 (0.04 – 0.95) 0.043
   PR3-ANCA 1 35/90 0.28 (0.06 – 1.25) 0.096
   MPO-ANCA 1 22/90 0.70 (0.20 – 2.51) 0.586
   c-ANCA 1 16/472 1.63 (0.56 – 4.77) 0.371
HLA-DR7
   GPA 5 368/5802 0.92 (0.71 – 1.19) 0.508
   MPA 1 15/113 0.70 (0.20 – 2.44) 0.575
   EGPA 3 164/804 1.71 (1.24 – 2.37) 0.001
   PR3-ANCA 1 32/91 1.00 (0.40 – 2.48) 0.991
HLA-DR8
   GPA 5 381/6206 0.89 (0.57 – 1.39) 0.610
   MPA 1 51/5442 0.31 (0.04 – 2.21) 0.242
   EGPA 2 114/5811 3.08 (1.75 – 5.41) <0.001
   PR3-ANCA 3 157/560 0.68 (0.33 – 1.42) 0.308
   MPO-ANCA 2 69/469 1.70 (0.80 – 3.60) 0.170
   c-ANCA 1 16/472 1.63 (0.66 – 4.05) 0.291
HLA-DR9
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   GPA 6 402/6369 0.90 (0.58 – 1.39) 0.623
   MPA 3 218/578 1.14 (0.83 – 1.56) 0.423
   EGPA 3 164/832 1.07 (0.33 – 3.42) 0.915
   PR3-ANCA 2 122/470 0.47 (0.09 – 2.58) 0.383
   MPO-ANCA 3 175/1116 1.83 (1.29 – 2.60) 0.001
   c-ANCA 1 16/472 3.03 (1.40 – 6.56) 0.005
HLA-DRB1*0401
   GPA 1 45/200 0.49 (0.06 – 3.90) 0.499
   MPA 2 157/465 1.42 (0.60 – 3.41) 0.426
   MPO-ANCA 1 64/265 2.10 (0.52 – 8.50) 0.300
HLA-DRB1*0403
   GPA 1 45/200 0.26 (0.02 – 4.46) 0.349
   MPA 2 157/465 0.48 (0.14 – 1.59) 0.227
   MPO-ANCA 1 64/265 0.95 (0.27 – 3.40) 0.943
HLA-DRB1*0405
   GPA 1 45/200 0.15 (0.01 – 2.49) 0.184
   MPA 2 157/465 0.95 (0.56 – 1.62) 0.862
   MPO-ANCA 1 64/265 0.61 (0.30 – 1.22) 0.159
HLA-DRB1*0406
   GPA 1 45/200 2.28 (0.67 – 7.74) 0.187
   MPA 2 157/465 1.31 (0.62 – 2.78) 0.483
   MPO-ANCA 1 64/265 0.65 (0.19  – 2.22) 0.487
HLA-DRB1*0407
   GPA 1 45/200 1.47 (0.06 – 36.42) 0.813
   MPA 2 157/465 1.95 (0.54 – 6.99) 0.306
   MPO-ANCA 1 64/265 2.82 (0.78 – 10.14) 0.113
HLA-DRB1*0410
   GPA 1 45/200 1.47 (0.06 – 36.42) 0.813
   MPA 2 157/465 1.53 (0.35 – 6.64) 0.569
   MPO-ANCA 1 64/265 1.67 (0.32 – 8.69) 0.544
HLA-DRB1*0802
   GPA 1 45/200 0.88 (0.04 – 18.50) 0.935
   MPA 2 157/465 0.99 (0.35 – 2.79) 0.984
   MPO-ANCA 1 64/265 1.16 (0.42 – 3.18) 0.778
HLA-DRB1*0803
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   GPA 1 45/200 1.18 (0.43 – 3.25) 0.749
   MPA 2 157/465 1.25 (0.73 – 2.13) 0.413
   MPO-ANCA 1 64/265 1.51 (0.78 – 2.93) 0.226
HLA-DRB1*10
   GPA 2 83/142 2.61 (0.45 – 15.24) 0.286
   EGPA 1 102/369 0.40 (0.02 – 7.44) 0.538
   PR3-ANCA 2 122/470 0.59 (0.13 – 2.65) 0.487
   MPO-ANCA 1 47/379 1.48 (0.32 – 6.76) 0.616
HLA-DRB1*11
   GPA 2 83/142 0.97 (0.49 – 1.94) 0.932
   EGPA 1 102/369 0.88 (0.53 – 1.48) 0.632
   PR3-ANCA 2 122/470 0.97 (0.58 – 1.62) 0.908
   MPO-ANCA 1 47/379 1.10 (0.51 – 2.38) 0.805
HLA-DRB1*1101
   GPA 1 45/200 0.16 (0.02 – 1.21) 0.076
   MPA 2 223/465 2.57 (1.56 – 4.23) <0.001
   MPO-ANCA 1 116/265 2.79 (0.84 – 9.23) 0.093
HLA-DRB1*12
   GPA 2 83/142 4.06 (1.27 – 12.99) 0.018
   EGPA 1 102/369 0.57 (0.17 – 1.93) 0.362
   PR3-ANCA 2 122/470 1.01 (0.36 – 2.81) 0.983
   MPO-ANCA 1 47/379 1.16 (0.26 – 5.16) 0.850
HLA-DRB1*1201
   GPA 1 45/200 0.15 (0.01 – 2.49) 0.184
   MPA 2 157/465 0.51 (0.21 – 1.26) 0.146
   MPO-ANCA 1 64/265 0.21 (0.03 – 1.60) 0.132
HLA-DRB1*1202
   GPA 1 45/200 2.92 (1.37 – 6.23) 0.005
   MPA 2 157/465 1.07 (0.55 – 2.09) 0.838
   PR3-ANCA 1 19/200 1.63 (0.46 – 5.75) 0.449
   MPO-ANCA 2 89/465 1.00 (0.38 – 2.61) 1.000
HLA-DRB1*13
   GPA 2 83/142 0.61 (0.34 – 1.12) 0.111
   EGPA 2 150/691 0.40 (0.24 – 0.68) 0.001
   PR3-ANCA 1 32/91 0.56 (0.20 – 1.53) 0.257
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
HLA-DRB1*1302
   GPA 1 45/200 0.89 (0.19 – 4.12) 0.878
   MPA 2 157/465 0.46 (0.20 – 1.02) 0.055
   MPO-ANCA 1 64/265 0.54 (0.24 – 1.23) 0.142
HLA-DRB1*14
   GPA 2 83/142 1.26 (0.40 – 4.01) 0.698
   EGPA 1 102/341 1.83 (0.72 – 4.65) 0.205
   PR3-ANCA 2 122/470 2.00 (0.87 – 4.56) 0.101
   MPO-ANCA 1 47/379 2.04 (0.43 – 9.74) 0.372
HLA-DRB1*1403
   GPA 1 45/200 2.24 (0.20 – 24.93) 0.513
   MPA 2 157/465 0.81 (0.21 – 3.19) 0.767
   MPO-ANCA 1 64/265 1.25 (0.34 – 4.60) 0.739
HLA-DRB1*1405
   GPA 1 45/200 1.51 (0.53 – 4.27) 0.437
   MPA 2 157/465 0.45 (0.18 – 1.15) 0.096
   MPO-ANCA 1 64/265 0.11 (0.01 – 1.91) 0.131
HLA-DRB1*15
   GPA 2 83/142 0.97 (0.57 – 1.65) 0.921
   PR3-ANCA 2 131/582 2.82 (2.00 – 3.96) <0.001
   MPO-ANCA 1 51/491 0.80 (0.37 – 1.73) 0.566
HLA-DRB1*1501
   GPA 1 45/200 1.70 (0.98 – 2.94) 0.059
   MPA 2 157/465 1.65 (1.14 – 2.38) 0.007
   PR3-ANCA 1 19/200 0.98 (0.40 – 2.45) 0.973
   MPO-ANCA 2 89/465 2.03 (1.26 – 3.29) 0.004
HLA-DRB1*1502
   GPA 1 45/200 0.80 (0.18 – 3.69) 0.779
   MPA 2 157/465 0.60 (0.30 – 1.21) 0.154
   MPO-ANCA 1 64/265 0.67 (0.32 – 1.39) 0.279
HLA-DRB1*16
   GPA 2 83/142 0.23 (0.03 – 1.85) 0.166
   PR3-ANCA 2 131/582 1.00 (0.29 – 3.41) 0.996
   MPO-ANCA 1 51/491 3.55 (1.02 – 12.38) 0.047
HLA-DRB1*1602
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   GPA 1 45/200 0.40 (0.02 – 7.25) 0.533
   MPA 2 157/465 0.23 (0.03 – 1.72) 0.151
   MPO-ANCA 1 64/265 0.24 (0.01 – 4.17) 0.327
HLA-DRB3
   GPA 1 51/51 1.41 (0.76 – 2.60) 0.276
   EGPA 2 150/691 0.58 (0.45 – 0.76) <0.001
HLA-DRB4
   GPA 1 51/51 0.89 (0.46 – 1.72) 0.738
   EGPA 2 150/691 2.06 (1.57 – 2.69) <0.001
IL-1β (A2)
   GPA 3 714/5491 1.07 (0.93 – 1.22) 0.336
   MPA 1 262/5259 0.89 (0.72 – 1.10) 0.286
   PR3-ANCA 2 557/5455 1.01 (0.87 – 1.17) 0.930
   MPO-ANCA 2 294/5455 1.00 (0.82 – 1.21) 0.971
IL1RN*1
   GPA 1 61/200 0.88 (0.57 – 1.37) 0.573
   MPA 1 105/200 1.21 (0.83 – 1.77) 0.325
   PR3-ANCA 2 122/434 1.12 (0.82 – 1.54) 0.476
   MPO-ANCA 2 92/434 0.98 (0.69 – 1.40) 0.916
IL1RN*2
   GPA 1 61/200 1.22 (0.78 – 1.92) 0.380
   MPA 1 105/200 0.77 (0.52 – 1.16) 0.212
   PR3-ANCA 2 122/434 0.95 (0.68 – 1.31) 0.748
   MPO-ANCA 2 92/434 1.02 (0.71 – 1.47) 0.921
IL1RN*3
   GPA 1 61/200 0.72 (0.15 – 3.40) 0.682
   MPA 1 105/200 1.50 (0.55 – 4.08) 0.429
   PR3-ANCA 2 122/434 0.61 (0.21 – 1.76) 0.358
   MPO-ANCA 2 92/434 0.71 (0.22 – 2.29) 0.571
IL1RN*4
   GPA 1 61/200 0.65 (0.03 – 13.64) 0.782
   MPA 1 105/200 1.91 (0.27 – 13.68) 0.518
   PR3-ANCA 2 122/434 0.95 (0.11 – 8.63) 0.964
   MPO-ANCA 2 92/434 3.08 (0.58 – 16.42) 0.188
IL1RN*5
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   GPA 1 61/200 1.09 (0.04 – 26.86) 0.959
   MPA 1 105/200 0.63 (0.03 – 15.60) 0.779
   PR3-ANCA 2 122/434 0.87 (0.10 – 7.74) 0.901
   MPO-ANCA 2 92/434 2.18 (0.32 – 14.79) 0.424
IL-6 rs1800795 (C)
   GPA 4 1360/1558 0.99 (0.94 – 1.04) 0.750
   MPA 2 315/6593 0.98 (0.84 – 1.16) 0.829
   EGPA 1 426/6593 0.96 (0.76 – 1.21) 0.730
   PR3-ANCA 3 NR/6694 0.98 (0.89 – 1.09) 0.751
   MPO-ANCA 2 NR/6603 1.04 (0.90 – 1.20) 0.616
IL-10 rs1800872 (A)
   GPA 2 435/598 1.03 (0.84 – 1.27) 0.762
   EGPA 1 103/507 0.89 (0.62 – 1.27) 0.512
   PR3-ANCA 1 32/91 1.10 (0.55 – 2.20) 0.793
IL-10 rs1800896 (G)
   GPA 5 993/6183 0.95 (0.85 – 1.05) 0.293
   MPA 2 192/5513 0.95 (0.78 – 1.17) 0.655
   EGPA 1 103/507 0.68 (0.50 – 0.92) 0.012
   PR3-ANCA 2 358/5451 1.05 (0.90 – 1.22) 0.527
   MPO-ANCA 1 167/5360 0.96 (0.77 – 1.19) 0.693
IRF5 rs10954213 (G)
   GPA 2 1021/6267 0.66 (0.59 – 0.74) <0.001
   MPA 2 333/6075 1.22 (1.03 – 1.44) 0.018
   PR3-ANCA 1 326/5365 1.09 (0.93 – 1.28) 0.293
   MPO-ANCA 2 399/6075 1.12 (0.96 – 1.31) 0.142
LEPR rs8179183 (C)
   GPA 1 682/1326 0.72 (0.60 – 0.86) <0.001
   EGPA 1 196/1327 1.41 (1.10 – 1.81) 0.007
MPO rs2333227 (A)
   GPA 1 69/150 0.70 (0.41 – 1.21) 0.204
   MPA 1 65/150 1.18 (0.72 – 1.93) 0.523
   PR3-ANCA 3 258/549 1.00 (0.77 – 1.31) 0.977
   MPO-ANCA 3 141/549 0.94 (0.68 – 1.31) 0.719
PTPN22 rs2476601 (A)
   GPA 4 1616/8678 1.43 (1.26 – 1.62) <0.001
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
   MPA 2 258/6310 1.42 (1.06 – 1.89) 0.018
   EGPA 1 99/945 0.52 (0.21 – 1.29) 0.158
   PR3-ANCA 2 419/6310 1.42 (1.14 – 1.77) 0.002
   MPO-ANCA 2 183/6310 1.47 (1.08 – 2.00) 0.014
RING1/RXRB rs213213 
(A)
   GPA 3 1132/7238 1.91 (1.73 – 2.10) <0.001
   MPA 1 156/5366 1.15 (0.90 – 1.45) 0.264
   PR3-ANCA 1 326/5366 2.06 (1.75 – 2.41) <0.001
   MPO-ANCA 1 167/5366 1.05 (0.83 – 1.32) 0.687
RXRB rs6531 (C)
   GPA 3 1211/6955 1.70 (1.55 – 1.86) <0.001
   MPA 1 262/5251 1.38 (1.15 – 1.66) 0.001
   PR3-ANCA 1 478/5251 2.19 (1.92 – 2.51) <0.001
   MPO-ANCA 1 264/5251 1.21 (1.00 – 1.46) 0.046
   ANCA negative 1 36/201 1.02 (0.59 – 1.74) 0.948
RXRB rs9277935 (T)
   GPA 3 1135/7233 0.37 (0.31 – 0.43) <0.001
   MPA 1 156/5350 0.93 (0.70 – 1.24) 0.629
   PR3-ANCA 1 326/5350 0.24 (0.17 – 0.33) <0.001
   MPO-ANCA 1 167/5350 1.18 (0.92 – 1.53) 0.193
SERPINA1 S allele
   GPA 2 484/1079 1.72 (1.12 – 2.66) 0.014
   c-ANCA 3 145/3836 1.92 (1.12 – 3.29) 0.017
SERPINA1 Z allele
   GPA 4 972/2636 2.40 (1.73 - 3.33) <0.001
   MPA 1 143/805 1.60 (0.76 - 3.39) 0.218
   PR3-ANCA 1 322/805 2.58 (1.57 - 4.25) <0.001
   MPO-ANCA 1 166/805 2.01 (1.04 - 3.87) 0.037
   c-ANCA 5 280/4788 3.53 (2.28 – 5.49) <0.001
   p-ANCA 2 78/2510 3.13 (1.21 – 8.13) 0.019
STAT4 rs7574865 (T)
   GPA 2 1288/6246 1.06 (0.94 – 1.20) 0.331
   MPA 1 676/5366 1.12 (0.86 – 1.46) 0.392
   PR3-ANCA 1 676/5366 1.06 (0.88 – 1.28) 0.547
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis




   GPA 3 196/259 1.52 (0.93 – 2.48) 0.096
   MPA 1 36/96 1.03 (0.35 – 2.99) 0.960
   PR3-ANCA 1 32/91 1.86 (0.73 – 4.71) 0.193
TNFα rs1800629 (A)
   GPA 4 578/5691 1.15 (0.98 – 1.35) 0.098
   MPA 1 156/5366 1.13 (0.95 – 1.35) 0.182
   PR3-ANCA 2 357/5457 1.21 (0.93 – 1.57) 0.149
   MPO-ANCA 1 167/5366 0.88 (0.66 – 1.17) 0.375
TNFRII 196R
   GPA 1 177/123 1.05 (0.70 – 1.57) 0.819
   MPA 1 50/262 0.67 (0.31 – 1.45) 0.313
   MPO-ANCA 1 50/262 0.67 (0.31 – 1.45) 0.313
TLR9 rs352162 (T)
   GPA 1 919/1898 1.20 (1.07 – 1.34) 0.001
   MPA 1 153/1898 0.74 (0.58 – 0.95) 0.020
   EGPA 1 217/1898 1.28 (1.05 – 1.57) 0.015
   PR3-ANCA 1 NR/NR 1.30 (1.14 – 1.47) <0.001
   MPO-ANCA 1 NR/NR 0.79 (0.65 – 0.97) 0.028
   ANCA negative 1 NR/NR 1.22 (0.99 – 1.50) 0.060
TLR9 rs352140 (T)
   GPA 1 919/1898 1.20 (1.07 – 1.35) 0.001
   MPA 1 153/1898 0.71 (0.55 – 0.91) 0.006
   EGPA 1 217/1898 1.17 (0.96 – 1.43) 0.129
   PR3-ANCA 1 NR/NR 1.28 (1.12 – 1.45) <0.001
   MPO-ANCA 1 NR/NR 0.75 (0.62 – 0.91) 0.004
   ANCA negative 1 NR/NR 1.19 (0.97 – 1.47) 0.097
TLR9 rs352139 (T)
   GPA 1 919/1898 1.18 (1.06 – 1.32) 0.003
   MPA 1 153/1898 0.68 (0.52 – 0.87) 0.003
   EGPA 1 217/1898 1.21 (0.99 – 1.47) 0.057
   PR3-ANCA 1 NR/NR 1.23 (1.09 – 1.40) 0.001
   MPO-ANCA 1 NR/NR 0.78 (0.63 – 0.96) 0.017
   ANCA negative 1 NR/NR 1.20 (0.98 – 1.47) 0.086
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Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-
groups (Continued)
Variant by gene Publica-
tions (n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
TLR9 rs5743836 (G)
   GPA 1 919/1898 0.83 (0.70 – 0.99) 0.037
   MPA 1 153/1898 1.78 (1.32 – 2.39) <0.001
   EGPA 1 217/1898 0.90 (0.68 – 1.21) 0.499
   PR3-ANCA 1 NR/NR 0.83 (0.70 – 1.00) 0.045
   MPO-ANCA 1 NR/NR 1.20 (0.91 – 1.58) 0.207
   ANCA negative 1 NR/NR 0.99 (0.74 – 1.34) 0.970
Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups
Variant by gene Publications 
(n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
CTLA-4 (AT)86
   Asian 1 49/111 1.31 (0.76 – 2.25) 0.333
   Caucasian 3 254/432 0.46 (0.36 – 0.58) <0.001
CTLA-4 (AT)102
   Asian 1 49/111 0.89 (0.47 – 1.68) 0.714
   Caucasian 2 137/309 1.73 (0.87 – 3.44) 0.117
CTLA-4 (AT)104
   Asian 1 49/111 1.15 (0.70 – 1.91) 0.578
   Caucasian 2 137/309 1.24 (0.88 – 1.73) 0.215
CTLA-4 (AT)106
   Asian 1 49/111 0.41 (0.14 – 1.22) 0.109
   Caucasian 2 137/309 2.69 (1.28 – 5.63) 0.009
CTLA-4 (AT)108
   Asian 1 49/111 0.82 (0.33 – 2.02) 0.670
   Caucasian 2 137/309 0.92 (0.44 – 1.92) 0.831
CTLA-4 (AT)110
   Asian 1 49/111 0.25 (0.01 – 4.62) 0.349
   Caucasian 2 137/309 0.84 (0.37 – 1.91) 0.679
CTLA-4 (AT)116
   Asian 1 49/111 0.75 (0.03 – 18.56) 0.860
   Caucasian 2 137/309 0.80 (0.26 – 2.50) 0.705
CTLA-4 (AT)118
   Asian 1 49/111 0.75 (0.08 – 7.33) 0.807
   Caucasian 2 137/309 0.41 (0.12 – 1.39) 0.152
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Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)
Variant by gene Publications 
(n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
CTLA-4 (AT)122
   Asian 1 49/111 2.32 (0.57 – 9.45) 0.241
   Caucasian 2 137/309 1.22 (0.27 – 5.49) 0.799
CTLA-4 (AT)124
   Asian 1 49/111 2.28 (0.14 – 36.80) 0.562
   Caucasian 2 137/309 1.94 (0.67 – 5.58) 0.222
CTLA-4 (AT)126
   Asian 1 49/111 0.45 (0.05 – 3.88) 0.466
   Caucasian 2 137/309 1.65 (0.63 – 4.32) 0.305
CTLA-4 (AT)128
   Asian 1 49/111 6.98 (0.72 – 67.95) 0.094
   Caucasian 2 137/309 0.72 (0.24 – 2.15) 0.560
FCGR2A rs1801274 (C)
   Asian 1 50/303 0.68 (0.37 – 1.24) 0.208
   Caucasian 5 1126/5969 0.91 (0.82 – 1.00) 0.043
FCGR3A rs396991 (G)
   Asian 1 50/303 0.65 (0.39 – 1.07) 0.090
   Caucasian 1 91/154 1.30 (0.89 – 1.91) 0.172
FCGR3B (NA1)
   Asian 1 50/303 1.29 (0.82 – 2.03) 0.267
   Caucasian 3 865/667 0.93 (0.80 – 1.08) 0.343
HLA-A2
   Asian 1 16/472 0.90 (0.37 – 2.23) 0.826
   Caucasian 4 427/7324 0.96 (0.81 – 1.13) 0.595
HLA-A11
   Asian 1 16/472 0.71 (0.17 – 3.03) 0.644
   Caucasian 5 450/7635 1.01 (0.50 – 2.05) 0.978
HLA-A24
   Asian 1 16/472 0.75 (0.34 – 1.65) 0.476
   Caucasian 2 92/751 1.16 (0.57 – 2.38) 0.683
HLA-A26
   Asian 1 16/472 2.36 (1.00 – 5.60) 0.051
   Caucasian 3 115/1156 1.21 (0.58 – 2.55) 0.612
HLA-A31
   Asian 1 16/472 1.55 (0.46 – 5.24) 0.479
   Caucasian 2 92/751 0.73 (0.21 – 2.52) 0.613
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Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)
Variant by gene Publications 
(n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
HLA-A32
   Asian 1 16/472 2.07 (0.61 – 7.04) 0.246
   Caucasian 2 92/751 1.41 (0.52 – 3.84) 0.500
HLA-B35
   Asian 1 16/472 0.80 (0.17 – 3.40) 0.757
   Caucasian 3 396/6623 0.78 (0.58 – 1.06) 0.115
HLA-B39
   Asian 1 16/472 0.86 (0.11 – 6.51) 0.887
   Caucasian 1 51/51 0.33 (0.01 – 8.20) 0.499
HLA-B44
   Asian 1 16/472 2.50 (0.85 – 7.40) 0.098
   Caucasian 2 92/751 1.41(0.85 – 2.35) 0.188
HLA-B51
   Asian 1 16/472 1.87 (0.64 – 5.49) 0.255
   Caucasian 1 51/51 0.61 (0.19 – 1.92) 0.394
HLA-B55
   Asian 1 16/472 7.35 (2.34 – 23.14) 0.001
   Caucasian 1 51/51 0.07 (0.00 – 1.30) 0.075
HLA-B60
   Asian 1 16/472 1.19 (0.28 – 5.13) 0.814
   Caucasian 1 41/700 3.51 (0.99 – 12.36) 0.051
HLA-B62
   Asian 1 16/472 1.71 (0.58 – 4.99) 0.331
   Caucasian 1 41/700 2.38 (0.70 – 8.12) 0.166
HLA-Cw1
   Asian 1 16/472 1.45 (0.58 – 3.58) 0.426
   Caucasian 1 52/51 0.98 (0.24 – 4.03) 0.978
HLA-Cw3
   Asian 1 16/472 1.40 (0.66 – 3.01) 0.384
   Caucasian 1 52/51 1.32 (0.62 – 2.81) 0.479
HLA-Cw7
   Asian 1 16/472 0.50 (0.12 – 2.10) 0.340
   Caucasian 1 52/51 1.10 (0.62 – 1.96) 0.735
HLA-DPB1*0201
   Asian 1 50/77 1.38 (0.75 – 2.52) 0.298
   Caucasian 3 385/827 0.76 (0.56 – 1.03) 0.073
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Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)
Variant by gene Publications 
(n)
Cases (n) / 
Controls (n)
OR (95% CI) P value for 
meta-analysis
HLA-DQB1*0303
   Asian 1 50/77 2.11 (1.14 – 3.90) 0.018
   Caucasian 2 126/141 1.35 (0.55 – 3.33) 0.515
HLA-DR1
   Asian 1 64/265 1.12 (0.48 – 2.64) 0.793
   Caucasian 9 945/6840 0.91 (0.61 – 1.36) 0.651
HLA-DR2
   Asian 1 16/472 0.33 (0.08 – 1.38) 0.128
   Caucasian 4 471/5750 1.06 (0.87 – 1.29) 0.565
HLA-DR4
   Asian 1 16/472 0.72 (0.27 – 1.88) 0.498
   Caucasian 10 882/7262 1.23 (0.97 – 1.57) 0.088
HLA-DR6
   Asian 1 16/472 1.63 (0.56 – 4.77) 0.371
   Caucasian 4 471/5750 0.43 (0.30 – 0.61) <0.001
HLA-DR8
   Asian 1 16/472 1.63 (0.66 – 4.05) 0.291
   Caucasian 8 597/1483 1.05 (0.75 – 1.49) 0.768
HLA-DR9
   Asian 4 296/1409 1.67 (0.83 – 3.34) 0.148
   Caucasian 7 510/1443 0.63 (0.34 – 1.19) 0.152
IRF5 rs10954213 (G)
   Asian 1 232/710 1.28 (1.04 – 1.58) 0.022
   Caucasian 2 1303/6267 0.69 (0.63 – 0.76) <0.001
STAT4 rs7574865 (T)
   Asian 1 232/710 1.10 (0.89 – 1.37) 0.388
   Caucasian 2 1288/6246 1.11 (1.00 – 1.24) 0.044
TNFRII 196R
   Asian 1 50/262 0.67 (0.31 – 1.45) 0.313
   Caucasian 1 117/123 1.05 (0.70 – 1.57) 0.819
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Supplementary figure 1. Forest plots
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.444)
Study
Chung et al. 2012 (1)
Chung et al. 2012 (2)
Wieczorek et al. 2009 (2)
Previously unpublished Lyons et al. 2012 GWAS data
















Protective effect  Increased risk 
1.649 1.54
CD226 rs763361 (T)
CD226 rs763361 (T) forest plot. Harbold test: N/A, Egger test: p=0.792.
References: 1**, 2**, 3
Overall  (I-squared = 88.7%, p = 0.000)
Zhou et al. 2004
Tsuchiya et al. 2003
Study
Persson et al. 2013














Protective effect  Increased risk 
1.0951 10.5
CTLA-4 (AT)86
CTLA-4 (AT)86 forest plot. Harbold test: p=0.946, Egger test: p=0.788.
References: 4, 5, 6, 7
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Overall  (I-squared = 60.4%, p = 0.080)
Kamesh et al. 2009
Slot et al. 2008













Protective effect  Increased risk 
1.461 2.17
CTLA-4 rs231775 (G)
CTLA-4 rs231775 (G) forest plot. Harbold test: p=0.080, Egger test: p=0.081.
References: 8, 9, 3
Overall  (I-squared = 24.9%, p = 0.262)
Study
Previously unpublished Lyons et al. 2012 GWAS data
Chung et al. 2012 (2)
Chung et al. 2012 (1)














Protective effect  Increased risk 
1.538 1.86
CTLA-4 rs3087243 (A)
CTLA-4 rs3087243 (A) forest plot. Harbold test: N/A, Egger test: p=0.122.
References: 9, 2**, 3
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FCGR2A rs1801274 (C) forest plot. Harbold test: p=0.788, Egger test: p=0.829.
References: 11, 12, 13, 5, 7, 3
Overall  (I-squared = 0.0%, p = 0.432)
Stassen et al. 2009











Protective effect  Increased risk 
1.283 3.53
HLA-B5
HLA-B5 forest plot. Harbold test: N/A, Egger test: N/A.
References: 16, 19
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HLA-B8 forest plot. Harbold test: p=0.063, Egger test: p=0.077.
References: 16, 21, 23, 17, 18, 19
Overall  (I-squared = 53.6%, p = 0.116)
Xie et al. 2013 (1)
Study
Xie et al. 2013 (2)












Protective effect  Increased risk 
1.244 4.1
HLA-DPA1 rs9277341 (C)
HLA-DPA1 rs9277341 (C) forest plot. Harbold test: p=0.215, Egger test: p=0.219.
References: 24, 25**
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 78.0%, p = 0.000)
Study
Heckmann et al. 2008
Arning et al. 2011 (1)
Zhang et al. 1995
Jagiello et al. 2004
Wieczorek et al. 2008


















Protective effect  Increased risk 
1.00278 359
HLA-DPB1*0301
HLA-DPB1*0301 forest plot. Harbold test: p=0.938, Egger test: p=0.744.
References: 26, 27, 24, 29, 30**
NOTE: Weights are from random effects analysis
Overall  (I-squared = 83.7%, p = 0.000)
Jagiello et al. 2004
Arning et al. 2011 (2)
Wieczorek et al. 2008
Heckmann et al. 2008
Zhang et al. 1995



















Protective effect  Increased risk 
1.171 5.84
HLA-DPB1*0401
HLA-DPB1*0401 forest plot. Harbold test: p=0.738, Egger test: p=0.759.
References: 26, 27, 24, 29, 30**
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Overall  (I-squared = 98.5%, p = 0.000)
Heckmann et al. 2008
Xie et al. 2013
Study












Protective effect  Increased risk 
1.341 2.94
HLA-DPB2 rs3130215 (A)
HLA-DPB2 rs3130215 (A) forest plot. Harbold test: p=0.446, Egger test: p=0.431.
References: 24, 3, 25
Overall  (I-squared = 16.7%, p = 0.301)
Tsuchiya et al. 2006
Spriewald et al. 2005
Study












Protective effect  Increased risk 
1.0818 12.2
HLA-DQB1*0303
HLA-DQB1*0303 forest plot. Harbold test: p=0.916, Egger test: p=0.834.
References: 26, 31, 28
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HLA-DR6 forest plot. Harbold test: p=0.997, Egger test: p=0.989.
References: 23, 32, 26, 20, 19
Overall  (I-squared = 0.0%, p = 0.487)
Luo et al. 2011
Study










Protective effect  Increased risk 
1.108 9.23
HLA-DRB1*1101
HLA-DRB1*1101 forest plot. Harbold test: N/A, Egger test: N/A.
References: 34, 37
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Overall  (I-squared = 0.0%, p = 0.491)
Tsuchiya et al. 2003
Study










Protective effect  Increased risk 
1.0281 35.6
HLA-DRB1*1201
HLA-DRB1*1201 forest plot. Harbold test: N/A, Egger test: N/A.
References: 5, 34
Overall  (I-squared = 0.0%, p = 0.504)
Wieczorek et al. 2008
Vaglio et al. 2007
Spriewald et al. 2005















Protective effect  Increased risk 
1.0704 14.2
HLA-DRB1*13
HLA-DRB1*13 forest plot. Harbold test: p=0.884, Egger test: p=0.467.
References: 31, 18, 35, 29
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Overall  (I-squared = 0.0%, p = 0.728)
Spriewald et al. 2005
Study
Wieczorek et al. 2008
Cao et al. 2011














Protective effect  Increased risk 
1.0442 22.6
HLA-DRB1*14
HLA-DRB1*14 forest plot. Harbold test: p=0.700, Egger test: p=0.706.
References: 31, 18, 29, 33
Overall  (I-squared = 69.1%, p = 0.021)
Study
Cao et al. 2011 (1)
Von Vietinghoff et al. 2006
Cao et al. 2011 (2)














Protective effect  Increased risk 
1.199 5.03
HLA-DRB1*15
HLA-DRB1*15 forest plot. Harbold test: p=0.347, Egger test: p=0.214.
References: 31, 18, 33**
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Overall  (I-squared = 0.0%, p = 0.925)
Luo et al. 2011
Study










Protective effect  Increased risk 
1.299 3.35
HLA-DRB1*1501
HLA-DRB1*1501 forest plot. Harbold test: N/A, Egger test: N/A.
References: 5, 34
Overall  (I-squared = 68.2%, p = 0.024)
Study
Von Vietinghoff et al. 2006
Spencer et al. 1992
Wieczorek et al. 2008














Protective effect  Increased risk 
1.105 9.51
HLA-DRB3
HLA-DRB3 forest plot. Harbold test: p=0.689, Egger test: p=0.958.
References: 38, 18, 35, 29
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Overall  (I-squared = 60.6%, p = 0.055)
Study
Spencer et al. 1992
Von Vietinghoff et al. 2006
Vaglio et al. 2007














Protective effect  Increased risk 
1.256 3.9
HLA-DRB4
HLA-DRB4 forest plot. Harbold test: p=0.533, Egger test: p=0.388.
References: 38, 18, 35, 29
Overall  (I-squared = 0.0%, p = 0.620)
Heckmann et al. 2008











Protective effect  Increased risk 
1.319 3.14
HSD17B8 rs421446 (C)
HSD17B8 rs421446 (C) forest plot. Harbold test: N/A, Egger test: N/A.
References: 24, 25
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Overall  (I-squared = 98.7%, p = 0.000)
Kawasaki et al. 2013
Wieczorek et al. 2010













Protective effect  Increased risk 
1.26 3.85
IRF5 rs10954213 (G)
IRF5 rs10954213 (G) forest plot. Harbold test: p=0.948, Egger test: p=0.833.
References: 44, 3, 45
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.693)
Jagiello et al. 2005
Study
Chung et al. 2012 (1)
Martorana et al. 2012
Chung et al. 2012 (2)
















Protective effect  Increased risk 
1.401 2.49
PTPN22 rs2476601 (A)
PTPN22 rs2476601 (A) forest plot. Harbold test: N/A, Egger test: p=0.500.
References: 50, 2**,51, 3
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Overall  (I-squared = 72.5%, p = 0.026)
Heckmann et al. 2008
Study
Previously unpublished Lyons et al. 2012 GWAS data












Protective effect  Increased risk 
1.374 2.67
RING1/RXRB rs213213 (A)
RING1/RXRB rs213213 (A) forest plot. Harbold test: p=0.187, Egger test: p=0.169.
References: 24, 3, 25
Overall  (I-squared = 96.0%, p = 0.000)
Xie et al. 2013
Previously unpublished Lyons et al. 2012 GWAS data













Protective effect  Increased risk 
1.447 2.24
RXRB rs6531 (C)
RXRB rs6531 (C) forest plot. Harbold test: p=0.292, Egger test: p=0.301.
References: 52, 3, 25
On the pathogenesis and clinical outcome of ANCA-associated vasculitis
252
Overall  (I-squared = 73.0%, p = 0.025)
Study
Previously unpublished Lyons et al. 2012 GWAS data
Wieczorek et al. 2009












Protective effect  Increased risk 
1.269 3.72
RXRB rs9277935 (T)
RXRB rs9277935 (T) forest plot. Harbold test: p=0.393, Egger test: p=0.406.
References: 53, 3, 25
Overall  (I-squared = 3.0%, p = 0.357)
Previously unpublished Lyons et al. 2012 GWAS data
Kawasaki et al. 2013
Study












Protective effect  Increased risk 
1.73 1.37
STAT4 rs7574865 (T)
STAT4 rs7574865 (T) forest plot. Harbold test: p=0.590, Egger test: p=0.567.
References: 44, 45, 3
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Overall  (I-squared = 96.2%, p = 0.000)
Husmann et al. 2014 (2)











Protective effect  Increased risk 
1.468 2.14
TLR9 rs352162 (T)
TLR9 rs352162 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: 40**
Overall  (I-squared = 0.0%, p = 0.432)
Husmann et al. 2014 (1)
Study










Protective effect  Increased risk 
1.764 1.31
TLR9 rs352140 (T)
TLR9 rs352140 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: 40**
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Overall  (I-squared = 0.0%, p = 0.756)
Husmann et al. 2014 (2)
Study










Protective effect  Increased risk 
1.77 1.3
TLR9 rs352139 (T)
TLR9 rs352139 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: 40**
**Two cohorts described in the same publication.
***Three cohorts described in the same publication.
N/A, not applicable
255
I. Supplementary data Chapter II
Supplementary figure 2. Forest plots by diagnostic and serologic subgroups
GPA
Wieczorek et al. 2009 (1)
Wieczorek et al. 2009 (2)
Chung et al. 2012 (1)
Chung et al. 2012 (2)
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 72.2%, p = 0.006)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
EGPA
Wieczorek et al. 2009
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Wieczorek et al. 2009
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 86.6%, p = 0.006)
MPO-ANCA
Wieczorek et al. 2009
Previously unpublished Lyons et al. 2012 GWAS data





































Protective effect  Increased risk 
1.362 2.76
Subgroup analysis CD226 rs763361 (T)
References: 1**, 2**, 3







Huang et al. 2000
Zhou et al. 2004
Persson et al. 2013
Subtotal  (I-squared = 86.5%, p = 0.001)
MPA
Tsuchiya et al. 2003
Persson et al. 2013
Subtotal  (I-squared = 73.6%, p = 0.052)
PR3-ANCA
Tsuchiya et al. 2003
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Tsuchiya et al. 2003
Persson et al. 2013





























Protective effect  Increased risk 
1.0951 10.5
Subgroup analysis CTLA-4 (AT)86
References: 4, 5, 6, 7
257
I. Supplementary data Chapter II
References: 4, 7, 5
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References: 4, 7, 5
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GPA
Kamesh et al. 2009
Chung et al. 2012 (1)
Chung et al. 2012 (2)
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 38.7%, p = 0.180)
MPA
Kamesh et al. 2009
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 0.0%, p = 0.574)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data





























Protective effect  Increased risk 
1.45 2.22
Subgroup analysis CTLA-4 rs3087243 (A)
References: 9, 2**, 3
On the pathogenesis and clinical outcome of ANCA-associated vasculitis
260
References: 11, 12, 13, 5, 7, 3
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References: 12, 14, 10, 5






Strimlan et al. 1978
Murty et al. 1991
Nakamaru et al. 1996
Von Vietinghoff et al. 2006
Stassen et al. 2009
Subtotal  (I-squared = 51.4%, p = 0.084)
MPA
Papasteriades et al. 1997
Subtotal  (I-squared = .%, p = .)
c-ANCA
Nakamaru et al. 1996

























Protective effect  Increased risk 
1.135 7.41
Subgroup analysis HLA-A11
References: 16, 17, 20, 22, 18, 19
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Nakamaru et al. 1996
Von Vietinghoff et al. 2006
Subtotal  (I-squared = 92.9%, p = 0.000)
c-ANCA
Nakamaru et al. 1996























Heckmann et al. 2008
Xie et al. 2013 (1)
Xie et al. 2013 (2)
Subtotal  (I-squared = 54.8%, p = 0.109)
c-ANCA
Xie et al. 2013

















Protective effect  Increased risk 
1.221 4.53
Subgroup analysis HLA-DPA1 rs9277341 (C)
References: 24, 25**
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References: 27, 26
References: 27, 24, 28, 29









Jagiello et al. 2004
Heckmann et al. 2008
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 61.7%, p = 0.050)
MPA
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 0.0%, p = 0.525)
EGPA
Wieczorek et al. 2008
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 72.1%, p = 0.028)
PR3-ANCA
Zhang et al. 1995
Jagiello et al. 2004
Subtotal  (I-squared = 90.8%, p = 0.001)
MPO-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
ANCA-negative
Heckmann et al. 2008











































Protective effect  Increased risk 
1.00278 359
Subgroup analysis HLA-DPB1*0301
References: 26, 27, 24, 29, 30**
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Jagiello et al. 2004
Heckmann et al. 2008
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 67.5%, p = 0.026)
MPA
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 0.0%, p = 0.765)
EGPA
Wieczorek et al. 2008
Arning et al. 2011 (1)
Arning et al. 2011 (2)
Subtotal  (I-squared = 58.2%, p = 0.092)
PR3-ANCA
Zhang et al. 1995
Jagiello et al. 2004
Subtotal  (I-squared = 0.0%, p = 0.960)
MPO-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
ANCA-negative
Heckmann et al. 2008











































Protective effect  Increased risk 
1.108 9.24
Subgroup analysis HLA-DPB1*0401
References: 26, 27, 24, 29, 30**







Heckmann et al. 2008
Previously unpublished Lyons et al. 2012 GWAS data
Xie et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.991)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data

























Protective effect  Increased risk 
1.333 3.01
Subgroup analysis HLA-DPB2 rs3130215 (A)






Spriewald et al. 2005
Subtotal  (I-squared = .%, p = .)
MPA
Tsuchiya et al. 2006
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Zhang et al. 1995
Spriewald et al. 2005
Subtotal  (I-squared = 81.0%, p = 0.022)
MPO-ANCA
Zhang et al. 1995
Tsuchiya et al. 2006

























Protective effect  Increased risk 
1.0562 17.8
Subgroup analysis HLA-DQB1*0303
References: 26, 31, 28
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References: 23, 32, 31, 18, 19, 34, 5, 29, 26, 33








Elkon et al. 1983
Papiha et al. 1992
Nakamaru et al. 1996
Stassen et al. 2009
Subtotal  (I-squared = 71.1%, p = 0.016)
EGPA
Elkon et al. 1983
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
c-ANCA
Nakamaru et al. 1996































Protective effect  Increased risk 
1.0773 12.9
Subgroup analysis HLA-DR2
References: 23, 32, 26, 20, 19
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References: 23, 17, 32, 20, 31, 18, 19, 35, 29, 26, 33









Elkon et al. 1983
Papiha et al. 1992
Nakamaru et al. 1996
Stassen et al. 2009
Subtotal  (I-squared = 59.8%, p = 0.058)
MPA
Stassen et al. 2009
Subtotal  (I-squared = .%, p = .)
EGPA
Elkon et al. 1983
Stassen et al. 2009
Subtotal  (I-squared = 0.0%, p = 0.724)
PR3-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Zhang et al. 1995
Subtotal  (I-squared = .%, p = .)
c-ANCA
Nakamaru et al. 1996





































Protective effect  Increased risk 
1.00627 160
Subgroup analysis HLA-DR6
References: 23, 32, 26, 20, 19
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References: 23, 32, 31, 18, 19, 35, 29
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References: 17, 20, 31, 18, 19, 29, 26, 33
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References: 23, 20, 31, 18, 19, 34, 37, 35, 29, 33, 36






Luo et al. 2011
Subtotal  (I-squared = .%, p = .)
MPA
Luo et al. 2011
Tsuchiya et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.885)
MPO-ANCA
Tsuchiya et al. 2013























References: 31, 18, 29, 33
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Luo et al. 2011
Subtotal  (I-squared = .%, p = .)
MPA
Tsuchiya et al. 2003
Luo et al. 2011
Subtotal  (I-squared = 0.0%, p = 0.391)
PR3-ANCA
Luo et al. 2011
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Tsuchiya et al. 2003
Luo et al. 2011


































Spriewald et al. 2005
Von Vietinghoff et al. 2006
Subtotal  (I-squared = 0.0%, p = 0.807)
EGPA
Vaglio et al. 2007
Wieczorek et al. 2008
Subtotal  (I-squared = 29.2%, p = 0.235)
PR3-ANCA
Spriewald et al. 2005





















Protective effect  Increased risk 
1.0704 14.2
Subgroup analysis HLA-DRB1*13
References: 31, 18, 35, 29






Spriewald et al. 2005
Von Vietinghoff et al. 2006
Subtotal  (I-squared = 0.0%, p = 0.511)
PR3-ANCA
Spriewald et al. 2005
Cao et al. 2011 (1)
Cao et al. 2011 (2)
Subtotal  (I-squared = 84.0%, p = 0.002)
MPO-ANCA
Cao et al. 2011 (1)
Cao et al. 2011 (2)

























Protective effect  Increased risk 
1.0203 49.1
Subgroup analysis HLA-DRB1*15






Luo et al. 2011
Subtotal  (I-squared = .%, p = .)
MPA
Tsuchiya et al. 2003
Luo et al. 2011
Subtotal  (I-squared = 0.0%, p = 0.805)
PR3-ANCA
Luo et al. 2011
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Tsuchiya et al. 2003
Luo et al. 2011



































Spriewald et al. 2005
Von Vietinghoff et al. 2006
Subtotal  (I-squared = 0.0%, p = 0.623)
PR3-ANCA
Spriewald et al. 2005
Cao et al. 2011 (1)
Cao et al. 2011 (2)
Subtotal  (I-squared = 51.0%, p = 0.130)
MPO-ANCA
Cao et al. 2011 (1)
Cao et al. 2011 (2)

























Protective effect  Increased risk 
1.00707 141
Subgroup analysis HLA-DRB1*16




Von Vietinghoff et al. 2006
Subtotal  (I-squared = .%, p = .)
EGPA
Vaglio et al. 2007
Wieczorek et al. 2008















Protective effect  Increased risk 
1.346 2.89
Subgroup analysis HLA-DRB3
References: 18, 35, 29





Von Vietinghoff et al. 2006
Subtotal  (I-squared = .%, p = .)
EGPA
Vaglio et al. 2007
Wieczorek et al. 2008















Protective effect  Increased risk 
1.256 3.9
Subgroup analysis HLA-DRB4
References: 18, 35, 29
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Murakozy et al. 2001
Bartfai et al. 2003
Spriewald et al. 2005
Wieczorek et al. 2008
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 21.3%, p = 0.279)
MPA
Bartfai et al. 2003
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 71.8%, p = 0.060)
EGPA
Wieczorek et al. 2008
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Spriewald et al. 2005
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 0.0%, p = 0.669)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data





































Protective effect  Increased risk 
1.337 2.97
Subgroup analysis IL-10 rs1800896 (G)
References: 42, 43, 31, 41, 3
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GPA
Wieczorek et al. 2010
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 99.1%, p = 0.000)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Kawasaki et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.406)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Kawasaki et al. 2013



























Protective effect  Increased risk 
1.26 3.85
Subgroup analysis IRF5 rs10954213 (G)




Wieczorek et al. 2010 (1)
Wieczorek et al. 2010 (2)
Subtotal  (I-squared = 0.0%, p = 0.968)
EGPA
Wieczorek et al. 2010















Protective effect  Increased risk 
1.523 1.91
Subgroup analysis LEPR rs8179183 (C)
References: 15**
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GPA
Jagiello et al. 2005
Chung et al. 2012 (1)
Chung et al. 2012 (2)
Martorana et al. 2012
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 0.0%, p = 0.411)
MPA
Martorana et al. 2012
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 0.0%, p = 0.641)
EGPA
Martorana et al. 2012
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Martorana et al. 2012
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = 13.2%, p = 0.283)
MPO-ANCA
Martorana et al. 2012
Previously unpublished Lyons et al. 2012 GWAS data







































Protective effect  Increased risk 
1.102 9.84
Subgroup analysis PTPN22 rs2476601 (A)
References: 50, 2**, 51, 3







Heckmann et al. 2008
Previously unpublished Lyons et al. 2012 GWAS data
Xie et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.551)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data

























Protective effect  Increased risk 
1.374 2.67
Subgroup analysis RING1/RXRB rs213213 (A)







Szyld et al. 2006
Previously unpublished Lyons et al. 2012 GWAS data
Xie et al. 2013
Subtotal  (I-squared = 96.5%, p = 0.000)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
ANCA-negative
Szyld et al. 2006





























Protective effect  Increased risk 
1.399 2.51
Subgroup analysis RXRB rs6531 (C)
References: 52, 3, 25
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Wieczorek et al. 2009
Previously unpublished Lyons et al. 2012 GWAS data
Xie et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.798)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data

























Protective effect  Increased risk 
1.173 5.79
Subgroup analysis RXRB rs9277935 (T)




Mahr et al. 2010
Chorostowska-Wynimko et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.588)
c-ANCA
Lhotta et al. 1994
Griffith et al. 1996
Chorostowska-Wynimko et al. 2013



















Protective effect  Increased risk 
1.0472 21.2
Subgroup analysis SERPINA1 S allele
References: 54, 55, 56, 58









Borgmann et al. 2001
Mahr et al. 2010
Previously unpublished Lyons et al. 2012 GWAS data
Chorostowska-Wynimko et al. 2013
Subtotal  (I-squared = 0.0%, p = 0.763)
MPA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
PR3-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
MPO-ANCA
Previously unpublished Lyons et al. 2012 GWAS data
Subtotal  (I-squared = .%, p = .)
c-ANCA
Lhotta et al. 1994
Griffith et al. 1996
Callea et al. 1997
Borgmann et al. 2001
Chorostowska-Wynimko et al. 2013
Subtotal  (I-squared = 21.3%, p = 0.279)
p-ANCA
Griffith et al. 1996
Callea et al. 1997













































Protective effect  Increased risk 
1.0366 27.4
Subgroup analysis SERPINA1 Z allele
References: 54, 55, 59, 60, 56, 3,58
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References: 44, 45
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GPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 56.9%, p = 0.128)
MPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 88.0%, p = 0.004)
EGPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.410)
PR3-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.503)
MPO-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.402)
ANCA-negative
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)









































Protective effect  Increased risk 
1.285 3.51
Subgroup analysis TLR9 rs352162 (T)
References: 40**
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GPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 39.7%, p = 0.198)
MPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 71.4%, p = 0.062)
EGPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 54.6%, p = 0.138)
PR3-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.782)
MPO-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.471)
ANCA-negative
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)









































Protective effect  Increased risk 
1.333 3
Subgroup analysis TLR9 rs352140 (T)
References: 40**
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GPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.366)
MPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 86.6%, p = 0.006)
EGPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 64.5%, p = 0.093)
PR3-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.910)
MPO-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 37.4%, p = 0.206)
ANCA-negative
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)









































Protective effect  Increased risk 
1.254 3.94
Subgroup analysis TLR9 rs352139 (T)
References: 40**
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GPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 70.5%, p = 0.066)
MPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.927)
EGPA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 0.0%, p = 0.545)
PR3-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 81.9%, p = 0.019)
MPO-ANCA
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)
Subtotal  (I-squared = 26.4%, p = 0.244)
ANCA-negative
Husmann et al. 2014 (1)
Husmann et al. 2014 (2)









































Protective effect  Increased risk 
1.361 2.77
Subgroup analysis TLR9 rs5743836 (G)
References: 40**
**Two cohorts described in the same publication.
***Three cohorts described in the same publication.
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Supplementary figure 3. Forest plots by ethnic subgroups
References: 4, 5, 6, 7
References: 4, 5, 7
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References: 23, 32, 26, 20, 19
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Supplementary table 1. ENT manifestations
ENT symptom Patients
Nasal obstruction 76 (43)
Bloody nasal discharge 70 (40)
Nasal crusting 60 (34)
Sinus involvement 45 (25)
Hearing loss 46 (26)
Hoarseness/stridor 12 (7)
Otorhinolaryngologist’s opinion
Granulomatous sinusitis 28 (16)
Conductive hearing loss 20 (11)
Sensorineural hearing loss 9 (5)
Significant subglottic inflammation 4 (2)
All data are presented as n (%). ENT symptoms scored using the Birmingham Vasculitis Activity Score 
are shown. Data were available for 177 of the 185 patients with ENT involvement. Percentages are 
expressed relative to the number of patients with ENT involvement. All items below ‘otorhinolaryn-
gologist’s opinion’ were only scored by the otorhinolaryngologist. ENT, ear-, nose-, and throat.
Supplementary table 2. Associations between ENT symptoms and ANCA-subtype in patients with 
ENT involvement





Nasal obstruction 57 (49) 14 (30) 0.03
Bloody nasal discharge 45 (39) 19 (41) 0.77
Nasal crusting 43 (37) 13 (28) 0.29
Sinus involvement 30 (26) 13 (28) 0.76
Hearing loss 34 (29) 7 (15) 0.06
Hoarseness/stridor 7 (6) 5 (11) 0.30
Otorhinolaryngologist’s opinion
Granulomatous sinusitis 25 (22) 2 (4) 0.008
Conductive hearing loss 16 (14) 3 (7) 0.20
Sensorineural hearing loss 5 (4) 2 (4) 0.99
Significant subglottic
inflammation 2 (2) 2 (4) 0.33
Data are presented as n (%). The distribution of ANCA-subtype in patients with ENT involvement 
is shown. Data regarding the specific ENT symptoms were available for 177 of the 185 patients with 
ENT involvement. All 8 patients with missing ENT symptoms data were PR3-ANCA positive. All 
items listed under ‘otorhinolaryngologist’s opinion’ were scored by the otorhinolaryngologist alone. 
ENT, ear-, nose-, and throat; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; 
MPO-ANCA, anti-myeloperoxidase anti-neutrophil cytoplasm antibody.
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Supplementary table 3. Associations between ENT symptoms and baseline eGFR






95% CI P Value
Nasal obstruction 43.09 26.59 9.91 – 23.10 <0.001
Bloody nasal discharge 37.81 28.05 2.82 – 16.71 0.006
Nasal crusting 43.25 27.36 8.60 – 23.19 <0.001
Sinus involvement 36.38 28.93 -0.95 – 15.84 0.08
Hearing loss 36.78 28.86 -0.40 – 16.23 0.06
Hoarseness/stridor 28.70 29.82 -16.72 – 14.47 0.89
Otorhinolaryngologist’s 
opinion
Granulomatous sinusitis 41.56 28.88 2.32 – 23.03 0.02
Conductive hearing loss 44.89 29.98 3.80 – 28.02 0.01
Sensorineural hearing loss 26.88 29.86 -20.91 – 14.96 0.74
Significant subglottic
inflammation 45.53 29.63 -10.78 – 42.60 0.24
ENT symptoms were scored using the Birmingham Vasculitis Activity Score. Data regarding the spe-
cific ENT symptoms were available for 177 of the 185 patients with ENT involvement. All items listed 
under ‘otorhinolaryngologist’s opinion’ were scored by the otorhinolaryngologist alone. ENT, ear-, 
nose-, and throat; eGFR, estimated glomerular filtration rate.
Supplementary table 4. Correlations of clinical and histological parameters with baseline and 5-year 
follow-up eGFR
Baseline eGFR 5-year follow-up eGFR
r p Value r P Value
ENT involvement 0,274 < 0.001 0,224 0.005
Age -0,379 < 0.001 -0,395 < 0.001
PR3-ANCA 0,240 < 0.001 0,097 <0.24
Tubulitis -0,445 < 0.001 -0,266 0.12
Interstitial infiltrate -0,477 < 0.001 -0,396 < 0.001
IFTA -0,436 < 0.001 -0,477 < 0.001
AAGN classification -0,424 < 0.001 -0,511 < 0.001
ENT, ear-, nose-, and throat; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; 
IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated 
glomerulonephritis; eGFR, estimated glomerular filtration rate. 
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Supplementary table 5. Three multivariable regression models investigating the association between 
ENT involvement and baseline eGFR
Model 1 β (95% CI) P Value
ENT involvement 10.40 (5.24 – 15.55) < 0.001
Age -0.65 (-0.82 – -0.47) < 0.001
PR3-ANCA 6.21 (1.03 – 11.38) 0.02
Model 2 β (95% CI) P Value
ENT involvement 10.32 (4.05 – 16.59) 0.001
Age -0.46 (-0.68 – -0.24) < 0.001
PR3-ANCA -1.43 (-7.73 – 4.88) 0.66
Tubulitis -13.93 (-20.87 – -6.99) < 0.001
Interstitial infiltrate -8.56 (-12.64 – -4.47) < 0.001
IFTA -10.54 (-15.61 – -5.47) < 0.001
Model 3 β (95% CI) P Value
ENT involvement 9.14 (2.30 – 15.98) 0.009
Age -0.60 (-0.83 – -0.36) < 0.001
PR3-ANCA -1.26 (-8.28 – 5.75) 0.71
Tubulitis -17.82 (-25.78 – -9.86) < 0.001
Interstitial infiltrate -6.86 (-11.20 – -2.52) 0.002
IFTA -8.72 (-14.67 – -2.77) 0.004
AAGN classification -6.20 (-9.84 – -2.57) 0.001
Since renal biopsies were not available for all patients, including the histopathological parameters 
limited the number of patients included in the analysis. To be able to include all patients we therefore 
created three models. The first model included only clinical parameters (n=412). In the second model, 
we added tubulointerstitial parameters (n=195). The third model, we added the histopathological 
classification (n=149). In all models, age is included per year unit. ENT involvement was significantly 
associated with higher baseline eGFR. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; 
eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm 
antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody 
associated glomerulonephritis.
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Supplementary table 6. Multivariable regression analyses investigating the relationship between ENT 
involvement and eGFR in GPA patients
β (95% CI) P Value
ENT involvement 12.44 (0.08 – 24.80) 0.04
Age -1.26 (-8.28 – 5.75) 0.02
PR3-ANCA -5.17 (-17.02 – 6.68) 0.39
Tubulitis -9.47 (-23.10 – 4.15) 0.17
Interstitial infiltrate -16.29 (-24.93 – -7.64) < 0.001
IFTA -9.35 (-18.46 – -0.24) 0.01
AAGN classification -9.79 (-15.58 – -4.00) 0.001
ENT involvement is associated with higher baseline eGFR in GPA patients. Age is included per year 
unit in the model. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated 
glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, 
interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomer-
ulonephritis.
Supplementary table 7. Multivariable regression analyses investigating the relationship between ENT 
involvement and 5-year follow-up eGFR
Model investigating 5-year 
follow-up eGFR
Model investigating 5-year 
follow-up eGFR in PR3-ANCA 
positive patients
β (95% CI) P Value β (95% CI) P Value
ENT involvement 2.12 (-4.90 – 9.14) 0.55 8.10 (-1.73 – 17.93) 0.10
Age -0.27 (-0.52 – -0.03) 0.03 -0.03 (-0.37 – 0.30) 0.84
PR3-ANCA -6.28 (-13.33 – 0.77) 0.08 N/A N/A
Baseline eGFR 0.33 (0.17 – 0.48) < 0.001 0.43 (0.24 – 0.61) < 0.001
Tubulitis 4.25 (-4.43 – 12.92) 0.33 -1.92 (-13.49 – 9.64) 0.74
Interstitial infiltrate -2.42 (-8.13 – 3.29) 0.40 -0.86 (-9.05 – 7.32) 0.83
IFTA -1.65 (-8.23 – 4.92) 0.62 -2.73 (-11.14 – 5.69) 0.52
AAGN classification -5.44 (-9.71 – -1.17) 0.01 N/A N/A
ENT involvement is no longer associated with 5-year follow-up eGFR when baseline eGFR is included 
in the model. Both models are adjusted for within-trial therapy. Age is included per year unit in both 
models. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated glomerular 
filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial 
fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephri-
tis; N/A, not applicable.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































III. Supplementary data Chapter VI
Effect of rituximab on malignancy risk in patients with 
ANCA-associated vasculitis
Table S1.  Subgroup analysis
Table S2. Cyclophosphamide and rituximab treatment in the 
subgroups
Table S3. SIR according to cumulative cyclophosphamide and 
rituximab dose
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Supplementary table 3. SIR for non-melanoma skin cancer according to cumulative cyclophosphamide 
and rituximab dose*
Cumulative dose (g) N patients N observed 
non-melanoma 
skin cancer
SIR (95% CI)† SIR p value†
Cyclophosphamide
   0 89 3 2.17 (0.45– 6.34) 0.16
   0.1–20 207 18 4.89 (2.90 – 7.72) <0.001
   20–108 16 3 11.72 (2.42 – 34.25) 0.002
Rituximab
   0 167 23 8.47 (5.37 – 12.71) <0.001
   0.1–6 70 1 0.83 (0.02 – 4.64) 0.66
   6–18 83 0 0 (0 – 2.47) 0.23
* SIR, standardised incidence ratio; the SIR is the ratio of the observed to expected malignancies ad-
justed for sex, age (per 5-year age group), and calendar time period (per 1-year calendar time period).
† Calculated by exact Poisson regression analysis.
















Lung 4 36.0; 21.1; 4.9; 0.0 0.0; 7.0; 0.0; 5.0 3.7; 4.8; 0.5; 8.5
Breast 3 18.0; 6.0; 3.4 0; 4.0; 8.0 0.9; 1.1; 4.0
Colon or rectum 3 13.8; 9.5; 4.0 0.0; 0.0; 0.0 2.4; 4.5; 4.0
Prostate 2 10.0; 0.0 0.0; 0.0 7.4; 1.2
Bladder 1 0.0 1.0 2.4
Pancreas 1 0.0 0.0 1.4
Testis 1 7.0 5.0 4.6
Ovary 1 3.0 6.6 2.4
Melanoma 1 3.3 0.0 1.8
Tongue 1 0.0 0.0 4.5
Central nervous 
system 1 2.0 5.6 3.2
Kidney 1 7.0 4.0 2.4
* The cumulative doses of each patient with a malignancy is given. Patients with a cumulative dose of 
0.0 did not receive the treatment. When more cases of the malignancy were observed, the first report-
ed cumulative cyclophosphamide dose corresponds to the first reported cumulative rituximab dose, 
and to the first reported time to malignancy.
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